

(19)日本国特許庁 (J P)

(12) 公開特許公報 (A)

(11)特許出願公開番号

特開2002 - 355054

(P2002 - 355054A)

(43)公開日 平成14年12月10日(2002.12.10)

(51) Int. Cl ⁷	識別記号	F I	テ-マコード (参考)
C 1 2 N 15/09	ZNA	A 6 1 K 39/106	2 G 0 4 5
A 6 1 K 38/00		39/118	4 B 0 2 4
39/106		39/12	4 B 0 5 0
39/118		39/175	4 B 0 6 3
39/12		39/23	4 B 0 6 5

審査請求 未請求 請求項の数 22 O L (全149数) 最終頁に続く

(21)出願番号 特願2001 - 214711(P2001 - 214711)

(22)出願日 平成13年7月16日(2001.7.16)

(31)優先権主張番号 00202565.8

(32)優先日 平成12年7月17日(2000.7.17)

(33)優先権主張国 欧州特許庁 (EP)

(71)出願人 394010986

アクゾ・ノベル・エヌ・ベー

オランダ国、6824・ベー・エム・アーネム、

フェルペルウエヒ・76

(72)発明者 ヨハネス・ヘラルドウス・クステルス

オランダ国、3981・テー・カー・ブニツク、

マルスクラメルスパーン・20

(72)発明者 ジョバンニ・カツトリ

イタリア国、35133・パドバ、ピア・アマア

テイ・1

(74)代理人 100062007

弁理士 川口 義雄 (外 4 名)

最終頁に続く

(54)【発明の名称】 ヘリコバクター・フェリス・ワクチン

(57)【要約】 (修正有)

【課題】本発明は、ヘリコバクター・フェリス由来の抗原性ポリペプチドをコードするポリヌクレオチドを提供する。さらにヘリコバクター・フェリスに対するワクチン、その感染診断法なども提供する。

【解決手段】新規なヘリコバクター・フェリス・ウレアーゼ・サブユニット・ポリペプチド、これらのサブユニット・ポリペプチドをコードする核酸配列、これらのサブユニット・ポリペプチドをコードする核酸配列を含むDNA断片及び組換えDNA分子、組換え生キャリアー、並びにこれらのサブユニット・ポリペプチドをコードする核酸配列を含む宿主細胞に関する。また、本発明は、ワクチンにおいて使用するためのサブユニット・ポリペプチド、それらの製造における使用、該サブユニット・ポリペプチドを含むワクチン、及びそのようなワクチンの調製のための方法に関する。

【特許請求の範囲】

【請求項1】 ヘリコバクター・フェリス (*Helicobacter felis*) により発現されるようなウレアーゼ複合体の2つのサブユニット・ポリペプチドをコードし、かつ配列番号1と少なくとも85%の相同性を有する核酸配列、又は該サブユニットのうち一つの免疫原性断片を少なくともコードし、かつ少なくとも40ヌクレオチド、好ましくは45ヌクレオチド、より好ましくは50ヌクレオチドの長さを有するその一部。

【請求項2】 ウレアーゼXサブユニット・ポリペプチド又はウレアーゼYサブユニット・ポリペプチドをコードすることを特徴とする、請求項1に記載の核酸配列。

【請求項3】 配列番号1と少なくとも90%、好ましくは94%、より好ましくは97%の相同性を有することを特徴とする、請求項1又は2に記載の核酸配列。

【請求項4】 請求項1～3に記載の核酸配列を含むDNA断片。

【請求項5】 機能的に連結したプロモーターの調節下で、請求項1～3に記載の核酸配列又は請求項4に記載のDNA断片を含む組換えDNA分子。

【請求項6】 請求項5に記載の組換えDNA分子を含む組換え生キャリアー。

【請求項7】 請求項1～3に記載の核酸配列、請求項4に記載のDNA断片、請求項5に記載の組換えDNA分子、又は請求項6に記載の組換え生キャリアーを含む宿主細胞。

【請求項8】 配列番号2と少なくとも85%相同なアミノ酸配列を有するヘリコバクター・フェリス・ウレアーゼXサブユニット・ポリペプチド、又は少なくとも40アミノ酸、好ましくは45アミノ酸、より好ましくは50アミノ酸の長さを有し、かつウレアーゼXYに対する免疫応答を誘導する能力を有する該ポリペプチドの免疫原性断片。

【請求項9】 配列番号2と少なくとも90%、好ましくは94%、より好ましくは97%の配列相同性を有する、請求項8に記載のポリペプチド、又はウレアーゼXYに対する免疫応答を誘導する能力を有する該ポリペプチドの免疫原性断片。

【請求項10】 配列番号3と少なくとも85%相同なアミノ酸配列を有するヘリコバクター・フェリス・ウレアーゼYサブユニット・ポリペプチド、又は少なくとも40アミノ酸、好ましくは45アミノ酸、より好ましくは50アミノ酸の長さを有し、かつウレアーゼXYに対する免疫応答を誘導する能力を有する、該ポリペプチドの免疫原性断片。

【請求項11】 配列番号3と少なくとも90%、好ましくは94%、より好ましくは97%の配列相同性を有する、請求項10に記載のポリペプチド、又はウレアーゼXYに対する免疫応答を誘導する能力を有する該ポリペプチドの免疫原性断片。

【請求項12】 ワクチンにおいて使用するための、請求項8～11に記載のポリペプチド。

【請求項13】 ヘリコバクター・フェリス感染に対抗するためのワクチンの製造における、請求項8～11に記載のポリペプチドの使用。

【請求項14】 請求項1～3に記載の核酸配列、請求項4に記載のDNA断片、請求項5に記載の組換えDNA分子、請求項6に記載の組換え生キャリアー、請求項7に記載の宿主細胞、又は請求項8～11に記載のポリペプチドと、薬学的に許容される担体とを含むことを特徴とする、ヘリコバクター・フェリス感染に対抗するためのワクチン。

【請求項15】 アジュバントを含むことを特徴とする、請求項14に記載のワクチン。

【請求項16】 哺乳動物にとって病原性のウイルスもしくは微生物に由来する抗原、又は該抗原をコードする遺伝情報を、さらに含むことを特徴とする、請求項14又は15に記載のワクチン。

【請求項17】 哺乳動物にとって病原性のウイルス又は微生物が、ネコ伝染性腹膜炎ウイルス (*Feline Infectious Peritonitis virus*)、ネコ免疫不全ウイルス (*Feline Immunodeficiency virus*)、イヌ及びネコのパルボウイルス (*Canine and Feline Parvovirus*)、ジステンパーウイルス (*Distemper virus*)、アデノウイルス (*Adenovirus*)、カリシウイルス (*Calicivirus*)、ボーデテラ・ブロンキセプチカ (*Bordetella bronchiseptica*)、ボレリア・ブルグドルフェリ (*Borrelia burgdorferi*)、レプトスピラ・インテロガンズ (*Leptospira interrogans*)、クラミジア (*Chlamydia*) 及びバートネラ・ヘンセリ (*Bartonella henselii*) からなる群より選択されることを特徴とする、請求項16に記載のワクチン。

【請求項18】 請求項8～11に記載のポリペプチドに対する抗体を含むことを特徴とする、ヘリコバクター・フェリス感染に対抗するためのワクチン。

【請求項19】 請求項8～11に記載のポリペプチドと薬学的に許容される担体とを混合することを含む、請求項14～17に記載のワクチンを調製する方法。

【請求項20】 請求項1～3に記載の核酸配列又はその断片を含むことを特徴とする、ヘリコバクター・フェリス特異的DNAの検出のための診断テスト。

【請求項21】 請求項8～11に記載のポリペプチド又はその断片を含むことを特徴とする、ヘリコバクター・フェリスに対する抗体の検出のための診断テスト。

【請求項22】 請求項8～11に記載のポリペプチド又はその断片に対する抗体を含むことを特徴とする、ヘ

リコバクター・フェリスの抗原性物質の検出のための診断テスト。

【発明の詳細な説明】

【0001】本発明は、新規なヘリコバクター (*Helicobacter*) ウレアーゼ・サブユニット・ポリペプチド、これらのポリペプチドをコードする核酸配列、ワクチンにおいて使用するためのポリペプチド、それらの製造における使用、該ポリペプチドを含むワクチン、及びそのようなワクチンの調製のための方法に関する。さらに、本発明は、核酸配列、ポリペプチド、及びポリペプチドに対する抗体の検出のための診断法に関する。

【0002】いくつかのヘリコバクター種が、胃上皮の病因となる。ヘリコバクター・ピロリ (*Helicobacter pylori*)、そして程度は低い *H. ヘイルマンニ* (*heilmanni*) が、ヒトにおける消化性潰瘍及び胃リンパ腫の発生における主要な要因である胃炎を引き起こすことが知られている。ヘリコバクター・フェリス (*Helicobacter felis*) は、ネコ及びイヌの両方における胃感染の最も多い原因である。高度に酸性の胃環境で生存するため、ヘリコバクター科の細菌は、胃液中に存在する尿素を加水分解することができるウレアーゼを産生する。この加水分解は、細菌の環境を中和するために十分な量の NH_4OH を放出させる。ウレアーゼは、細菌のコロニー形成においても、その病原においても役割を果たすことが知られている。ウレアーゼをコードする遺伝子は、ヘリコバクター・ピロリ (*Labigne et al., J. Bacteriol.* 173:1920-1931 (1991)) 及びヘリコバクター・フェリス (*Ferreiro et al., Molec. Microbiol.* 9, 323-333 (1993)) の両方について記載され、配列決定されている。ウレアーゼの発現及び分泌に関与している7つの遺伝子のうち、2つの遺伝子のみが、ウレアーゼ酵素の2つの構造サブユニット、ウレアーゼA及びB; *ureA* 及び *ureB* をコードしている。これら2つのポリペプチドは、ウレアーゼ活性を有するポリペプチド複合体を形成する。

【0003】*H. ピロリ* 及び *フェリス* の両方により引き起こされる感染に対するワクチンが製造されており、特に、国際特許出願 *WO94/09823* 及び *WO96/34624* の主題となっている。*H. フェリス* 感染からネコを防御するためのワクチン成分として *H. ピロリ* のウレアーゼを使用しようとする試みが、いくつかなされている。実際、ある程度の防御は得られるが、結果は、

望ましいであろう100%防御にはほど遠い。これまでに発表された動物実験から、*H. ピロリ* で予防接種された動物の相当数が、その後の *H. フェリス* 接種から全く防御されないことは明らかである。*H. フェリス* 又は *ピロリ* のいずれかから精製されたウレアーゼで予防接種されたネコの防御は、記載されていない。*H. フェリス* 完全細胞溶解物によるネコの予防接種は、理論的には可能であるが、実用的には選択されていない。これは、改良のための多くの試みにも関わらず、*H. フェリス* を増殖させることが困難なためである。明らかに、同種成分に基づく有効なワクチンの必要性が存在しており、そして既知の *H. フェリス*・ウレアーゼが完全な防御を与えないことは明らかである。

【0004】イヌ及びネコにおけるヘリコバクター・フェリス感染からの防御を誘導することができる *H. フェリス*・ウレアーゼを提供することが、特に、本発明の目的である。驚くべきことに、*H. フェリス* には第2のウレアーゼが存在し、その構造サブユニットをコードする遺伝子は、既知の *H. フェリス* の *ureA* 及び *B* 遺伝子と低い相同性しか有しないことが本発明において見出された。新規なウレアーゼは、既知のウレアーゼ *AB* と区別するため、ウレアーゼ *XY* と命名されている。新規に見出されたウレアーゼは、*H. フェリス* において発見され、*H. ピロリ* には存在しない。2つの構造ウレアーゼ・サブユニット *UreX* 及び *UreY* をコードする遺伝子の全体的な遺伝子構造は、*H. フェリス* 及び *H. ピロリ* における既知の *UreA* 及び *B* のそれと比較可能である。しかしながら、配列相同性は、驚くほど低い。さらに驚くべきことに、ある単一の *H. フェリス* 株における *ureA* 及び *B* 遺伝子と新規 *ureX* 及び *Y* 遺伝子との間の相同性は、様々なヘリコバクター種由来の様々な *ureA* 及び *B* 遺伝子の間の相同性よりも顕著に低い。

【0005】表1a、1b、及び1cは、5つの異なるヘリコバクター・フェリス種に由来する *ureX* 及び *Y* 遺伝子並びにそれらがコードするポリペプチドと、ヘリコバクター・フェリス、ピロリ及びヘイルマンニに由来する *ureA* 及び *B* 並びにポリペプチドとの比較を示している。

【0006】既知の *ureA* 及び *B* 遺伝子並びにポリペプチド・サブユニットのものと比較した、新規な構造ウレアーゼ・サブユニット *X* 及び *Y* をコードする遺伝子並びにそれらがコードするポリペプチドの相同性のレベルを、表1a、b及びcに提示する。

【0007】

【表1】

参照分子:H.フェリス ureX CS1	アミノ酸	核酸
H.フェリス ureA	50%	57%
H.ピロリ ureA	52%	60%
H.ヘイルマンニ ureA	54%	62%
H.フェリス Kukka 株 ureX	100%	91%
H.フェリス Ds4 株 ureX	99%	91%
H.フェリス 2301 株 ureX	99%	91%
H.フェリス 390 株 ureX	99%	91%

表1a: H.フェリス ureX と様々な ureA サブユニットとの間のアミノ酸及び核酸の
相同性

【0008】

* * 【表2】

参照分子:H.フェリス ureY CS1	アミノ酸	核酸
H.フェリス ureB	73%	71%
H.ピロリ ureB	73%	70%
H.ヘイルマンニ ureB	74%	71%
H.フェリス Kukka 株 ureY	99%	95%
H.フェリス Ds4 株 ureY	98%	94%
H.フェリス 2301 株 ureY	99%	95%

表1b: H.フェリス ureY と様々な ureB サブユニットとの間のアミノ酸及び核酸の
相同性

【0009】

【表3】

参照分子:H.フェリス ureXY CS1	核酸
H.フェリス ureAB	67%
H.ピロリ ureAB	67%
H.ヘイルマンニ ureAB	68%
H.フェリス Kukka 株 ureXY	94%
H.フェリス Ds4 株 ureXY	94%
H.フェリス 2301 株 ureXY	94%

表1c: H.フェリス ureXY 遺伝子と様々な ureAB 遺伝子との間の核酸相同性

【0010】従って、本発明の一つの実施形態は、新規なウレアーゼX及びYサブユニットをコードする核酸配列に関する。

【0011】第一に、本発明のこの実施形態は、配列番号1と少なくとも85%の相同性を有する、ヘリコバクター・フェリスにより発現されるようなウレアーゼ複合体の2つのサブユニットをコードする核酸配列、又は該サブユニットのうちの一つの免疫原性断片を少なくともコードする、少なくとも40ヌクレオチド、好ましくは45ヌクレオチド、より好ましくは50ヌクレオチドの長さを有するその一部に関する。少なくとも55核酸、60核酸又は70核酸の長さを有する、さらに長い断片は、その順にさらに好ましい。

【0012】この実施形態の好ましい形態は、ウレアーゼXサブユニット・ポリペプチドもしくはウレアーゼYサブユニット・ポリペプチドをコードし、かつ配列番号

1と少なくとも85%の相同性を有する核酸配列、又はウレアーゼXサブユニット・ポリペプチドもしくはウレアーゼYサブユニット・ポリペプチドの免疫原性断片を少なくともコードする、少なくとも40ヌクレオチド、好ましくは45ヌクレオチド、より好ましくは50ヌクレオチドの長さを有するそれらの一部に関する。単なる例として、ヘリコバクター・フェリスCS1株のウレアーゼXサブユニットをコードする核酸配列は、206/207/208位(GTG)(図1a(1)参照)で開始し、884/885/886位(TAA)で終了する。ヘリコバクター・フェリスCS1株のウレアーゼYサブユニットをコードする核酸配列は、897/898/899位(ATG)で開始し、2601/2602/2603位(TAG)で終了する。少なくとも55核酸、60核酸又は70核酸の長さを有する、さらに長い断片は、その順にさらに好ましい。

【0013】この実施形態のさらに好ましい形態は、配列番号1と少なくとも90%、好ましくは94%、より好ましくは97%の相同性を有する核酸配列に関する。

【0014】相同率の決定は、サイエンティフィックアンドエデュケーションソフトウェア(Scientific and Educational Software)(P.O.Box72045 Durham, NC27722-2045, USA)から入手可能なコンピュータプログラム、アラインプラスフォーウィンドウズ(登録商標)(Align Plus for Windows(登録商標))を用いて実施された。核酸比較に使用された設定は、図1a、1b及び1cに示されている。

【0015】本発明は、新規な構造ヘリコバクター・フェリス・ウレアゼ・サブユニットをコードする核酸配列を開示しているため、そのようなポリペプチドを十分な量で入手することが初めて可能となった。これは、例えば、UreX及びUreYサブユニットをコードする遺伝子を発現させるため発現系を使用することにより実施されうる。従って、より好ましい実施形態において、本発明は、本発明に係る核酸配列を含むDNA断片に関する。そのようなDNA断片は、例えば、本発明に係る核酸がクローニングされているプラスミドでありうる。そのようなDNA断片は、例えば、下記のように、プロープとして使用するためDNAの量を増強するために有用である。

【0016】核酸配列の発現のための必須の要件は、核酸配列と機能的に連結した適切なプロモーターである。プロモーターの選択が、タンパク質発現のため宿主細胞として使用される細胞において遺伝子転写を指図することができる任意の真核生物、原核生物又はウイルスのプロモーターに及ぶことは、当業者には明らかである。従って、この実施形態のさらに好ましい形態は、機能的に連結したプロモーターの調節下に置かれた本発明に係るDNA断片又は核酸配列を含む組換えDNA分子に関する。これは、例えば標準的な分子生物学的技術により入手可能である。(Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989. ISBN0-87969-309-6)。

【0017】機能的に連結したプロモーターとは、それらが連結している核酸配列の転写を調節することができるプロモーターである。宿主細胞が細菌である場合、使用されうる有用な発現調節配列には、Trpプロモーター及びオペレーター(Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980)、lacプロモーター及びオペレーター(Chang, et al., Nature, 275, 615, 1978)、アウターメンブレンプロテイン・プロモーター(Nakamura, K., and Inoug

e, M., EMBO J., 1, 771-775, 1982)、バクテリオファージラムダ・プロモーター及びオペレーター(Remaut, E. et al., Nucl. Acid Res., 11, 4677-4688, 1983)、 λ -アミラーゼ(B.ズブチリス)プロモーター及びオペレーター、終結配列、並びに選択された宿主細胞と適合性のその他の発現増強調節配列が含まれる。宿主細胞が酵母である場合、有用な発現調節配列には、例えば λ -接合因子が含まれる。昆虫細胞の場合、バキュロウイルスのポリヘドリン・プロモーター又はp10プロモーターが使用されうる(Smith, G.E. et al., Mol. Cell. Biol., 3, 2156-65, 1983)。宿主細胞が哺乳動物起源である場合、例示的な有用な発現調節配列には、SV-40プロモーター(Berman, P.W. et al., Science, 222, 524-527, 1983)又はメタロチオネイン・プロモーター(Brinster, R.L., Nature, 296, 39-42, 1982)又は熱ショック・プロモーター(Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985)が含まれる。

【0018】細菌、酵母、真菌、昆虫及び哺乳動物の細胞発現系は、極めて頻繁に使用されている系である。そのような系は、当分野において周知であり、一般的に、例えばクロンテックラボラトリーズ社(Clontech Laboratories, Inc.)(4030 Fabian Way, Palo Alto, California 94303-4607, USA)から市販されている。これらの発現系の次に、寄生虫に基づく発現系が、極めて魅力的な発現系である。そのような系は、例えば、公開第2714074号のフランス特許出願及びUSNTIS公開第08/043109号(Hoffman, S. and Rogers, W.: 公開日1993年12月1日)に記載されている。

【0019】従って、本発明のこの実施形態のさらに好ましい形態は、本発明に係るUreXもしくはUreYポリペプチド又はそれらの免疫原性断片をコードする遺伝子を含む組換え生キャリアー(Live Recombinant Carrier)微生物(LRC)に関する。そのような微生物は、例えば、細菌及びウイルスである。これらのLRC微生物は、付加的な遺伝情報、この場合には、本発明に係るUreXもしくはUreYポリペプチド又はそれらの免疫原性断片をコードする遺伝子がクローニングされている微生物である。そのようなLRCに感染した動物は、ベクターの免疫原に対してのみならず、遺伝暗号、例えばUreX又はY遺伝子がLRCにクローニングされている(一つ又は複数の)ポリペプチドの免疫原性部分に対しても免疫原性応答を生じるであろう。細菌LRCの例として、当分野において

既知の弱毒化サルモネラ株が、魅力的に使用されうる。組換え生キャリアー寄生虫は、特に、バーメウレン (*Vermeulen*) A. N. (*Int. Journ. Parasitol.* 28:1121-1130 (1998)) により記載されている。また、LRCウイルスは、核酸配列を標的細胞に輸送するための手段として使用されうる。組換え生キャリアーウイルスは、ベクターウイルスとも呼ばれる。UreX又はYポリペプチドをコードする遺伝子の組み込み部位は、ウイルスにとって必須ではないウイルス遺伝子内の部位、又は遺伝子間領域内の部位でありうる。ベクターとしてしばしば使用されるウイルスは、ワクシニアウイルス (*E. P. A. 0473210A2*) 及びレトロウイルス (*Valerio, D. et al: in Baum, S. J., Dicke, K. A., Lotzova, E. and Pluznik, D. H., Experimental Haematology today - 1988, Springer Verlag, New York: 92~99頁 (1989)*) である。

【0020】挿入された本発明に係る核酸配列の宿主動物における発現を誘導することができる、選択された細菌、寄生虫又はウイルスのゲノムへ、組換え核酸配列を導入するためには、当分野において周知のインピボ相同的組換え技術が使用されうる。

【0021】本発明のこの実施形態の最後のもう一つの形態は、本発明に係るポリペプチドをコードする核酸配列、そのような核酸配列を含むDNA断片、又は機能的に連結したプロモーターの調節下でそのような核酸配列を含む組換えDNA分子を含む宿主細胞に関する。この形態は、本発明に係るUreXもしくはYポリペプチド又はそれらの免疫原性断片をコードする核酸分子を含有する組換え生キャリアーを含有する宿主細胞にも関する。宿主細胞は、pBR322のような細菌プラスミド又はpGEXのような細菌発現ベクター、又はバクテリオファージと組み合わせられた、細菌起源、例えば大腸菌、パチルス・ズブチリス (*Bacillus subtilis*)、及びラクトパチルス (*Lactobacillus*) 種の細胞でありうる。宿主細胞は、真核生物起源のもの、例えば酵母特異的ベクター分子と組み合わせられた酵母細胞、又はベクターもしくは組換えバキ
 ュロウイルスと組み合わせられた昆虫細胞 (*Luckow et al; Bio-technology 6: 47-55 (1988)*)、例えばTiプラスミド型ベクターもしくは植物ウイルスベクター (*Barton, K. A. et al; Cell 32: 1033 (1983)*) と組み合わせられた植物細胞、やはり適切なベクターもしくは組換えウイルスと組み合わせられたHeLa細胞、チャイニーズハムスター卵巣細胞 (CHO) もしくは克蘭デル (*Crandell*) ネコ腎細胞のような哺乳動物細胞のような高等真核細胞であつてもよ

い。

【0022】本発明のもう一つの実施形態は、核酸配列によりコードされるポリペプチド、即ち、ウレアーゼXサブユニット及びウレアーゼYサブユニットに関し、そして本発明に係るそれらの免疫原性断片に関する。

【0023】従って、本発明のこの実施形態は、配列番号2と少なくとも85%相同なアミノ酸配列を有する、ヘリコバクター・フェリス・ウレアーゼXポリペプチド、又はウレアーゼXYに対する免疫応答を誘導する能力を有する、少なくとも40アミノ酸の長さを有する、該ポリペプチドの免疫原性断片に関する。好ましくは、該断片の長さは40アミノ酸超であり、少なくとも45アミノ酸、50アミノ酸、55アミノ酸、60アミノ酸又は70アミノ酸が、この順に、より好ましい。

【0024】好ましくは、この実施形態は、配列番号2と少なくとも90%、より好ましくは94%、さらに好ましくは97%の配列相同性を有するそのようなポリペプチド、又はウレアーゼXYに対する免疫応答を誘導する能力を有する、少なくとも40アミノ酸、より好ましくは少なくとも45アミノ酸、50アミノ酸、55アミノ酸、60アミノ酸もしくは70アミノ酸 (この順に、より好ましい) の長さを有する、該ポリペプチドの免疫原性断片に関する。

【0025】本発明のこの実施形態は、配列番号3と少なくとも85%相同なアミノ酸配列を有する、ヘリコバクター・フェリス・ウレアーゼYポリペプチド、又はウレアーゼXYに対する免疫応答を誘導する能力を有する、少なくとも40アミノ酸の長さを有する、該ポリペプチドの免疫原性断片に関する。好ましくは、該断片の長さは40アミノ酸超であり、少なくとも45アミノ酸、50アミノ酸、55アミノ酸、60アミノ酸又は70アミノ酸が、この順に、より好ましい。

【0026】好ましくは、この実施形態は、配列番号3と少なくとも90%、より好ましくは94%、さらに好ましくは97%の配列相同性を有するそのようなポリペプチド、又はウレアーゼXYに対する免疫応答を誘導する能力を有する、少なくとも40アミノ酸、より好ましくは少なくとも45アミノ酸、50アミノ酸、55アミノ酸、60アミノ酸もしくは70アミノ酸 (この順に、より好ましい) の長さを有する、該ポリペプチドの免疫原性断片に関する。

【0027】ヌクレオチド配列比較の場合と同様に、サイエンティフィックアンドエデュケーションソフトウェア (*Scientific and Educational Software*) (P.O. Box 72045 Durham, NC 27722-2045, USA) から入手可能なアラインプラスフォーウィンドウズ (*Align Plus for Windows*) を使用して様々なアミノ酸配列間の比較を実施した。アミノ酸比較に使用された設定は、図1a、1b及び1cに

示されている。

【0028】本明細書に含まれている特定のポリペプチドについて、個々のヘリコバクター・フェリス株の間には天然の差異が存在しうることが理解されよう。これらの差異は、全体的な配列における(一つ又は複数の)アミノ酸の違い、又は該配列内の(一つ又は複数の)アミノ酸の欠失、置換、挿入、逆位もしくは付加により示されうる。生物学的活性及び免疫学的活性を本質的に改変しないアミノ酸置換は、例えば「タンパク質(the Proteins)」Academic Press New York(1979)においてニューラス(Neurath)らにより記載されている。関連アミノ酸間のアミノ酸交換、又は進化において高頻度に行っている交換は、特に、Ser/Ala、Ser/Gly、Asp/Gly、Asp/Asn、Ile/Valである(Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978年、第5巻増補3参照)。その他のアミノ酸置換には、Asp/Glu、Thr/Ser、Ala/Gly、Ala/Thr、Ser/Asn、Ala/Val、Thr/Phe、Ala/Pro、Lys/Arg、Leu/Ile、Leu/Val及びAla/Gluが含まれる。この情報に基づき、リップマン(Lipman)及びピアソン(Pearson)は、迅速かつ高感度にタンパク質を比較し(Science, 227, 1435-1441, 1985)、相同タンパク質間の機能的類似性を決定する方法を開発した。本発明の例示的な実施形態のそのようなアミノ酸置換も、欠失及び/又は挿入を有する差異も、得られたポリペプチドが免疫応答性を保持している限りにおいて、本発明の範囲に含まれる。従って、配列番号2又は3に示されたような野生型ポリペプチドと比較した場合の、ポリペプチドの免疫原性に本質的に影響を与えない差異は、本発明の範囲に含まれると見なされる。H.フェリス感染、又は少なくとも感染の臨床的発現に対する免疫応答を誘導する能力を有するポリペプチドを提供する、本発明に係るいくつかの構造サブユニットX又はYのアミノ酸配列のこれらの差異は、「免疫原性に本質的に影響を与えない」と見なされる。

【0029】例えばワクチン目的又は抗体の惹起のためポリペプチドを使用する場合、完全なポリペプチドを使用する必要はない。そのまま、又は例えばKLHのような担体とカップリングして、ポリペプチドに対する免疫応答を有する能力を有するポリペプチドの断片、いわゆる免疫原性断片を使用することも可能である。「免疫原性断片」とは、宿主において免疫応答を誘導する能力を保持している、即ちB細胞エピトープ又はT細胞エピトープを含む、構造サブユニットX又はYの全長ポリペ

プチドの断片と理解される。現時点で、抗原性断片(決定基)をコードするDNA断片を容易に同定するための多様な技術が利用可能である。ゲイセン(Geyesen)ら(特許出願WO84/03564、特許出願WO86/06487、米国特許第NR.4,833,092号、Proc. Natl. Acad. Sci. USA, 81:3998-4002(1984)、J. Imm. Meth. 102, 259-274(1987))により記載された方法、いわゆるPEPSCAN法は、エピトープ、ポリペプチドの免疫学的に重要な領域を検出するための、実施が容易で、迅速で、かつ十分に確立されている方法である。この方法は世界中で使用されており、当業者に自体周知である。この(経験的な)方法は、B細胞エピトープの検出に特に適している。また、任意のタンパク質をコードする遺伝子の配列が与えられれば、コンピュータアルゴリズムが、現在既知であるエピトープとの配列及び/又は構造の一致性に基づき、免疫学的に重要なエピトープとして特定のポリペプチド断片を指定することができる。これらの領域の決定は、ホップ(Hopp)及びウッズ(Woods)(Proc. Natl. Acad. Sci. USA, 78:38248-3828(1981))による親水性基準と、チョウ(Chou)及びファスマン(Fasman)(Advances in Enzymology 47:45-148(1987)及び米国特許第4,554,101号)による二次構造面との組み合わせに基づいている。T細胞エピトープは、同様に、バーゾフスキー(Berzofsky)の両親媒性基準(Science 235, 1059-1062(1987)及び米国特許出願NTIS US 07/005,885)を利用して、コンピュータにより配列から予測されうる。要約された概要が、一般原理についてはShan Lu: Tibtech 9:238-242(1991)に、マラリア・エピトープについてはGood et al; Science 235:1059-1062(1987)に、概説についてはLu; Vaccine 10:3-7(1992)に、HIVエピトープについてはBerzowsky; The FASEB Journal 5:2412-2418(1991)に見出される。

【0030】例えば、唯一つのウレアーゼを有するヘリコバクター・ピロリに対するワクチンが、前記のように、このウレアーゼに基づき製造されうる。しかしながら、ヘリコバクター・フェリスの特定の場合、既知のヘリコバクター・フェリス構造サブユニットure A及びBに基づくワクチンは、ヘリコバクター・フェリス感染に対する十分な防御を提供することができない。報告によると、構造サブユニットure A及びBに対する免疫は、新たに見出された異種構造サブユニットUre X及びYのウレアーゼ活性を中和しない。

【0031】従って、ヘリコバクター・フェリス感染からの動物の防御のためのワクチンは、少なくとも、新規なウレアーゼXYに対するものでなければならない。従って、本発明のさらにもう一つの実施形態の一つの形態は、本発明に係る構造サブユニットXもしくはY、好ましくはX及びY、より好ましくはX、Y、A及びB、又はX及び/もしくはYの免疫原性断片を、薬学的に許容される担体と共に含む、ヘリコバクター・フェリス感染からイヌ及びネコのような動物を防御することができるワクチンに関する。

【0032】本発明のさらにもう一つの実施形態は、ワクチンにおいて使用するための本発明に係るポリペプチドに関する。

【0033】さらにもう一つの実施形態は、ヘリコバクター・フェリス感染に対抗するためのワクチンの製造における本発明に係るポリペプチドの使用に関する。

【0034】本発明に係るワクチンを製造する一つの方法は、ウレアーゼXYポリペプチド又はそのサブユニットの細菌培養物からの生化学的な精製による。これは、例えば、細菌の遠心分離、及びウレアーゼポリペプチド又はそのサブユニットの他の成分からの分離のためのゲル濾過カラムの使用により実施されうる。さらなる精製は、例えば、硫酸アンモニウムで選択的に沈殿させ、続いて遠心分離、ゲル電気泳動を行い、そして、所望により、ウレアーゼABサブユニットからの分離を行い、そして適当な緩衝液にペレットを溶解させることにより実施されうる。しかしながら、これは、ヘリコバクター・フェリスを増殖させることが困難である場合には特に、多大の時間を要するワクチン製造法である。

【0035】従って、本発明に係るウレアーゼX及びYサブユニットをコードする遺伝子の発現産物をワクチンにおいて使用する方が、はるかに便利である。そのようなワクチンは、本発明に係るウレアーゼXY又はUreXもしくはYサブユニット又はそれらの免疫原性断片と、下記のような薬学的に許容される担体とを混合することにより、容易に製造されうる。

【0036】さらに、ワクチンは、本発明に係るウレアーゼXY、UreXもしくはUreYサブユニット、又はそれらの免疫原性断片を発現することができる、前記のような組換え生キャリアーを含んでいてもよい。例えば、胃上皮に感染するサルモネラキャリアー又はウイルスキャリアーに基づく、そのようなワクチンは、天然のヘリコバクター・フェリス感染様式を、よりよく模倣するという、他のサブユニットワクチンより優れた利点を有する。さらに、それらの自己繁殖は、少量の組換えキャリアーのみが免疫感作に必要となるため、有利である。

【0037】前記のワクチンは、全て、能動予防接種に寄与する、即ち宿主の免疫系が、これらのポリペプチドに対する抗体を作るよう、UreX及び/もしくはYポ

リペプチド、又はそれらの免疫原性断片により誘発される。又は、そのような抗体を、例えばウサギにおいて惹起させることもできるし、又は下記のような抗体産生細胞系から入手することもできる。次いで、そのような抗体は、宿主動物へ投与されうる。この予防接種法、受動予防接種は、動物が既に感染しており、天然の免疫応答が誘発されるのを待つ時間が存在しない場合に、選択される予防接種である。また、免疫不全動物を予防接種するための好ましい方法でもある。投与されたヘリコバクターUreX又はUreYに対する抗体は、これらの場合、細菌により分泌されたウレアーゼと直接結合することができる。これは、ウレアーゼ活性が直接的に排除され、従って、環境が酸性化され、ヘリコバクター増殖が減少又は停止するという利点を有する。従って、本発明のこの実施形態のもう一つの形態は、配列番号2と少なくとも85%相同なアミノ酸配列を有するヘリコバクター・フェリス・ウレアーゼXポリペプチド、もしくはウレアーゼXYに対する免疫応答を誘導する能力を有する少なくとも40アミノ酸長を有するポリペプチドの免疫原性断片に対する抗体、又は配列番号3と少なくとも85%相同なアミノ酸配列を有するヘリコバクター・フェリス・ウレアーゼYポリペプチド、もしくはウレアーゼXYに対する免疫応答を誘導する能力を有する少なくとも40アミノ酸長を有するポリペプチドの免疫原性断片に対する抗体を含むワクチンに関する。

【0038】ワクチンは、本発明に係るウレアーゼXY、UreXもしくはUreYサブユニット、又はそれらの免疫原性断片を含む、前記のような宿主細胞に基づいていてもよい。

【0039】別の効率的な予防接種法は、関連抗原をコードするDNAによる直接予防接種である。ポリペプチドをコードするDNAによる直接予防接種は、多くの異なるポリペプチドについて成功している(例えば、Donnelly et al., The Immunologist 2:20-26(1993)に概説されている)。この予防接種法は、ヘリコバクター・フェリス感染に対するネコ及びイヌ両方の予防接種にとって極めて魅力的である。従って、本発明のこの実施形態のさらに他の形態は、本発明に係るポリペプチド又は本発明に係るそれらの免疫原性断片をコードする核酸配列を含むワクチンに関し、そしてそのような核酸配列を含むDNA断片を含むワクチンに関する。この実施形態のさらに他の形態は、本発明に係る組換えDNA分子を含むワクチンに関する。DNAワクチンは、例えば針なしの注射器を使用して、経皮的適用により容易に投与されうる。この投与法は、予防接種すべき動物の細胞へDNAを直接輸送する。1~100µgのマイクログラム範囲の量のDNAが、極めて良好な結果を提供する。

【0040】さらなる実施形態において、本発明に係るワクチンは、イヌもしくはネコにとって病原性の生物及

びウイルスに由来する抗原、又はそのような抗原をコードする遺伝情報を含んでいてもよい。そのような生物及びウイルスは、例えば、ネコ伝染性腹膜炎ウイルス(Feline Infectious Peritonitis virus)、ネコ免疫不全ウイルス(Feline Immunodeficiency virus)、イヌ及びネコのパルボウイルス(Canine and Feline Parvovirus)、ジステンパーウイルス(Distemper virus)、アデノウイルス(Adenovirus)、カリシウイルス(Calicivirus)、ポーデテラ・ブロンキセプチカ(Bordetella bronchiseptica)、ボレリア・ブルグドルフェリ(Borrelia burgdorferi)、レプトスピラ・インテロガンス(Leptospira interrogans)、クラミジア(Chlamydia)及びパートネラ・ヘンセリ(Bartonella henseli)である。

【0041】また、本発明は、ヘリコバクター・フェリス感染に対抗するためのワクチンの製造において使用するための、本発明に係るポリペプチドに関する。

【0042】本発明に係るワクチンは、全て、薬学的に許容される担体を含む。薬学的に許容される担体は、例えば、無菌水又は無菌生理的塩溶液である。より複雑な形態において、担体は、例えば緩衝液であってもよい。

【0043】本発明に係るワクチンは、好ましくは、アジュバントも含有していてもよい。アジュバントは、一般的に、非特異的に宿主の免疫応答を強化する物質を含む。多数の異なるアジュバントが、当分野において既知である。アジュバントの例は、フロイント完全アジュバント及び不完全アジュバント、ビタミンE、非イオン性ブロック重合体、ムラミルジペプチド、Quill A (登録商標)、鉱油、例えばBayol (登録商標)又はMarkol (登録商標)、植物油、及びCarbopol (登録商標) (同種重合体)又はDiluvac (登録商標) Forteである。ワクチンは、いわゆる「媒体」を含んでいてもよい。媒体とは、ポリペプチドが、共有結合することなく接着する化合物である。しばしば使用される媒体化合物は、例えばアルミニウムの水酸化物、リン酸塩、又は酸化物、シリカ、カオリン及びベントナイトである。抗原が媒体に部分的に埋め込まれている特別な形態のそのような媒体は、いわゆるISCOMである(EP109,942、EP180,564、EP242,380)。さらに、ワクチンは、一つ又は複数の適当な界面活性化合物又は乳化剤、例えばスパン(Span)又はトウィーン(Tween)を含みうる。しばしば、ワクチンは、例えば分解傾向のあるポリペプチドを分解から防御するため、ワクチンの貯蔵寿命を増強するため、又は凍結乾燥効率を改善するため、安定化剤と混合される。有用な安定化剤は、特に、SP

GA (Bovarnik et al; J. Bacteriology 59:509 (1950))、炭水化物、例えばソルビトール、マンニトール、トレハロース、デンプン、ショ糖、デキストラン又はグルコース、アルブミンもしくはカゼインのようなタンパク質又はそれらの分解産物、並びにアルカリ金属リン酸塩のような緩衝剤である。さらに、生理学的に許容される希釈剤にワクチンを懸濁させてもよい。言及するまでもなく、アジュバントによる強化、媒体化合物又は希釈剤の添加、ポリペプチドの乳化又は安定化のその他の方法も、本発明に包含される。

【0044】UreX又はUreYサブユニット・ポリペプチドを含む本発明に係るワクチンは、1~100マイクログラムの範囲の量で、特に好適に投与されうるが、それより少ない用量も、原則的には使用されうる。

100マイクログラムを越える量は、免疫学的には極めて適当であるが、商業的な理由からは魅力的ではない。

【0045】前記のLRCウイルス及びLRC細菌のような生弱毒化組換えキャリアーに基づくワクチンは、感染中に自己複製するため、はるかに少ない用量で投与されうる。従って、極めて適当な量は、それぞれ細菌及びウイルスについて $10^3 \sim 10^9$ CFU/PFUの間であらう。

【0046】多くの投与法が適用されうる。鼻腔内適用は、ワクチンを投与するための高頻度で使用されている方法である。感染はしばしば消化管上部に位置しているため、経口投与も魅力的な投与法である。経口投与の好ましい方法は、高度に酸性の胃環境においてのみ崩壊する、当分野において既知であり高頻度で使用されているカプセル内へのワクチンのパッケージングである。また、ワクチンを胃のpHを一時的に増強するための、当分野において既知の化合物と混合してもよい。例えば、ワクチンの筋肉内適用による全身適用も適当である。この経路による場合、全身適用のための当分野において既知の標準的な手法が、非常に適している。

【0047】本発明のもう一つの実施形態は、H.フェリス感染の検出のための診断テストに関する。H.ビッゾゼロニー(bizzozeronii)、H.フェリス及びH.サロモニス(salomonis)のようないくつかのヘリコバクター種が、ネコ及びイヌの両方に感染する能力を有する。これらの3種のうち、H.ビッゾゼロニー及びH.サロモニスはしばしば数で勝るが、病理の大部分を引き起こしていると推測される種は、H.フェリスである。従って、ヘリコバクター・フェリスにより引き起こされたネコ及びイヌの両方における疾患の迅速かつ正確な診断は、重要である。しかしながら、これらの3種は極めて密接に関連しているため、区別することが極めて困難であった。従って、他のヘリコバクター種からH.フェリスを区別するために適した診断道具を提供することが、本発明のもう一つの目的であ

る。

【0048】新規なウレアーゼポリペプチド及びウレアーゼポリペプチドをコードする遺伝子に基づき、ヘリコバクター科の他の細菌からH. フェリスを区別するために特に適した少なくとも3つの異なる診断テストが開発された。1) 特異的なUreX及びUreY構造サブユニットをコードするDNAの存在又は欠如に基づく診断テスト。2) 特異的なUreX及びUreY構造サブユニットに対する抗体の検出に基づく診断テスト。3) 特異的なUreX及びUreY構造サブユニットの抗原性物質の検出に基づく診断テスト。

【0049】1)の診断テストは、例えば、試験すべき動物から単離された細菌DNAと、ureX又はY遺伝子の配列に基づく特異的なプローブ又はPCRプライマーとの反応に基づいている。H. フェリスDNAが動物に存在する場合には、これは、例えばureX又はY特異的PCRプライマーと特異的に結合し、その後、PCR反応において増幅されるであろう。次いで、PCR反応産物は、DNAゲル電気泳動において容易に検出される。DNAは、試験すべき動物の消化管上部のスワブ又は唾液に存在する微生物から最も容易に単離される。特異的プライマーは、ureABコーディング配列内の比較可能な領域とは配列が異なる、ureX及びureYコーディング配列並びに非コーディング遺伝子間配列の多くの領域から容易に選択される。一般的な核酸相同性レベルの決定及びヌクレオチド配列の比較に適した多くのアルゴリズムのうちの一つは、「クラスタル(Clustal)W」として既知である。それは、Nucleic Acid Research 22:4673-4680(1994)にトンプソン(Thompson)らにより記載されている。このプログラムは、インターネット上のいくつかのサイトに見出される。このプログラムのより最近の代替物は、例えば、サイエンティフィックアンドエデュケーションソフトウェア(Scientific and Educational Software)(P.O. Box 72045 Durham, NC 27722-2045, USA)から入手可能なアラインプラスフォーウィンドウズ(Align Plus for Windows)である。図1の通り、ureX又はureYに特異的な可能性のあるPCRプライマーを、極めて多数見出すことができる。極めて特異的なPCRプローブ対は、例えば、5'に位置する配列CATGCACTTTTGA AAAAAGA(配列番号16)及び3'に位置する配列TATGGTGGTCTTCTCT(配列番号17)である。当然、ureXもしくはY又は遺伝子間領域に特異的なその他の多くの配列が適している。標準的なPCR参考書は、ureX又はureYとの選択的なPCR反応のためのプローブの妥当性を決定するための方法を与えている。PCR技術は、(Dieffenbac

h&Dreksler; PCR primers, a laboratory manual, ISBN 0-87969-447-5(1995))に詳細に記載されている。

【0050】もう一つのDNA型テストは、スワブから得られた細菌物質の増殖、それに続く古典的なDNA精製、それに続く放射性又は色素で標識されたureXY特異的DNA断片との古典的ハイブリダイゼーションに基づく。H. フェリス及びその他のヘリコバクター種、両方のureXYコーディング領域とureABコーディング領域との間の相同性は極めて低いいため、ハイブリダイゼーションは、H. フェリスの存在又は欠如を明確に示す。PCR反応及びハイブリダイゼーション反応は、いずれも、当分野において周知であり、特に、Maniatis/Sambrook(Sambrook, J. et al. Molecular cloning: a laboratory manual, ISBN 0-87969-309-6)に記載されている。PCRプライマーによる選択的検出又はureXY特異的DNA断片との古典的ハイブリダイゼーションは、好ましくは短い断片を用いて実施されるが、実用的な理由から、好ましくは配列番号1の少なくとも10連続ヌクレオチドのストレッチからなる断片を用いて実施される。ハイブリダイゼーション実験には、ヘリコバクターureA又はureBサブユニットをコードする配列との相同性よりも、配列番号1との相同性の方が高いプローブを選択する必要がある。そのようなプローブは、前記のようなアラインプラスフォーウィンドウズ(Align Plus for Windows)プログラム又はクラスタルWプログラムを利用して、極めて容易に選択される。比較ハイブリダイゼーション実験において、診断すべきDNAは、例えばH. ピロリDNAの隣でテストされる。ureABをコードする遺伝子との相同性よりも配列番号1との相同性の方が高い、本発明に係るプローブは、他のヘリコバクター種のDNAよりも、H. フェリスDNA(試料中に存在する場合)と強く結合し、従って、テストすべき試料中のH. フェリスDNAの存在を特異的に示すであろう。前記の配列番号16又は17の配列は、標識し、その後、記載されたようなH. フェリス特異的ハイブリダイゼーション・アッセイにおいて使用するために極めて適しているプローブの例にすぎない。

【0051】従って、本発明の一つの実施形態は、特異的なヘリコバクターUreX及びUreYサブユニット・ポリペプチドをコードするDNAの検出のための診断テストに関する。そのようなテストは、UreX及びUreYをコードするDNA、又はUreXとUreYとの間の遺伝子間領域に特異的な、本発明に係る核酸配列又はそれらの断片を含む。そのDNAに特異的な断片は、UreA及びUreBをコードするDNA、又はU

reAとUreBとの間の遺伝子間領域よりも、UreX及びUreYをコードするDNA、又はUreXとUreYとの間の遺伝子間領域と、強く結合する断片である。

【0052】ヘリコバクター・フェリスDNAの検出方法は、テストすべきDNAとUreX又はY DNAとのハイブリダイゼーション、又はテストすべきDNAのUreX又はY DNA特異的プローブによるPCR反応を含む。

【0053】血清中のヘリコバクター・フェリス抗体の検出のための2)の診断テストは、例えば、精製された本発明に係るUreXもしくはUreYサブユニット・ポリペプチド又はそれらの抗原性断片を、ELISAプレートのウェルの壁にコーティングする、単純なサンドイッチELISAテストである。そのような抗体の検出のための方法は、例えば、精製されたUreX又はYポリペプチドを、試験すべき哺乳動物由来の血清と共にインキュベートし、それに続き、例えば関連哺乳動物抗体に対する標識抗体と共にインキュベートする方法である。次いで、呈色反応により、ヘリコバクター・フェリスウレアーゼXYに対する抗体の存在又は欠如を明らかにすることができる。使用される標識抗体によっては、この系の選択性は、非XY特異的反応を回避するため、試験すべき血清をウレアーゼABと共にプレインキュベートし、それに続き、沈殿物の遠心分離を行うことにより改善される。本発明に係るUreX又はUreY構造サブユニットの抗原性断片をコーティングに使用する場合、プレインキュベーション工程を省略することができる。

【0054】診断テスト系のもう一つの例は、例えば、本発明に係るUreXもしくはUreYポリペプチド又はそれらの抗原性断片を含むウェスタンブロットと、テストすべき哺乳動物の血清とのインキュベーション、それに続くブロットの分析である。ELISAプレートのコーティング又はウェスタンブロットにに適した、精製された本発明に係るUreXもしくはUreY構造サブユニット又はそれらの抗原性断片は、ureA及びBについてフェレロ(Ferrero et al., Molec. Microbiol. 9, 323-333 (1993))が記載したような、ureX及びureY遺伝子の発現により容易に入手される。

【0055】又、本発明は、血清と、本発明に係るUreXもしくはUreYポリペプチド又はそれらの抗原性断片とのインキュベーションを含む、ヘリコバクター・フェリス抗体に対する抗体の血清中の検出のための方法に関する。

【0056】ヘリコバクター・フェリス抗原の特異的UreX及びUreY構造サブユニットの抗原性物質の検出に基づいており、従って、ヘリコバクター・フェリス感染の検出に適した3)の診断テストは、標準的なEL

ISAテストでありうる。そのような試験の一つの例においては、ELISAプレートのウェルの壁に、ヘリコバクター・フェリスの特異的UreX及びUreY構造サブユニットに対する抗体をコーティングする。試験すべき抗原性物質は、必要に応じて、UreA及びBに対する抗体とプレインキュベートされる。これにより、UreX及びY特異的エピトープはカバーされず、従って、プレインキュベートされたヘリコバクター種は、UreX又はYを含む場合にのみ、即ち特異的にヘリコバクター・フェリスである場合にのみ、ELISAプレートと結合するであろう。UreX又はYに特異的であり、UreA又はBとは反応しないモノクローナル抗体の使用は、プレインキュベーション工程を不要とするため、そのようなテストにおける好ましい抗体である。そのようなモノクローナル抗体は、当分野において既知の技術により、本発明に係るUreX又はYの免疫感作断片で、近交系マウスを免疫感作することにより容易に得ることができる(下記Kohler and Milstein論文参照)。

【0057】前記のようにして発現させた本発明に係るポリペプチド又はそれらの免疫原性断片は、ポリクローナルであっても、単一特異的もしくはモノクローナルであってもよい抗体(又はそれらの誘導体)を製造するために使用される。ポリクローナル抗体が望ましい場合、ポリクローナル血清を製造し、加工する技術は、当分野において周知である(例えば、Mayer and Walter, *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987)。本発明に係るポリペプチド(又はそれらの異型又は断片)と反応する、本発明に係るモノクローナル抗体は、やはり当分野において既知の技術により近交系マウスを免疫感作することにより調製される(Kohler and Milstein, *Nature*, 256, 495-497, 1975)。

【0058】最後に、本発明は、血清、組織又は体液を、本発明に係るUreXもしくはUreYポリペプチド又はそれらの断片に対する抗体と共にインキュベートすることを含む、ヘリコバクター・フェリス由来の抗原性物質の検出のための方法に関する。

【0059】実施例1

ヘリコバクター・フェリスCS1株のureX及びureY遺伝子：大腸菌におけるクローニング及び発現
以下のようにして、H.フェリスCS1株のureX及びureY遺伝子を、大腸菌T7発現ベクターpET3aにオペロンとしてクローニングした。pET3a(Novagen, 601 Science Drive, Madison WI, USA)におけるUreX及びYタンパク質の適切な発現のため、遺伝子をNdeI-B

amHI DNA断片として、このベクターのNdeI - BamHIにクローニングした。ウレアーゼXYオペロンは、内部NdeI部位を含有しており、それに、2つのPCR断片のオーバーラップ伸長PCRにより突然変異を導入した。その目的のため、2つのPCR断片(5'及び3'産物)を、H.フェリスCS1の染色体DNAを鋳型として使用して増幅した。5' PCR産物は、完全なureX遺伝子及びureY遺伝子の最初の部分を含んでいた。順向きプライマーは、NdeI制限部位及びureXの開始コドンを含んでおり(GG 10 AGTAACATATGAACTCACACCCAAAGAGC)(配列番号18)、逆向きプライマーは、点突然変異を含有している(CACACCCACGACCATGTGAGGGCTTAC)(配列番号19)。第二の3' PCR産物は、ureY遺伝子の3'末からなっていた。この順向きプライマーは、第一PCR産物の逆向きプライマーと相補的であり、同一の点突然変異も含有しており(GTAAGCCCTCACATGGTCGTGGGTGTG)(配列番号20)、逆向きプライマーは、ureY遺伝子の終止コドンの直下流にBa 20 mHI制限部位を含有していた(CG AATTCGGA TCCTAGAAGAAAGTG TAGCGCTGG)(配列番号21)。ureY内の内部NdeI部位を欠失させるための突然変異を、相補的プライマー内に作成し、それは、CAIATG(His-Met)をCACATG(His-Met)に交換した。両PCR産物の増幅後、両PCR産物を鋳型として使用した、ureXの順向きプライマー及びureYの逆向きプライマーによるオーバーラップ伸長PCRにより、完全なオペロン

を得た。得られたPCR産物を、PCR-blunt11-TOPO(Invitrogen、P.O.Box 2312, 9704CH Groningen, The Netherlands)へクローニングし、大腸菌TOP10F'細胞(Invitrogen)へ形質転換した。陽性クローンを単離し、ウレアーゼXY遺伝子をpET3aにNdeI-BamHIを用いてサブクローニングした。得られたプラスミドをpUreXY-1と命名し、発現株HMS174(DE3)/pLysS(Novagen)へと形質転換した。

【0060】以下のようにして、pUreXY-1のureX遺伝子及びureY遺伝子をHMS174(DE3)/pLysSにおいて発現させた。一夜培養物をTBamp¹⁰⁰Cam²⁵で1/100に希釈し、この培養物を37℃で200rpmで3時間インキュベートした。1mMのIPTGを添加することにより培養物を誘導し、200rpmで37℃でさらに3時間インキュベートした。誘導を、小規模で1回、大規模で1回、計2回実施した。誘導した試料を、SDS-PAGEゲルで分析した(図2)。レーン9に明確に見られるように、誘導した場合のUreX及びUreYの発現は、2つの構造サブユニットを、UreXサブユニットについては25kDa、UreYサブユニットについては62kDaの分子量を有するポリペプチド・バンドとして提供する。

【0061】

【配列表】

【0062】

【化1】

SEQUENCE LISTING

<110> AKZO Nobel N.V.

<120> Helicobacter vaccine

<130> Degoedesequenties

<140>

<141>

<160> 21

<170> PatentIn Ver. 2.1

<210> 1

<211> 2883

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (206)..(886)

<220>

<221> CDS

<222> (897)..(2603)

<400> 1

rggragattt tccarcactt caagcacata ttgatcctgt gttgtgggtg gtaaattrcr 60

acttgtaat rctattatta atttttaat aattacttat tatcatatat aataatatta 120

ttacttatat taaaaagtta ataaaaagta acgaaattag gactataate ccattgcctt 180

taaaatttaa cacaaggagt aatag gtg aaa ctc aca ccc aaa gag caa gaa 232

Val Lys Leu Thr Pro Lys Glu Gln Glu

1

5

aag ttc ttg tta tat tat gcg ggc gaa gtg gct aga aag cgc aaa gca 280
Lys Phe Leu Leu Tyr Tyr Ala Gly Glu Val Ala Arg Lys Arg Lys Ala
10 15 20 25
gag ggc tta aag ctc aac caa ccc gaa gcc att gct tac att agt gcc 328
Glu Gly Leu Lys Leu Asn Gln Pro Glu Ala Ile Ala Tyr Ile Ser Ala
30 35 40
cat att atg gac gaa gcg cgc cgt gga aaa aaa acc gtt gcc cag ctt 376
His Ile Met Asp Glu Ala Arg Arg Gly Lys Lys Thr Val Ala Gln Leu
45 50 55
atg gaa gag tgc atg cac ttt ttg aaa aaa gat gaa gta atg ccc ggg 424
Met Glu Glu Cys Met His Phe Leu Lys Lys Asp Glu Val Met Pro Gly
60 65 70
gtg ggt aat atg gtt ccc gat cta ggt gta gaa gcc acc ttt cct gat 472
Val Gly Asn Met Val Pro Asp Leu Gly Val Glu Ala Thr Phe Pro Asp
75 80 85
ggt acg aaa ctt gta act gtg aat tgg ccc atc gaa cca gat gag cac 520
Gly Thr Lys Leu Val Thr Val Asn Trp Pro Ile Glu Pro Asp Glu His
90 95 100 105
ttc aaa gcg ggc gaa gtg aaa ttt ggt tgc gat aaa gac atc gag ctc 568
Phe Lys Ala Gly Glu Val Lys Phe Gly Cys Asp Lys Asp Ile Glu Leu
110 115 120
aat gca ggc aaa gaa gta acc gaa ctt gag gtt act aat gaa ggg cct 616
Asn Ala Gly Lys Glu Val Thr Glu Leu Glu Val Thr Asn Glu Gly Pro
125 130 135
aaa tcc ttg cat gtg ggt agc cat ttc cac ttc ttt gaa gct aac aag 664
Lys Ser Leu His Val Gly Ser His Phe His Phe Phe Glu Ala Asn Lys
140 145 150
gca cta aaa ttc gat cgt gaa aaa gcc tat ggc aaa cgc cta gat att 712

Ala Leu Lys Phe Asp Arg Glu Lys Ala Tyr Gly Lys Arg Leu Asp Ile
 155 160 165

ccc tct ggc aac acg cta cgc att ggg gca gga caa acc cgc aaa gtg 760
 Pro Ser Gly Asn Thr Leu Arg Ile Gly Ala Gly Gln Thr Arg Lys Val
 170 175 180 185

cag ttg att cct ctt ggt ggc agt aaa aaa gtg att ggc atg aac ggg 808
 Gln Leu Ile Pro Leu Gly Gly Ser Lys Lys Val Ile Gly Met Asn Gly
 190 195 200

ctt gtg aat aac atc gcg gat gaa cgc cat aaa cat aaa gcg ctt gac 856
 Leu Val Asn Asn Ile Ala Asp Glu Arg His Lys His Lys Ala Leu Asp
 205 210 215

aag gcg aaa tct cac gga ttt atc aag taa ggagactccc atg aaa atg 905
 Lys Ala Lys Ser His Gly Phe Ile Lys Met Lys Met
 220 225 230

aaa aaa caa gaa tat gta aat acc tac gga ccc acc aaa ggc gat aaa 953
 Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Lys Gly Asp Lys
 235 240 245

gtg cgc tta gga gat acc gat ctt tgg gca gaa gta gaa cat gac tat 1001
 Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu His Asp Tyr
 250 255 260

acc acc tat ggc gaa gaa ctt aaa ttt ggc gcg ggt aaa act atc cgt 1049
 Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys Thr Ile Arg
 265 270 275

gag ggt atg ggt cag agc aat agc cct gat gaa aac acc cta gat tta 1097
 Glu Gly Met Gly Gln Ser Asn Ser Pro Asp Glu Asn Thr Leu Asp Leu
 280 285 290

gtc atc act aac gcg atg att atc gac tac acc ggg att tac aaa gcc 1145
 Val Ile Thr Asn Ala Met Ile Ile Asp Tyr Thr Gly Ile Tyr Lys Ala
 295 300 305 310

gac att ggg att aaa aac ggc aaa atc cat ggc att ggc aag gca gga 1193
 Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly Lys Ala Gly
 315 320 325

aac aag gac atg caa gat³ggc gta agc cct cat atg gtc gtg ggt gtg 1241
 Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val Val Gly Val
 330 335 340

ggc aca gaa gca cta gca ggg gaa ggt atg att att acc gct ggg gga 1289
 Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr Ala Gly Gly
 345 350 355

atc gat tca cac acc cac ttc ctt tct cca caa caa ttc cct acc gct 1337
 Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe Pro Thr Ala
 360 365 370

cta gcc aat ggc gtt aca acc atg ttt gga ggc ggc aca ggt cct gta 1385
 Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr Gly Pro Val
 375 380 385 390

gat ggc acg aat gcg act act atc act ccg ggc aaa tgg aac ttg cac 1433
 Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp Asn Leu His
 395 400 405

cgc atg ttg cgc gca gca gaa gag tat tct atg aat gtg ggc ttt ttg 1481
 Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val Gly Phe Leu
 410 415 420

ggc aaa ggc aat agc tct agc aaa aaa caa ctt gta gaa caa gta gaa 1529
 Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu Gln Val Glu
 425 430 435

gcg ggc gcg att ggt ttt aaa ttg cat gaa gac tgg ggc aca aca cca 1577
 Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly Thr Thr Pro
 440 445 450

agt gcg atc gat cac tgc ttg agc gtc gca gat gaa tac gat gtg caa 1625

Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr Asp Val Gln	
455	460 465 470
ggt tgt atc cac acc gat aca gtc aat gag gca ggt tat gta gat gac	1673
Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr Val Asp Asp	
	475 480 485
acc cta aat gca atg aac ggg cgc gcc atc cat gcc tac cac att gag	1721
Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr His Ile Glu	
	490 495 500
gga gcg ggt gga gga cac tca cct gat gtt atc acc atg gca ggc gag	1769
Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met Ala Gly Glu	
	505 510 515
ctc aat att cta ccc tcc tcc acc acc ccc act att ccc tat acc att	1817
Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro Tyr Thr Ile	
	520 525 530
aat acg gtt gca gaa cac tta gac atg ctc atg aca tgc cac cac cta	1865
Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys His His Leu	
	535 540 545 550
gac aaa cgc atc cgc gag gat tta caa ttt tct caa agc cgt atc cgc	1913
Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser Arg Ile Arg	
	555 560 565
ccc ggc tct atc gcg gct gaa gat gtg ctc cat gat atg ggt gtg atc	1961
Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Met Gly Val Ile	
	570 575 580
gcg atg aca agc tcg gat tcg caa gca atg ggg cgt gca ggc gaa gtg	2009
Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala Gly Glu Val	
	585 590 595
att cct cga act tgg cag act gcg gat aag aat aaa aaa gaa ttt ggt	2057
Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys Glu Phe Gly	
	600 605 610

aag ctt cct gaa gat ggc aaa gat aac gat aat ttc cgc att aag cgc 2105
Lys Leu Pro Glu Asp Gly Lys Asp Asn Asp Asn Phe Arg Ile Lys Arg
615 620 625 630

tac atc tcc aaa tac act atc aac ccc gct ttg acc cac ggc gtg agc 2153
Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His Gly Val Ser
635 640 645

gag tat atc ggc tct gtg gaa gag ggc aag atc gcc gac ttg gtg gtg 2201
Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp Leu Val Val
650 655 660

tgg aat cct gcc ttt ttt ggc gta aaa ccc aaa atc gtg atc aaa ggc 2249
Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val Ile Lys Gly
665 670 675

ggc atg gtg gtc ttc tct gaa atg ggc gat tct aac ggc tct gtg ccc 2297
Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala Ser Val Pro
680 685 690

act ccc caa ccc gtt tat tac cgc gaa atg ttt ggg cat cac ggc aag 2345
Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His His Gly Lys
695 700 705 710

ccg aaa ttt gac acc agc atc act ttt gtt tcc aaa gtc gcc tat gaa 2393
Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val Ala Tyr Glu
715 720 725

aat ggc gtg aaa gaa aag ctg ggc tta gag cgc caa gtt cta ccg gtc 2441
Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Gln Val Leu Pro Val
730 735 740

aaa aac tgc cgt aac atc acc aag aaa gac ttc aag ttc aac gac aaa 2489
Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe Asn Asp Lys
745 750 755

acg gca aaa atc acc gtc gat ccg aaa acc ttc gag gtc ttt gta gat 2537

Thr Ala Lys Ile Thr Val Asp Pro Lys Thr Phe Glu Val Phe Val Asp
 760 765 770

ggc aaa ctc tgc acc tct aaa ccc acc tcg caa gtg cct cta gcc cag 2585
 Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser Gln Val Pro Leu Ala Gln
 775 780 785 790

cgc tac act ttc ttc tag gcacaatgcc cccttgagg gcaggttatt 2633
 Arg Tyr Thr Phe Phe
 795

ttaggaatct tcacaaacg cacctgcaat cggctctgcg tgtgcgatcg tgcgcttta 2693

aaacaacttt tcacttttaa gcaatcgcca ttttaatta atttaattct tataattaat 2753

attatattat gccccctcat ttttaaagga gaattatgcg taggtctttg gtattgotat 2813

gtgggggttg tttggtgctg ggcgcaaagg gtattgaaac ccacgcctc aaaaaagtag 2873

aagccacagg 2883

<210> 2

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 2

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Gln Leu Met Glu Glu Cys Met His Phe

<212> PRT

<213> Helicobacter felis

<400> 3

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Lys
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu
 20 25 30

His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys
 35 40 45

Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp Glu Asn Thr
 50 55 60

Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr Thr Gly Ile
 65 70 75 80

Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly
 85 90 95

Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val
 100 105 110

Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr
 115 120 125

Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe
 130 135 140

Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr
 145 150 155 160

Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp
 165 170 175

Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val

180	185	190
Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu		
195	200	205
Gln Val Glu Ala Gly Ala ² Ile Gly Phe Lys Leu His Glu Asp Trp Gly		
210	215	220
Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr		
225	230	235
Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr		
245	250	255
Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr		
260	265	270
His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met		
275	280	285
Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro		
290	295	300
Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys		
305	310	315
His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser		
325	330	335
Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Met		
340	345	350
Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala		
355	360	365
Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys		
370	375	380

Glu Phe Gly Lys Leu Pro Glu Asp Gly Lys Asp Asn Asp Asn Phe Arg
 385 390 395 400

Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His
 405 410 415

Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp
 420 425 430

Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val
 435 440 445

Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala
 450 455 460

Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His
 465 470 475 480

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val
 485 490 495

Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Gln Val
 500 505 510

Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe
 515 520 525

Asn Asp Lys Thr Ala Lys Ile Thr Val Asp Pro Lys Thr Phe Glu Val
 530 535 540

Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser Gln Val Pro
 545 550 555 560

Leu Ala Gln Arg Tyr Thr Phe Phe
 565

<210> 4

<211> 2405

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (1)..(681)

<220>

<221> CDS

<222> (692)..(2398)

<400> 4

gtg aaa ctc aca ccc aaa gag caa gaa aag ttc ttg tta tat tat gcg 48

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala

1 5 10 15

ggc gaa gtg gct aga aag cgc aaa gca gag ggc tta aag ctc aat caa 96

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln

20 25 30

ccc gaa gcc att gcc tac att agt gcc cat att atg gac gag gcg cgc 144

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg

35 40 45

cgt ggc aaa aaa acc gtt gct gaa ctt atg gaa gaa tgt atg cac ttt 192

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe

50 55 60

ttg aaa aaa gat gag gtg atg ccc ggt gtg ggg aat atg gtc cct gat 240

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp

65 70 75 80

ttg ggc gta gaa gcc act ttc ccc gat ggc acc aaa ctc gta acc gtg 288

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val

85 90 95

aat tgg ccc att gaa cct gat gaa cac ttt aaa gcc ggt gaa gtg aaa	336
Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys	
100 105 110	
ttt ggc tgt gat aaa gac att gag ctc aac gcg ggt aag gaa gtt acc	384
Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr	
115 120 125	
gag ctt gaa gtt acc aac gaa gga cct aaa tcc ttg cat gtg ggt agc	432
Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser	
130 135 140	
cat ttc cac ttc ttt gaa acc aac aag gca ttg aaa ttc gat cgg gaa	480
His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg Glu	
145 150 155 160	
aaa gcc tat ggc aaa cgc cta gat att ccc tct ggc aac acg cta cgc	528
Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg	
165 170 175	
att ggg gca gga caa acc cgt aaa gtg cag tta atc cct ctt ggc ggt	576
Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly	
180 185 190	
agt aaa aaa gtg att ggc atg aac ggg ctt gtg aat aat att gcg gac	624
Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp	
195 200 205	
gaa cgc cat aaa cac aaa gca cta gac aag gca aaa tct cac gga ttc	672
Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe	
210 215 220	
atc aag taa ggagactccc atg aaa atg aaa aaa caa gag tat gta aac	721
Ile Lys Met Lys Met Lys Lys Gln Glu Tyr Val Asn	
225 230 235	
acc tac gga ccc acc aca ggc gat aaa gtg cgc tta gga gat acc gat	769
Thr Tyr Gly Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp	

240	245	250	
ctt tgg gca gaa gta gaa cat gac tat acc act tat ggc gaa gag ctc			817
Leu Trp Ala Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu			
255	260	265	
aaa ttt ggc gcg ggt aaa act atc cgt gag ggt atg ggt cag agc aat			865
Lys Phe Gly Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser Asn			
270	275	280	285
agc cca gat gaa aac acc tta gat tta gtg atc acc aac gcg atg att			913
Ser Pro Asp Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met Ile			
290	295	300	
atc gac tac acc ggg att tat aaa gcc gac att ggt att aaa aat ggc			961
Ile Asp Tyr Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly			
305	310	315	
aaa atc cat ggt att ggc aag gcg ggg aac aaa gac atg caa gat ggc			1009
Lys Ile His Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp Gly			
320	325	330	
gta agc cct cat atg gtc gtg ggt gtg ggc aca gaa gca cta gca ggg			1057
Val Ser Pro His Met Val Val Gly Val Gly Thr Glu Ala Leu Ala Gly			
335	340	345	
gaa ggt atg att att acc gct ggg ggg atc gat tcg cac acc cac ttc			1105
Glu Gly Met Ile Ile Thr Ala Gly Gly Ile Asp Ser His Thr His Phe			
350	355	360	365
ctc tct ccc caa caa ttc cct acc gct cta gcc aat ggt gtt aca acc			1153
Leu Ser Pro Gln Gln Phe Pro Thr Ala Leu Ala Asn Gly Val Thr Thr			
370	375	380	
atg ttt gga ggt ggc aca ggt ccg gta gat ggc acg aat gcg acc acc			1201
Met Phe Gly Gly Gly Thr Gly Pro Val Asp Gly Thr Asn Ala Thr Thr			
385	390	395	

atc act ccg ggc aaa tgg aac ttg cac cgc atg ttg cgc gca gct gaa 1249
 Ile Thr Pro Gly Lys Trp Asn Leu His Arg Met Leu Arg Ala Ala Glu
 400 405 410

gag tat tct atg aat gtg ggc ttt ttg ggc aaa ggc aat agc tcc agt 1297
 Glu Tyr Ser Met Asn Val Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser
 415 420 425

aaa aaa caa ctc gta gaa caa gta gaa gcg ggc gcg att ggc ttt aaa 1345
 Lys Lys Gln Leu Val Glu Gln Val Glu Ala Gly Ala Ile Gly Phe Lys
 430 435 440 445

ttg cat gaa gac tgg ggc aca aca cca agt gcg atc gat cac tgc ttg 1393
 Leu His Glu Asp Trp Gly Thr Thr Pro Ser Ala Ile Asp His Cys Leu
 450 455 460

agc gta gca gat gaa tac gat gtg caa gtt tgt atc cac acc gat acg 1441
 Ser Val Ala Asp Glu Tyr Asp Val Gln Val Cys Ile His Thr Asp Thr
 465 470 475

gtc aat gag gca ggt tat gta gat gac acc cta aat gcg atg aac ggg 1489
 Val Asn Glu Ala Gly Tyr Val Asp Asp Thr Leu Asn Ala Met Asn Gly
 480 485 490

cgc gcc atc cat gcc tac cac att gag gga gcg ggc gga gga cac tca 1537
 Arg Ala Ile His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His Ser
 495 500 505

cct gat gtt atc acc atg gca ggc gag ctc aat att cta ccc tcc tcc 1585
 Pro Asp Val Ile Thr Met Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser
 510 515 520 525

acc acc ccc act att ccc tat acc att aat acg gtt gca gaa cac tta 1633
 Thr Thr Pro Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His Leu
 530 535 540

gac atg ctc atg acc tgc cac cac cta gac aaa cgc atc cgc gag gat 1681
 Asp Met Leu Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu Asp

545	550	555		
ctc cag ttt tcc caa agc cgt atc cgc ccc ggc tct att gcc gct gaa	1729			
Leu Gln Phe Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu				
560	565	570		
gat gtg ctc cat gat att ggc gtg atc gcg atg aca agc tcg gat tcg	1777			
Asp Val Leu His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp Ser				
575	580	585		
caa gca atg ggg cgc gct ggg gaa gtg att cct aga act tgg caa act	1825			
Gln Ala Met Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln Thr				
590	595	600	605	
gca gac aag aat aaa aaa gaa ttt ggt aag ctt cct gaa gat ggt gca	1873			
Ala Asp Lys Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala				
	610	615	620	
gat aat gac aac ttc cgc atc aaa cgc tat atc tcc aaa tac acc att	1921			
Asp Asn Asp Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile				
	625	630	635	
aat ccc gct ttg acc cat ggc gtg agc gag tat atc gcc tct gtg gaa	1969			
Asn Pro Ala Leu Thr His Gly Val Ser Glu Tyr Ile Gly Ser Val Glu				
	640	645	650	
gag ggc aag atc gcc gac ttg gtg gtg tgg aat cct gct ttc ttt ggt	2017			
Glu Gly Lys Ile Ala Asp Leu Val Val Trp Asn Pro Ala Phe Phe Gly				
	655	660	665	
gta aaa ccc aaa atc gtg atc aaa ggc ggt atg gtg gtg ttc tct gaa	2065			
Val Lys Pro Lys Ile Val Ile Lys Gly Gly Met Val Val Phe Ser Glu				
	670	675	680	685
atg ggc gat tct aac gcg tct gtg ccc aca cct cag ccg gtt tat tac	2113			
Met Gly Asp Ser Asn Ala Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr				
	690	695	700	

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr
 115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg Glu
 145 150 155 160

Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
 165 170 175

Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
 180 185 190

Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe
 210 215 220

Ile Lys

225

<210> 6

<211> 568

<212> PRT

<213> Helicobacter felis

<400> 6

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Thr
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu
 20 25 30

His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys
 35 40 45

Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp Glu Asn Thr
 50 55 60

Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr Thr Gly Ile
 65 70 75 80

Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly
 85 90 95

Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val
 100 105 110

Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr
 115 120 125

Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe
 130 135 140

Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr
 145 150 155 160

Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp
 165 170 175

Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val
 180 185 190

Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu
 195 200 205

Gln Val Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly
 210 215 220

Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr
 225 230 235 240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met
 275 280 285

Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro
 290 295 300

Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys
 305 310 315 320

His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser
 325 330 335

Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile
 340 345 350

Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala

355	360	365
Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys		
370	375	380
Glu Phe Gly Lys Leu Pro ² Glu Asp Gly Ala Asp Asn Asp Asn Phe Arg		
385	390	395
Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His		
	405	410
		415
Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp		
	420	425
		430
Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val		
	435	440
		445
Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala		
	450	455
		460
Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His		
465	470	475
		480
His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val		
	485	490
		495
Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Lys Val		
	500	505
		510
Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe		
	515	520
		525
Asn Asn Lys Thr Ala His Ile Thr Val Asp Pro Lys Thr Phe Glu Val		
	530	535
		540
Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Ala Ser Glu Val Pro		
545	550	555
		560

Leu Ala Gln Arg Tyr Thr Phe Phe
565

<210> 7

<211> 2183

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (3)..(683)

<220>

<221> CDS

<222> (694)..(2181)

<400> 7

tc gtg aaa ctc aca ccc aaa gag caa gaa aag ttc ttg tta tat tat 47
Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr
1 5 10 15

gcg ggc gaa gtg gct aga aag cgc aaa gca gag ggc tta aag ctc aat 95
Ala Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn
20 25 30

caa ccc gaa gcc att gcc tac att agt gcc cat att atg gac gag gcg 143
Gln Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala
35 40 45

cgc cgt ggc aaa aaa acc gtt gct gaa ctt atg gaa gaa tgt atg cac 191
Arg Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His
50 55 60

ttt ttg aaa aaa gat gag gtg atg ccc ggt gtg ggg aat atg gtc cct 239
Phe Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro
65 70 75

gat ttg ggc gta gaa gcc act ttc ccc gat ggc acc aaa ctc gta acc 287
Asp Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr
80 85 90 95

gtg aat tgg ccc att gaa cct gat gaa cac ttt aaa gcc ggt gaa gtg 335
Val Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val
100 105 110

aaa ttt ggc tgt gat aaa gac att gag ctc aac gtg ggt aag gaa gtt 383
Lys Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Val Gly Lys Glu Val
115 120 125

acc gag ctt gaa gtt acc aac gaa gga cct aaa tcc ttg cat gtg ggt 431
Thr Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly
130 135 140

agc cat ttc cac ttc ttt gaa acc aac aag gca ttg aaa ttc gat cgg 479
Ser His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg
145 150 155

gaa aaa gcc tat ggc aaa cgc cta gat att ccc tct ggc aac acg cta 527
Glu Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu
160 165 170 175

cgc att ggg gca gga caa acc cgt aaa gtg cag tta atc cct ctt ggc 575
Arg Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly
180 185 190

ggc agt aaa aaa gtg att ggc atg aac ggg ctt gtg aat aat att gcg 623
Gly Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala
195 200 205

gac gaa cgc cat aaa cac aaa gca cta gac aag gca aaa tct cac gga 671
Asp Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly
210 215 220

ttc atc aag taa ggagactccc atg aaa atg aaa aaa caa gag tat gta 720

Phe Ile Lys	Met Lys Met Lys Lys Gln Glu Tyr Val	
225	230	235
aac acc tac gga ccc acc aca ggc gat aaa gtg cgc tta gga gat acc		768
Asn Thr Tyr Gly Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr		
240	245	250
gat ctt tgg gca gaa gta gaa cat gac tat acc act tat ggc gaa gag		816
Asp Leu Trp Ala Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu		
255	260	265
ctc aaa ttt ggc gcg ggt aaa act atc cgt gag ggt atg ggt cag agc		864
Leu Lys Phe Gly Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser		
270	275	280
aat agc cca gat gaa aac acc tta gat tta gtg atc acc aac gcg atg		912
Asn Ser Pro Asp Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met		
285	290	295
att atc gac tac acc ggg att tat aaa gcc gac att ggt att aaa aat		960
Ile Ile Asp Tyr Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn		
305	310	315
ggc aaa atc cat ggt att ggc aag gcg ggg aac aaa gac atg caa gat		1008
Gly Lys Ile His Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp		
320	325	330
ggc gta agc cct cat atg gtc gtg ggt gtg ggc aca gaa gca cta gca		1056
Gly Val Ser Pro His Met Val Val Gly Val Gly Thr Glu Ala Leu Ala		
335	340	345
ggg gaa ggt atg att att acc gct ggg ggg atc gat tcg cac acc cac		1104
Gly Glu Gly Met Ile Ile Thr Ala Gly Gly Ile Asp Ser His Thr His		
350	355	360
ttc ctc tct ccc caa caa ttc cct acc gct cta gcc aat ggt gtt aca		1152
Phe Leu Ser Pro Gln Gln Phe Pro Thr Ala Leu Ala Asn Gly Val Thr		
365	370	375
		380

acc atg ttt gga ggt ggc aca ggt ccg gta gat ggc acg aat gcg acc 1200
 Thr Met Phe Gly Gly Gly Thr Gly Pro Val Asp Gly Thr Asn Ala Thr
 385 390 395

acc atc act ccg ggc aaa tgg aac ttg cac cgc atg ttg cgc gca gct 1248
 Thr Ile Thr Pro Gly Lys Trp Asn Leu His Arg Met Leu Arg Ala Ala
 400 405 410

gaa gag tat tct atg aat gta ggc ttt ttg ggc aaa ggc aat agt tct 1296
 Glu Glu Tyr Ser Met Asn Val Gly Phe Leu Gly Lys Gly Asn Ser Ser
 415 420 425

agc aaa aaa caa ctt gta gaa caa gta gaa gcg ggc gcg att ggc ttt 1344
 Ser Lys Lys Gln Leu Val Glu Gln Val Glu Ala Gly Ala Ile Gly Phe
 430 435 440

aaa ttg cat gaa gac tgg ggc aca aca cca agt gcg atc gat cac tgc 1392
 Lys Leu His Glu Asp Trp Gly Thr Thr Pro Ser Ala Ile Asp His Cys
 445 450 455 460

ttg agc gtg gca gat gaa tac gat gtg caa gtt tgt atc cac acc gat 1440
 Leu Ser Val Ala Asp Glu Tyr Asp Val Gln Val Cys Ile His Thr Asp
 465 470 475

acg gtc aat gag gca ggt tat gtg gat gac acc cta aat gca atg aac 1488
 Thr Val Asn Glu Ala Gly Tyr Val Asp Asp Thr Leu Asn Ala Met Asn
 480 485 490

ggg cgc gcc atc cat gcc tac cac att gag gga gcg ggc gga gga cac 1536
 Gly Arg Ala Ile His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His
 495 500 505

tca cct gat gtt atc acc atg gca ggc gag ctc aat att cta ccc tcc 1584
 Ser Pro Asp Val Ile Thr Met Ala Gly Glu Leu Asn Ile Leu Pro Ser
 510 515 520

tcc acc acc ccc act att ccc tat acc att aat acg gtt gca gaa cac 1632

Ser Thr Thr Pro Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His
 525 530 535 540

tta gac atg ctc atg acc tgc cac cac cta gat aag cgc atc cgc gag 1680
 Leu Asp Met Leu Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu
 545 550 555

gat tta caa ttt tct caa agc cgt atc cgc ccc gga tct att gcc gct 1728
 Asp Leu Gln Phe Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala
 560 565 570

gag gat gtg ctc cat gat att ggc gtg atc gcg atg act agc tcc gat 1776
 Glu Asp Val Leu His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp
 575 580 585

tcg caa gca atg ggg cgc gct ggg gaa gtg att cct aga act tgg caa 1824
 Ser Gln Ala Met Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln
 590 595 600

act gca gat aag aat aaa aaa gaa ttt ggt aag ctt cct gaa gat ggt 1872
 Thr Ala Asp Lys Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Gly
 605 610 615 620

gca gat aac gac aac ttc cgc atc aaa cgc tat atc tcc aaa tac acc 1920
 Ala Asp Asn Asp Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr
 625 630 635

att aat ccc gct ttg acc cat ggc gtg agc gag tat atc ggc tct gtg 1968
 Ile Asn Pro Ala Leu Thr His Gly Val Ser Glu Tyr Ile Gly Ser Val
 640 645 650

gaa gag ggc aag atc gcc gac ttg gtg gtg tgg aat cct gcc ttt ttt 2016
 Glu Glu Gly Lys Ile Ala Asp Leu Val Val Trp Asn Pro Ala Phe Phe
 655 660 665

ggc gtg aaa cct aag att gtg att aaa ggt ggc atg gtg gtc ttc tct 2064
 Gly Val Lys Pro Lys Ile Val Ile Lys Gly Gly Met Val Val Phe Ser
 670 675 680

gaa atg ggc gat tct aac gcg tcc gtg ccc acg cct cag cag gtt tat 2112
 Glu Met Gly Asp Ser Asn Ala Ser Val Pro Thr Pro Gln Pro Val Tyr
 685 690 695 700

tac cgc gaa atg ttt ggg cac cac ggc aag gcg aaa ttt gac acc agc 2160
 Tyr Arg Glu Met Phe Gly His His Gly Lys Ala Lys Phe Asp Thr Ser
 705 710 715

atc act ttt cgt gtc tca agc gg 2183
 Ile Thr Phe Arg Val Ser Ser
 720

<210> 8

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 8

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Val Gly Lys Glu Val Thr
 115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg Glu
 145 150 155 160

Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
 165 170 175

Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
 180 185 190

Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe
 210 215 220

Ile Lys
 225

<210> 9

<211> 496

<212> PRT

<213> Helicobacter felis

<400> 9

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Thr
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu

Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr
 225 230 235 240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met
 275 280 285

Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro
 290 295 300

Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys
 305 310 315 320

His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser
 325 330 335

Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile
 340 345 350

Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala
 355 360 365

Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys
 370 375 380

Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala Asp Asn Asp Asn Phe Arg
 385 390 395 400

Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His
 405 410 415

Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp
 420 425 430

Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val
 435 440 445

Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala
 450 455 460

Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His
 465 470 475 480

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Arg Val Ser Ser
 485 490 495

<210> 10

<211> 2407

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (2)..(682)

<220>

<221> CDS

<222> (693)..(2399)

<400> 10

c gtg aaa ctc aca ccc aaa gag caa gaa aag ttc ttg tta tat tat gcg 49
 Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

ggc gaa gtg gct aga aag cgc aaa gcg gag ggc tta aag ctc aac caa 97
 Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

ccc gaa gcc att gcc tac att agt gcc cat att atg gac gag gcg cgc 145

Pro	Glu	Ala	Ile	Ala	Tyr	Ile	Ser	Ala	His	Ile	Met	Asp	Glu	Ala	Arg		
		35					40					45					
cgt	ggc	aaa	aag	acc	gtt	gcg	gaa	ctt	atg	gaa	gag	tgt	atg	cac	ttt	193	
Arg	Gly	Lys	Lys	Thr	Val	Ala	Glu	Leu	Met	Glu	Glu	Cys	Met	His	Phe		
		50					55					60					
ttg	aaa	aaa	gac	gag	gtg	atg	ccc	ggt	gtg	ggg	aat	atg	gtc	cct	gat	241	
Leu	Lys	Lys	Asp	Glu	Val	Met	Pro	Gly	Val	Gly	Asn	Met	Val	Pro	Asp		
	65					70				75					80		
tta	ggc	gtg	gaa	gct	act	ttt	ccc	gat	ggc	acc	aaa	ctc	gta	acc	gtg	289	
Leu	Gly	Val	Glu	Ala	Thr	Phe	Pro	Asp	Gly	Thr	Lys	Leu	Val	Thr	Val		
					85					90					95		
aat	tgg	ccc	atc	gaa	ccc	gat	gaa	cac	ttc	aaa	gcg	ggc	gaa	gtc	aaa	337	
Asn	Trp	Pro	Ile	Glu	Pro	Asp	Glu	His	Phe	Lys	Ala	Gly	Glu	Val	Lys		
			100					105						110			
ttt	ggc	tgt	gat	aaa	gac	att	gaa	ctc	aac	gca	ggt	aag	gaa	gtt	acc	385	
Phe	Gly	Cys	Asp	Lys	Asp	Ile	Glu	Leu	Asn	Ala	Gly	Lys	Glu	Val	Thr		
			115					120						125			
gaa	cta	gaa	ggt	acc	aac	gaa	gga	cct	aaa	tcc	ttg	cat	gtg	ggt	agc	433	
Glu	Leu	Glu	Val	Thr	Asn	Glu	Gly	Pro	Lys	Ser	Leu	His	Val	Gly	Ser		
		130					135							140			
cat	ttc	cac	ttc	ttt	gaa	gcc	aac	aag	gca	ttg	aaa	ttc	gat	cgg	gaa	481	
His	Phe	His	Phe	Phe	Glu	Ala	Asn	Lys	Ala	Leu	Lys	Phe	Asp	Arg	Glu		
	145					150					155				160		
aaa	gcc	tat	ggc	aaa	cgc	cta	gat	att	ccc	tct	ggc	aac	acg	cta	cgc	529	
Lys	Ala	Tyr	Gly	Lys	Arg	Leu	Asp	Ile	Pro	Ser	Gly	Asn	Thr	Leu	Arg		
				165						170					175		
att	ggg	gca	gga	caa	acc	cgt	aaa	gtg	cag	tta	atc	cct	ctt	ggc	ggc	577	
Ile	Gly	Ala	Gly	Gln	Thr	Arg	Lys	Val	Gln	Leu	Ile	Pro	Leu	Gly	Gly		
				180						185					190		

agt aaa aaa gtg att ggc atg aac ggg ctt gtg aat aat att gca gat 625
 Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

gaa cgc cat aaa cac aaa gcg tta gaa aaa gca aaa tct cac gga ttt 673
 Glu Arg His Lys His Lys Ala Leu Glu Lys Ala Lys Ser His Gly Phe
 210 215 220

atc aaa taa ggagactccc atg aaa atg aaa aaa caa gag tat gta aat 722
 Ile Lys Met Lys Met Lys Lys Gln Glu Tyr Val Asn
 225 230 235

acc tac gga cct acc aca ggc gac aaa gtg cgc tta gga gat acc gat 770
 Thr Tyr Gly Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp
 240 245 250

ctt tgg gca gaa gta gaa cat gac tat acc act tat ggc gaa gag ctc 818
 Leu Trp Ala Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu
 255 260 265

aaa ttt ggc gcg ggt aaa act atc cgt gag ggc atg ggt cag agc aat 866
 Lys Phe Gly Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser Asn
 270 275 280 285

agt cca gat gaa aac acc cta gat tta gtc atc acc aac gcg atg att 914
 Ser Pro Asp Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met Ile
 290 295 300

att gac tac acc ggg att tac aaa gcc gac att ggc att aaa aat ggc 962
 Ile Asp Tyr Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly
 305 310 315

aaa atc cat ggc att ggc aag gca gga aac aag gac atg caa gat ggc 1010
 Lys Ile His Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp Gly
 320 325 330

gta agc cct cat atg gtc gtg ggt gtg ggc aca gaa gca tta gca ggg 1058

Val	Ser	Pro	His	Met	Val	Val	Gly	Val	Gly	Thr	Glu	Ala	Leu	Ala	Gly		
	335						340					345					
gaa	ggt	atg	att	att	acc	gct	ggg	ggg	atc	gat	tca	cac	acc	cac	ttc		1106
Glu	Gly	Met	Ile	Ile	Thr	Ala	Gly	Gly	Ile	Asp	Ser	His	Thr	His	Phe		
350							355 ²				360				365		
ctc	tct	cca	caa	caa	ttc	cct	acc	gct	cta	gcc	aat	ggc	ggt	aca	acc		1154
Leu	Ser	Pro	Gln	Gln	Phe	Pro	Thr	Ala	Leu	Ala	Asn	Gly	Val	Thr	Thr		
					370						375				380		
atg	ttt	ggc	ggt	ggc	aca	ggt	ccg	gta	gat	ggc	acg	aat	gcg	act	acc		1202
Met	Phe	Gly	Gly	Gly	Thr	Gly	Pro	Val	Asp	Gly	Thr	Asn	Ala	Thr	Thr		
			385						390					395			
atc	act	ccg	ggc	aaa	tgg	aac	ttg	cac	cgc	atg	ttg	cgc	gca	gct	gaa		1250
Ile	Thr	Pro	Gly	Lys	Trp	Asn	Leu	His	Arg	Met	Leu	Arg	Ala	Ala	Glu		
		400						405						410			
gag	tat	tct	atg	aat	gtg	ggc	ttt	ttg	ggc	aaa	ggc	aat	agc	tcc	agt		1298
Glu	Tyr	Ser	Met	Asn	Val	Gly	Phe	Leu	Gly	Lys	Gly	Asn	Ser	Ser	Ser		
	415						420					425					
aaa	aaa	caa	ctt	gta	gaa	caa	ata	gaa	gcg	ggc	gcg	atc	ggc	ttt	aaa		1346
Lys	Lys	Gln	Leu	Val	Glu	Gln	Ile	Glu	Ala	Gly	Ala	Ile	Gly	Phe	Lys		
430						435					440				445		
ttg	cat	gaa	gac	tgg	ggc	aca	act	cca	agt	gca	atc	gat	cac	tgc	ttg		1394
Leu	His	Glu	Asp	Trp	Gly	Thr	Thr	Pro	Ser	Ala	Ile	Asp	His	Cys	Leu		
				450						455					460		
agc	gta	gca	gat	gaa	tac	gat	gtg	caa	ggt	tgt	atc	cac	acc	gat	acg		1442
Ser	Val	Ala	Asp	Glu	Tyr	Asp	Val	Gln	Val	Cys	Ile	His	Thr	Asp	Thr		
			465						470					475			
gtc	aat	gag	gca	ggt	tat	gta	gat	gac	acc	ctg	aat	gcg	atg	aac	ggg		1490
Val	Asn	Glu	Ala	Gly	Tyr	Val	Asp	Asp	Thr	Leu	Asn	Ala	Met	Asn	Gly		
		480							485					490			

cgc gcc atc cat gcc tac cac att gag gga gcg ggc gga gga cac tca 1538
 Arg Ala Ile His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His Ser
 495 500 505

cct gat gtt atc acc atg³gca ggc gag ctc aat att cta ccc tcc tcc 1586
 Pro Asp Val Ile Thr Met Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser
 510 515 520 525

aca acc ccc act atc ccc tat acc att aat acg gtt gca gaa cac tta 1634
 Thr Thr Pro Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His Leu
 530 535 540

gac atg ctc atg acc tgc cac cac cta gat aaa cgc atc cgc gag gat 1682
 Asp Met Leu Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu Asp
 545 550 555

tta caa ttt tcc caa agc cgt atc cgc ccc ggc tct atc gcc gct gaa 1730
 Leu Gln Phe Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu
 560 565 570

gat gtg ctc cat gat att ggc gtg atc gcg atg aca agc tcg gat tcg 1778
 Asp Val Leu His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp Ser
 575 580 585

caa gca atg ggg cgc gct ggc gaa gtg att cct cga act tgg cag act 1826
 Gln Ala Met Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln Thr
 590 595 600 605

gcg gat aag aat aaa aaa gaa ttt ggt aag ctt cct gaa gat agt gca 1874
 Ala Asp Lys Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Ser Ala
 610 615 620

gat aac gac aac ttc cgt atc aaa cgc tac atc tcc aaa tac act att 1922
 Asp Asn Asp Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile
 625 630 635

aac ccc gct cta acc cat ggg gta agc gag tat atc ggc tct gtg gaa 1970

Asn	Pro	Ala	Leu	Thr	His	Gly	Val	Ser	Glu	Tyr	Ile	Gly	Ser	Val	Glu		
		640					645					650					
gag	ggc	aaa	atc	gct	gat	ttg	gtg	gtg	tgg	aat	cct	gcc	ttt	ttt	ggt	2018	
Glu	Gly	Lys	Ile	Ala	Asp	Leu	Val	Val	Trp	Asn	Pro	Ala	Phe	Phe	Gly		
		655				660						665					
gtg	aaa	cct	aag	att	gtg	atc	aaa	ggc	ggt	atg	gtg	gtc	ttc	tct	gaa	2066	
Val	Lys	Pro	Lys	Ile	Val	Ile	Lys	Gly	Gly	Met	Val	Val	Phe	Ser	Glu		
670					675					680					685		
atg	ggc	gac	tcc	aac	gcg	tcc	gtg	cct	aca	cct	cag	ccg	gtt	tat	tac	2114	
Met	Gly	Asp	Ser	Asn	Ala	Ser	Val	Pro	Thr	Pro	Gln	Pro	Val	Tyr	Tyr		
				690						695					700		
cgc	gaa	atg	ttt	ggg	cat	cac	ggc	aag	gcg	aaa	ttt	gac	acc	agc	atc	2162	
Arg	Glu	Met	Phe	Gly	His	His	Gly	Lys	Ala	Lys	Phe	Asp	Thr	Ser	Ile		
			705					710							715		
act	ttt	ggt	tcc	aaa	gtc	gcc	tat	gaa	aat	ggc	gtg	aaa	gaa	aaa	cta	2210	
Thr	Phe	Val	Ser	Lys	Val	Ala	Tyr	Glu	Asn	Gly	Val	Lys	Glu	Lys	Leu		
			720					725							730		
ggc	tta	gag	cgc	aag	gtg	cta	ccc	gtg	aaa	aac	tgc	cgc	aac	atc	act	2258	
Gly	Leu	Glu	Arg	Lys	Val	Leu	Pro	Val	Lys	Asn	Cys	Arg	Asn	Ile	Thr		
		735				740						745					
aag	aaa	gac	ttc	aaa	ttc	aac	aac	aag	acg	gcg	cat	atc	act	gtc	gat	2306	
Lys	Lys	Asp	Phe	Lys	Phe	Asn	Asn	Lys	Thr	Ala	His	Ile	Thr	Val	Asp		
750					755					760					765		
cct	aaa	acc	ttc	gag	gtc	ttt	gta	gat	ggc	aaa	ctc	tgc	acc	tct	aaa	2354	
Pro	Lys	Thr	Phe	Glu	Val	Phe	Val	Asp	Gly	Lys	Leu	Cys	Thr	Ser	Lys		
					770					775					780		
ccc	gcc	tct	gaa	gtg	cct	cta	gcc	cag	cgc	tac	act	ttc	ttc	tag		2399	
Pro	Ala	Ser	Glu	Val	Pro	Leu	Ala	Gln	Arg	Tyr	Thr	Phe	Phe				
					785					790					795		

gcncaatg

2407

<210> 11

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 11

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr
 115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

His Phe His Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu

Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly
 85 90 95

Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val
 100 105 110

Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr
 115 120 125

Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe
 130 135 140

Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr
 145 150 155 160

Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp
 165 170 175

Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val
 180 185 190

Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu
 195 200 205

Gln Ile Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly
 210 215 220

Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr
 225 230 235 240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met

275	280	285
Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro		
290	295	300
Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys		
305	310	315
His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser		
	325	330
Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile		
	340	345
Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala		
	355	360
Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys		
	370	375
Glu Phe Gly Lys Leu Pro Glu Asp Ser Ala Asp Asn Asp Asn Phe Arg		
385	390	395
Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His		
	405	410
Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp		
	420	425
Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val		
	435	440
Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala		
	450	455
Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His		
465	470	475
		480

(53)

特開2002-355054

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val
485 490 495

Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Lys Val
500 505 510

Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe
515 520 525

Asn Asn Lys Thr Ala His Ile Thr Val Asp Pro Lys Thr Phe Glu Val
530 535 540

Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Ala Ser Glu Val Pro
545 550 555 560

Leu Ala Gln Arg Tyr Thr Phe Phe
565

<210> 13

<211> 2452

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (48)..(728)

<220>

<221> CDS

<222> (739)..(2445)

<400> 13

aggactataa tcccattgcc tttaaaattt aacacaagga gtaatag gtg aaa ctc 56
Val Lys Leu

1

aca ccc aaa gag caa gaa aag ttc ttg tta tat tat gcg ggc gaa gtg 104
 Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala Gly Glu Val
 5 10 15

gct aga aag cgc aaa gca gag ggc tta aag ctc aac caa ccc gaa gcc 152
 Ala Arg Lys Arg Lys Ala[~]Glu Gly Leu Lys Leu Asn Gln Pro Glu Ala
 20 25 30 35

att gcc tac att agt gcc cat att atg gac gag gcg cgt cgt ggc aaa 200
 Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg Arg Gly Lys
 40 45 50

aaa acc gtt gcg gaa ott atg gaa gag tgt atg cac ttt ttg aaa aaa 248
 Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe Leu Lys Lys
 55 60 65

gac gag gtg atg ccc ggg gtg ggg aat atg gtc cct gat ttg ggc gtg 296
 Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp Leu Gly Val
 70 75 80

gaa gcc act ttc ccc gat ggc acc aaa ctc gta act gtg aat tgg ccc 344
 Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val Asn Trp Pro
 85 90 95

atc gaa cct gat gaa cac ttt aag gcg ggt gaa gtg aaa ttt ggc tgt 392
 Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys Phe Gly Cys
 100 105 110 115

gat aaa gac att gaa ctc aac gca ggt aag gaa gtt acc gaa cta gaa 440
 Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr Glu Leu Glu
 120 125 130

gtt act aac gaa gga cct aaa tcc ttg cat gtg ggt agc cat ttc cac 488
 Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser His Phe His
 135 140 145

ttc ttt gaa gcc aac aaa gca ttg aaa ttc gat cgg gaa aaa gcc tat 536
 Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu Lys Ala Tyr

150	155	160	
ggc aaa cgc cta gat att ccc tct ggc aac aca cta cgc att ggg gca			584
Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg Ile Gly Ala			
165	170	175	
gga caa acc cgt aaa gtg cag tta atc cct ctt ggc ggt agt aaa aaa			632
Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly Ser Lys Lys			
180	185	190	195
gtg att ggc atg aac ggg ctt gtg aat aat att gcg gac gaa cgc cat			680
Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp Glu Arg His			
200	205	210	
aaa cac aaa gcg cta gac aaa gca aaa tct cac gga ttt atc aag taa			728
Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe Ile Lys			
215	220	225	
ggagactccc atg aaa atg aaa aaa caa gag tat gta aat acc tac gga			777
Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly			
230	235	240	
ccc acc aca ggc gat aaa gtg cgc tta gga gat acc gat ctt tgg gca			825
Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala			
245	250	255	
gaa gta gaa cat gac tat acc acc tat ggc gaa gaa ctc aaa ttc ggt			873
Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly			
260	265	270	
gca ggt aaa act atc cgt gag ggt atg ggt cag agc aat agc cca gat			921
Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp			
275	280	285	
gaa aac acc tta gat tta gtg atc acc aac gcg atg att att gac tac			969
Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr			
290	295	300	

acc ggg att tac aaa gcc gac att ggc att aaa aat ggc aaa atc cat 1017
 Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His
 305 310 315 320

ggc att ggc aag gca gga aac aag gac atg caa gat ggc gta agc cct 1065
 Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro
 325 330 335

cat atg gtc gtg ggt gtg ggc aca gaa gca cta gca ggg gaa ggt atg 1113
 His Met Val Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met
 340 345 350

att att acc gct ggg ggg atc gat tca cac acc cac ttc ctc tct cca 1161
 Ile Ile Thr Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro
 355 360 365

caa caa ttc cct acc gct cta gcc aat ggc gtt aca aca atg ttt ggc 1209
 Gln Gln Phe Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly
 370 375 380

ggt ggc aca ggc ccc gta gat ggc acg aat gcg act acc atc act ccg 1257
 Gly Gly Thr Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro
 385 390 395 400

ggc aaa tgg aac ttg cac cgc atg ttg cgc gca gca gaa gag tat tct 1305
 Gly Lys Trp Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser
 405 410 415

atg aat gtg ggc ttt ttg ggc aaa ggc aat agc tct agt aaa aaa caa 1353
 Met Asn Val Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln
 420 425 430

ctt gta gaa caa gta gaa gcg ggc gcg att ggt ttt aaa ttg cat gaa 1401
 Leu Val Glu Gln Val Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu
 435 440 445

gac tgg ggc aca act cca agt gcg atc gat cac tgc ttg agc gta gca 1449
 Asp Trp Gly Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala

450	455	460	
gat gaa tac gat gtg caa gtt tgt ata cac acc gat acg gtc aat gag			1497
Asp Glu Tyr Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu			
465	470	475	480
gca ggt tat gta gat gac acc cta aat gca atg aac ggg cgc gcc atc			1545
Ala Gly Tyr Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile			
	485	490	495
cat gcc tac cac att gag gga gcg ggt gga gga cac tca cct gat gtt			1593
His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val			
	500	505	510
atc acc atg gca ggc gaa gtg aat att cta ccc tcc tcc aca acc cct			1641
Ile Thr Met Ala Gly Glu Val Asn Ile Leu Pro Ser Ser Thr Thr Pro			
	515	520	525
act atc ccc tat acc att aat acg gtt gca gaa cac tta gac atg ctt			1689
Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu			
	530	535	540
atg acc tgc cac cac cta gat aaa cgc atc cgc gag gat ctc caa ttt			1737
Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe			
545	550	555	560
tct caa agc cgt atc cgc ccc ggc tct atc gcc gct gaa gat gtg ctc			1785
Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu			
	565	570	575
cat gat atc ggt gtg atc gcg atg aca agt tcc gat tcg caa gca atg			1833
His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met			
	580	585	590
ggg cgc gct ggg gaa gtg att cct aga act tgg caa act gca gac aag			1881
Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys			
	595	600	605

aat aaa aaa gaa ttt ggt aag ctt cct gaa gat ggt gca gat aat gac 1929
Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala Asp Asn Asp
610 615 620

aac ttc cgc atc aaa cgc tat atc tcc aaa tac acc att aat ccc gct 1977
Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala
625 630 635 640

ttg acc cat ggc gtg agc gag tat atc ggc tct gtg gaa gag ggc aag 2025
Leu Thr His Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys
645 650 655

atc gcc gac ttg gtg gtg tgg aat cct gcc ttt ttt ggc gta aaa ccc 2073
Ile Ala Asp Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro
660 665 670

aaa atc gtg atc aaa ggc ggt atg gtg gtg ttc tct gaa atg ggc gat 2121
Lys Ile Val Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp
675 680 685

tct aat gcg tct gtg ccc act cct cag ccg gtt tat tac cgc gaa atg 2169
Ser Asn Ala Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met
690 695 700

ttt ggg cat cac ggc aag gcg aaa ttt gac acc agc atc act ttt gtt 2217
Phe Gly His His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val
705 710 715 720

tcc aaa gtc gcc tat gaa aat ggt gtg aaa gaa aaa cta ggt tta gag 2265
Ser Lys Val Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu
725 730 735

cgc aag gtg ctc ccc gtg aaa aac tgc cgt aac atc acc aag aag gac 2313
Arg Lys Val Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp
740 745 750

ttc aag ttc aac gac aaa act gca aaa atc acc gtc gat ccg aaa acc 2361
Phe Lys Phe Asn Asp Lys Thr Ala Lys Ile Thr Val Asp Pro Lys Thr

755

760

765

ttc gag gtc ttt gta gat ggc aaa ctc tgc acc tct aaa ccc acc tct 2409
 Phe Glu Val Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser
 770 775 780

gaa gtg cct cta gcc caa cgc tac act ttc ttc tag gcataat 2452
 Glu Val Pro Leu Ala Gln Arg Tyr Thr Phe Phe
 785 790 795

<210> 14

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 14

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr
 115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

His Phe His Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu
 145 150 155 160

Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
 165 170 175

Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
 180 185 190

Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe
 210 215 220

Ile Lys
 225

<210> 15

<211> 568

<212> PRT

<213> Helicobacter felis

<400> 15

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Thr
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu
 20 25 30

His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys

35	40	45
Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp Glu Asn Thr		
50	55	60
Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr Thr Gly Ile		
65	70	75
Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly		
85	90	95
Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val		
100	105	110
Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr		
115	120	125
Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe		
130	135	140
Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr		
145	150	155
Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp		
165	170	175
Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val		
180	185	190
Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu		
195	200	205
Gln Val Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly		
210	215	220
Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr		
225	230	235
		240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met
 275 280 285

Ala Gly Glu Val Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro
 290 295 300

Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys
 305 310 315 320

His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser
 325 330 335

Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile
 340 345 350

Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala
 355 360 365

Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys
 370 375 380

Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala Asp Asn Asp Asn Phe Arg
 385 390 395 400

Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His
 405 410 415

Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp
 420 425 430

Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val
 435 440 445

Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala
 450 455 460
 Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His
 465 470 475 480
 His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val
 485 490 495
 Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Lys Val
 500 505 510
 Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe
 515 520 525
 Asn Asp Lys Thr Ala Lys Ile Thr Val Asp Pro Lys Thr Phe Glu Val
 530 535 540
 Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser Glu Val Pro
 545 550 555 560
 Leu Ala Gln Arg Tyr Thr Phe Phe
 565

<210> 16

<211> 21

<212> DNA

<213> Helicobacter felis.

<400> 16

catgcacttt.ttgaaaaaag a

21

<210> 17

<211> 16

<212> DNA
 <213> Helicobacter felis

 <400> 17
 tatggtggtc ttctct 16

 <210> 18
 <211> 32
 <212> DNA
 <213> Helicobacter felis

 <400> 18
 ggagtaacat atgaaactca cacccaaaga gc 32

 <210> 19
 <211> 27
 <212> DNA
 <213> Helicobacter felis

 <400> 19
 cacacccaacg accatgtgag ggcttac 27

 <210> 20
 <211> 27
 <212> DNA
 <213> Helicobacter felis

 <400> 20
 gtaagccctc acatggtcgt ggggtgtg 27

 <210> 21
 <211> 34
 <212> DNA
 <213> Helicobacter felis
 <400> 21
 cgaattcgga tcttagaaga aagtgtagcg ctgg 34

【図面の簡単な説明】

【図1 a】図1 a (1 ~ 4) : ヘリコバクター・フェリス種、CS1、Kukka、Ds4、2301及び390に由来する、2つのコーディング配列をつなぐ短い非コーディング領域を含むUreX及びYをコードする核

酸配列と、ヘリコバクター・フェリス、ピロリ及びヘイルマンニに由来する、2つのコーディング配列をつなぐ短い非コーディング領域を含むUreA及びBをコードする核酸配列との比較を示す図である。

【図1 b】図1 b : ヘリコバクター・フェリス種、CS

【図1c】

ALIGNED SEQUENCES

Reference molecule: ureYCS1 1 - 568 (568 aa) Homology

Sequence 2: ureYkuka 1 - 568 (568 aa) 99%

Sequence 3: ureYDS4 1 - 568 (568 aa) 98%

Sequence 4: ureY2301 1 - 568 (568 aa) 99%

Sequence 5: ureY390 1 - 498 (496 aa) 86%

Sequence 6: B fellis 1 - 569 (569 aa) 73%

Sequence 7: B pylori 1 - 569 (569 aa) 73%

Sequence 8: B heilman 1 - 568 (568 aa) 74%

Alignment type: Global Protein

Parameters: Mismatch 2; Open Gap 4; Extend Gap 1; Conserv N

```

ureYCS1 ( 1) mkmkkg-eyvntypgpkdgvrlgtdcdlwaevbedytygealkfgagktiremgsgsnpentldlvtnamidytykkaedigknkibgikagnkdmqdgvsphmvvvgvtea
ureYkuka ( 1) .....t.....
ureYDS4 ( 1) .....t.....
ureY2301 ( 1) .....t.....
ureY390 ( 1) .....t.....
B fellis ( 1) kiskr..sm..t..f..ll..C...i..g...d..s..t...ssy...i..l..v...d...a...d...c...p...a...
B pylori ( 1) kiskr..sm..t..f..ll..C...i..g...d..s..n..ske...i..l..v...d...a...g...l...k...l...p...a...
B heilman ( 1) kiskr..sm..t..f..ll..C...i..g...d..t..t..sshe...i..l..v...d...a...g...l...c...h...r...l...c...p...a...
ureYCS1 ( 120) lasegmliatgaidshthflspqgfpdalangvtmfggtgprvqgtnatitpgkwnlhmrlraaeysmnygflgkgnsskkqlveqveagaigfkllhedggtipsaidhclsvade
ureYkuka ( 120) .....t.....
ureYDS4 ( 120) .....t.....
ureY2301 ( 120) .....t.....
ureY390 ( 120) .....t.....
B fellis ( 121) a..l..v...t..i..i..i..f..s...i...a...k...s...a...l...a...v..y...e...s...r...d...i...i...s...a...h...n...
B pylori ( 121) s..l..v...t..i..i..i..f..s...i...a...z...k...w...l...a...a...r...d...a...s...a...d...i...i...i...s...a...h...n...
B heilman ( 121) s..l..v...t..i..i..i..f..s...i...a...r...k...e...s...a...i...y...v...f...e...p...a...i...d...l...i...i...s...n...a...n...l...k...
ureYCS1 ( 240) ydvqvcihcdtvneagyvddctnamngraiahayniegagqgthspdviemagelnlpsattptipyintvvaehldmlmtchidkxiredlqfsgsirpagsiaaecvlhdmgviant
ureYkuka ( 240) .....v.....
ureYDS4 ( 240) .....v.....
ureY2301 ( 240) .....v.....
ureY390 ( 241) s..h...a...l...c...e...e...i...a...t...t...f...t...a...k...f...a...n...f...k...e...m...v...s...k...v...a...d...q...t...g...f...f...s...i...
B fellis ( 241) a...a...l...c...e...m...a...i...a...t...m...t...f...t...a...i...k...v...h...a...n...f...v...e...m...v...s...k...v...a...d...q...t...c...f...f...s...i...
B pylori ( 241) a...a...l...c...e...e...i...a...t...t...f...t...a...k...f...a...n...f...k...e...m...v...s...k...v...a...d...q...t...c...f...f...s...i...
B heilman ( 241) a...a...l...c...e...e...i...a...t...t...f...t...a...k...f...a...n...f...k...e...m...v...s...k...v...a...d...q...t...c...f...f...s...i...
ureYCS1 ( 360) sdsqamgrageviprtqatadknkfkfklpedqkdndnfrkryiskytinpalthgvseyigsveegkiadlvvwpaffgvkpvivikgmvvfvsemgdsnasvptppqvyvrenarf
ureYkuka ( 360) .....a.....
ureYDS4 ( 360) .....a.....
ureY2301 ( 360) .....a.....
ureY390 ( 360) .....a.....
B fellis ( 361) .....V...t...t...f...k...e...g...i...d...i...v...v...y...l...s...i...r...m...i...f...i...a...l...q...a...i...
B pylori ( 361) .....V...t...t...f...k...e...g...i...a...i...v...v...v...l...s...i...r...m...i...f...i...a...l...q...a...i...
B heilman ( 360) .....V...t...t...f...k...e...g...i...i...i...v...v...y...l...s...i...r...m...i...f...i...a...l...q...a...i...

```

Figure 1c (1)

【図2】




Figure 2

フロントページの続き

(51)Int.Cl.⁷

識別記号

F I

テ-マコード (参考)

A 6 1 K 39/175
 39/23
 39/235
 39/39
 39/395
 A 6 1 P 1/04
 31/04
 C 1 2 N 1/15
 1/19
 1/21
 5/10
 9/80
 C 1 2 Q 1/68
 G 0 1 N 33/15
 33/50
 33/53

A 6 1 K 39/235
 39/39
 39/395
 A 6 1 P 1/04
 31/04
 C 1 2 N 1/15
 1/19
 1/21
 9/80
 C 1 2 Q 1/68
 G 0 1 N 33/15
 33/50
 33/53
 33/566
 33/569

4 C 0 8 4
 4 C 0 8 5
 D
 Z
 A
 Z
 Z
 D
 M
 B

33/566
 33/569
 //(C 1 2 N 9/80
 C 1 2 R 1:01)
 (C 1 2 Q 1/68
 C 1 2 R 1:01)

C 1 2 R 1:01
 C 1 2 N 15/00 Z N A A
 5/00 A
 A 6 1 K 37/02

Fターム(参考) 2G045 AA40 BA11 BB50 DA12 DA13
 DA36 FB02
 4B024 AA01 AA13 BA14 BA31 CA04
 DA02 DA05 DA12 EA04 FA02
 GA11 HA12 HA15
 4B050 CC03 DD02 LL01 LL03
 4B063 QA19 QQ44 QR08 QR42 QR56
 QS25 QS34 QX02
 4B065 AA01X AA01Y AA26X AA57X
 AA72X AA90X AB01 BA02
 CA31 CA43 CA46
 4C084 AA02 AA07 BA19 CA04 DC50
 NA14 ZA68 ZB35
 4C085 AA03 AA13 AA38 BA20 BA45
 BA51 BA75 BA77 CC07 CC08
 DD86 EE01 EE03 EE06

【外国語明細書】

1. Title of Invention

Helicobacter felis vaccine.

2. Claims

- 1) Nucleic acid sequence encoding two subunit polypeptides of a urease complex such as expressed by *Helicobacter felis*, said nucleic acid sequence having at least 85 % homology with SEQ ID NO: 1, or a part thereof encoding at least an immunogenic fragment of one of said subunits, said part having a length of at least 40, preferably 45, more preferably 50 nucleotides.
- 2) Nucleic acid sequence according to claim 1, characterised in that it encodes the urease X subunit polypeptide or the urease Y subunit polypeptide.
- 3) Nucleic acid sequence according to claim 1 or 2, characterised in that the sequence has at least 90 %, preferably 94 %, more preferably 97 % homology with SEQ ID NO: 1.
- 4) DNA fragment comprising a nucleic acid sequence according to claims 1-3
- 5) Recombinant DNA molecule comprising a nucleic acid sequence according to claims 1-3 or a DNA fragment according to claim 4, under the control of a functionally linked promoter.
- 6) Live recombinant carrier comprising a recombinant DNA molecule according to claim 5
- 7) Host cell comprising a nucleic acid sequence according to claims 1-3, a DNA fragment according to claim 4, a recombinant DNA molecule according to claim 5 or a live recombinant carrier according to claim 6.
- 8) *Helicobacter felis* urease X subunit polypeptide, said polypeptide having an amino acid sequence that is at least 85 % homologous to SEQ ID NO: 2 or an immunogenic fragment of said polypeptide with a length of at least 40, preferably 45, more preferably 50 amino acids said immunogenic fragment being capable of inducing an immune response against ureaseXY.
- 9) Polypeptide according to claim 8, having a sequence homology of at least 90 %, preferably 94 %, more preferably 97 % homology to SEQ ID NO: 2, or an immunogenic fragment of said polypeptide capable of inducing an immune response against ureaseXY.
- 10) *Helicobacter felis* urease Y subunit polypeptide, said polypeptide having an amino acid sequence that is at least 85 % homologous to SEQ ID NO: 3 or an immunogenic fragment of said polypeptide with a length of at least 40, preferably 45, more preferably 50 amino acids said immunogenic fragment being capable of inducing an immune response against ureaseXY.
- 11) Polypeptide according to claim 10, having a sequence homology of at least 90 %, preferably 94 %, more preferably 97 % homology to SEQ ID NO: 3, or an immunogenic fragment of said polypeptide capable of inducing an immune response

against ureaseXY.

- 12) Polypeptide according to claims 8-11 for use in a vaccine
- 13) Use of a polypeptide according to claims 8-11 in the manufacturing of a vaccine for combating *Helicobacter felis* infections.
- 14) Vaccine for combating *Helicobacter felis* infections, characterised in that it comprises a nucleic acid sequence according to claims 1-3, a DNA fragment according to claim 4, a recombinant DNA molecule according to claim 5, a live recombinant carrier according to claim 6, a host cell according to claim 7 or a polypeptide according to claims 8-11, and a pharmaceutically acceptable carrier.
- 15) Vaccine according to claim 14, characterised in that it comprises an adjuvant.
- 16) Vaccine according to claim 14 or 15, characterised in that it comprises an additional antigen derived from a virus or micro-organism pathogenic to mammals or genetic information encoding said antigen.
- 17) Vaccine according to claim 16, characterised in that said virus or micro-organism pathogenic to mammals is selected from the group of Feline Infectious Peritonitis virus, Feline Immune deficiency virus, Canine and Feline Parvovirus, Distemper virus, Adenovirus, Calicivirus, *Bordetella bronchiseptica*, *Borrelia burgdorferi*, *Leptospira interrogans*, *Chlamydia* and *Bartonella henseli*.
- 18) Vaccine for combating *Helicobacter felis* infections, characterised in that it comprises antibodies against a polypeptide according to claims 8-11.
- 19) Method for the preparation of a vaccine according to claims 14-17, said method comprising the admixing of a polypeptide according to claims 8-11 and a pharmaceutically acceptable carrier.
- 20) Diagnostic test for the detection of *Helicobacter felis* specific DNA characterised in that the test comprises a nucleic acid sequence according to claims 1-3, or a fragment thereof.
- 21) Diagnostic test for the detection of antibodies against *Helicobacter felis*, characterised in that said test comprises a polypeptide or a fragment thereof as described in claims 8-11.
- 22) Diagnostic test for the detection of antigenic material of *Helicobacter felis*, characterised in that said test comprises antibodies against a polypeptide or a fragment thereof as described in claims 8-11.

3. Detailed Description of Invention

The present invention relates to novel *Helicobacter* urease subunit polypeptides, nucleic acid sequences encoding these polypeptides, to the polypeptides for use in vaccines and to the use in the manufacturing thereof, to vaccines comprising said polypeptides and to methods for the preparation of such vaccines. Further, the invention relates to diagnostic methods for the detection of the nucleic acid sequences, the polypeptides and antibodies against the polypeptides.

Several *Helicobacter* species are the cause of pathogenesis of the gastric epithelium. *Helicobacter pylori*, and to a lesser extent *H. heilmannii* are known to cause gastritis, a major factor in the development of peptic ulcers and gastric lymphoma in humans. *Helicobacter felis* is most likely the cause of gastric infections in both cats and dogs. In order to survive the highly acidic environment of the stomach, members of the *Helicobacter* family produce an urease that is capable of hydrolysing the urea present in gastric juice. This hydrolysis sets free an amount of NH_4OH that suffices to neutralise the environment of the bacterium. It is known, that the urease plays a role in the colonisation of the bacterium as well as in its pathogenesis.

Genes encoding urease have been described and sequenced for both *Helicobacter pylori* (Labigne et al., J. Bacteriol. 173: 1920-1931 (1991)) and *Helicobacter felis* (Ferrero et al., Molec. Microbiol. 9, 323-333 (1993)). Of the seven genes involved in urease expression and secretion, only two genes encode the two structural subunits urease A and B of the urease enzyme; ureA and ureB. These two polypeptides form a polypeptide complex having urease activity.

Vaccines against infections caused by both *H. pylori* and *felis* have been made and have been the subject of i.a. International Patent Applications WO 94/09823 and WO 96/34624. Several attempts have been made, to use *H. pylori* urease as a vaccine component for the protection of cats against *H. felis* infection. Although indeed a certain level of protection can be obtained, the results are far from the 100 % protection that would be desirable. From animal experiments published so far it becomes clear that a significant number of animals vaccinated with *H. pylori* is not at all protected against subsequent challenge with *H. felis*. Protection of cats vaccinated with purified urease from either *H. felis* or *pylori* has not been described. Vaccinating cats with *H. felis* whole cell lysates might theoretically be feasible but is not a practical option. This is because in spite of many attempts for improvement, *H. felis* is difficult to grow.

There clearly is a need for an efficacious vaccine, based upon homologous components, and it is clear that the known *H. felis* urease does not confer full protection.

It is i.a. an object of the present invention to provide a *H. felis* urease which is able to induce protection against *Helicobacter felis* infection in dogs and cats. It was surprisingly found now, that in *H. felis* a second urease exists, of which the genes encoding the structural subunits share only low homology with the known *H. felis* ureA and B genes. The novel urease is named ureaseXY, in order to discriminate it from the known urease AB. The newly found urease has been discovered in *H. felis*, and is not present in *H. pylori*.

The overall genetic structure of the genes encoding the two structural urease subunits, UreX and UreY is comparable to that of the known UreA and B in *H. felis* and *H. pylori*. The sequence homology is however surprisingly low. It was even more surprisingly found, that the homology between the ureA and B genes and the novel ureX and Y genes in one single *H. felis* strain is even strikingly lower than the homology between the various ureA and B genes from the various *Helicobacter* species.

Table 1a, 1b and 1c show the comparison of the ureX and Y gene and the polypeptides they encode from five different *Helicobacter felis* species, with the ureA and B genes and polypeptides from *Helicobacter felis*, *pylori* and *heilmannii*.

The level of homology of the genes encoding the novel structural urease subunits X and Y and the polypeptides they encode as compared to that of known ureA and B genes and polypeptide subunits is presented in table 1a, b and c.

Reference molecule : <i>H. felis</i> ureX CS1	a.a.	n.a.
<i>H. felis</i> ureA	50 %	57 %
<i>H. pylori</i> ureA	52 %	60 %
<i>H. heilmannii</i> ureA	54 %	62 %
<i>H. felis</i> strain Kukka ureX	100 %	91 %
<i>H. felis</i> strain Ds4 ureX	99 %	91 %
<i>H. felis</i> strain 2301 ureX	99 %	91 %
<i>H. felis</i> strain 390 ureX	99 %	91 %

Table 1a: amino acid and nucleic acid homology between the *H. felis* ureX and various ureA subunits.

Reference molecule : <i>H. felis</i> ureY CS1	a.a.	n.a.
<i>H. felis</i> ureB	73 %	71 %
<i>H. pylori</i> ureB	73 %	70 %
<i>H. heilmannii</i> ureB	74 %	71 %
<i>H. felis</i> strain Kukka ureY	99 %	95 %
<i>H. felis</i> strain Ds4 ureY	98 %	94 %
<i>H. felis</i> strain 2301 ureY	99 %	95 %

Table 1b: amino acid and nucleic acid homology between the *H. felis* ureY and various ureB subunits.

Reference molecule: <i>H. felis</i> ureXY CSI	n.a.
<i>H. felis</i> ureAB	67 %
<i>H. pylori</i> ureAB	67 %
<i>H. heilmannii</i> ureAB	68 %
<i>H. felis</i> strain Kukka ureXY	94 %
<i>H. felis</i> strain Ds4 ureXY	94 %
<i>H. felis</i> strain 2301 ureXY	94 %

Table 1c: nucleic acid homology between *H. felis* ureXY and various ureAB genes.

One embodiment of the invention thus relates to nucleic acid sequences encoding the novel urease X and Y subunits.

First of all, this embodiment of the invention relates to nucleic acid sequences encoding two subunits of a urease complex such as expressed by *Helicobacter felis*, that have at least 85 % homology with SEQ ID NO: 1, or parts thereof with a length of at least 40, preferably 45, more preferably 50 nucleotides encoding at least an immunogenic fragment of one of the subunits. Still even longer fragments, with a length of at least 55, 60 or 70 nucleic acids are in that order even more preferred.

A preferred form of this embodiment relates to nucleic acid sequences that encode the urease X subunit polypeptide or the urease Y subunit polypeptide and that have at least 85 % homology with SEQ ID NO: 1, or parts thereof with a length of at least 40, preferably 45, more preferably 50 nucleotides encoding at least an immunogenic fragment of the urease X subunit polypeptide or the urease Y subunit polypeptide. Merely as an example: the nucleic acid sequence encoding the urease X subunit of *Helicobacter felis* strain CS1 starts at position 206/207/208 (GTG) (See figure 1a (1)) and stops at position 884/885/886 (TAA). the nucleic acid sequence encoding the urease Y subunit of *Helicobacter felis* strain CS1 starts at position 897/898/899 (ATG) and stops at position 2601/2602/2603 (TAG). Still even longer fragments, with a length of at least 55, 60 or 70 nucleic acids are in that order even more preferred.

A more preferred form of this embodiment relates to nucleic acid sequences having at least 90 %, preferably 94 %, more preferably 97 % homology with SEQ ID NO: 1.

The determination of the homology percentages was done with the computer program Align Plus for Windows, available from Scientific and Educational Software, P.O.Box 72045 Durham, NC 27722-2045, USA. Settings used for the nucleic acid comparisons are indicated in figures 1a, 1b and 1c.

Since the present invention discloses nucleic acid sequences encoding novel structural *Helicobacter felis* urease subunits, it is now for the first time possible to obtain such polypeptides in sufficient quantities. This can e.g. be done by using expression systems to express the genes encoding the UreX and UreY subunits. Therefore, in a more preferred embodiment, the invention relates to DNA fragments comprising a nucleic acid sequence according to the invention. Such DNA fragments can e.g. be plasmids, into which a nucleic acid sequence according to the invention is cloned. Such DNA fragments are useful e.g. for enhancing the amount of DNA for use as a probe, as described below.

An essential requirement for the expression of the nucleic acid sequence is an adequate promoter operably linked to the nucleic acid sequence. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.

Therefore, an even more preferred form of this embodiment relates to a recombinant DNA molecule comprising a DNA fragment or a nucleic acid sequence according to the invention that is placed under the control of a functionally linked promoter. This can be obtained by means of e.g. standard molecular biology techniques. (Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989. ISBN 0-87969-309-6).

Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acid sequences to which they are linked.

When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the α -amylase (*B. subtilis*) promoter and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell.

When the host cell is yeast, useful expression control sequences include, e.g., α -mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of mammalian origin illustrative useful expression control sequences include the SV-40 promoter (Berman, P.W. et al., Science, 222, 524-527, 1983) or the metallothionein promoter (Brinster, R.L., Nature, 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985).

Bacterial, yeast, fungal, insect and mammalian cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based expression systems are very attractive expression systems. Such systems are e.g. described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date 1 December 1993).

Thus a still even more preferred form of this embodiment of the invention relates to Live Recombinant Carrier micro-organisms (LRCs) comprising a gene encoding the UreX or UreY polypeptide or an immunogenic fragment thereof according to the invention. Such micro-organisms are e.g. bacteria and viruses. These LRC micro-organisms are micro-organisms in which additional genetic information, in this case a gene encoding the UreX or UreY polypeptide or an immunogenic fragment thereof according to the invention has been cloned. Animals infected with such LRCs will produce an immunogenic response not only against the immunogens of the vector, but also against the immunogenic parts of the polypeptide(s) for which the genetic code is additionally cloned into the LRC, e.g. the ureX or Y gene.

As an example of bacterial LRCs, attenuated Salmonella strains known in the art can attractively be used.

Live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998))

Also, LRC viruses may be used as a way of transporting the nucleic acid sequence into a target cell. Live recombinant carrier viruses are also called vector viruses. The site of integration of the gene encoding a UreX or Y polypeptide may be a site in a viral gene that is not essential to the virus, or a site in an intergenic region. Viruses often used as vectors are Vaccinia viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S.J., Dicke, K.A., Lotzova, E. and Pluznik, D.H. (Eds.), Experimental Haematology today - 1988. Springer Verlag, New York: pp. 92-99 (1989)).

The technique of *in vivo* homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.

Finally another form of this embodiment of the invention relates to a host cell comprising a nucleic acid sequence encoding a polypeptide according to the invention, a DNA fragment comprising such a nucleic acid sequence or a recombinant DNA molecule comprising such a nucleic acid sequence under the control of a functionally linked promotor. This form also relates to a host cell containing a live recombinant carrier containing a nucleic acid molecule encoding a UreX or Y polypeptide or an immunogenic fragment thereof according to the invention.

A host cell may be a cell of bacterial origin, e.g. *Escherichia coli*, *Bacillus subtilis* and *Lactobacillus* species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; *Bio-technology* 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; *Cell* 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

Another embodiment of the invention relates to the polypeptides encoded by the nucleic acid sequences, i.e. the urease X subunit and the urease Y subunit and to immunogenic fragments thereof according to the invention.

Therefore, this embodiment of the invention relates to the *Helicobacter felis* urease X polypeptide, said polypeptide having an amino acid sequence that is at least 85 % homologous to SEQ ID NO: 2 or an immunogenic fragment of that polypeptide with a length of at least 40 amino acids that is capable of inducing an immune response against ureaseXY. Preferably, the length of that fragment is more than 40 amino acids, more preferably at least 45, 50, 55, 60 or 70 amino acids in that order or preference.

Preferably this embodiment relates to such polypeptides having a sequence homology of at least 90 %, more preferably 94 %, even more preferably 97 % homology to SEQ ID NO: 2, or an immunogenic fragment of that polypeptide with a length of at least 40 amino acids, more preferably at least 45, 50, 55, 60 or 70 amino acids in that order or preference that is capable of inducing an immune response against ureaseXY.

This embodiment of the invention also relates to the *Helicobacter felis* urease Y polypeptide, said polypeptide having an amino acid sequence that is at least 85 % homologous to SEQ ID NO: 3 or an immunogenic fragment of that polypeptide with a length of at least 40 amino acids that is capable of inducing an immune response against ureaseXY. Preferably, the length of that fragment is more than 40 amino acids, more preferably at least 45, 50, 55, 60 or 70 amino acids in that order or preference.

Preferably this embodiment relates to such polypeptides having a sequence homology of at least 90 %, more preferably 94 %, even more preferably 97 % homology to SEQ ID NO: 3, or an immunogenic fragment of that polypeptide with a length of at least 40 amino acids, more preferably at least 45, 50, 55, 60 or 70 amino acids in that order or preference that is capable of inducing an immune response against ureaseXY.

As for the nucleotide sequence comparison, the comparison between the various amino acid sequences was made using Align Plus for Windows, available from Scientific and Educational Software, P.O.Box 72045 Durham, NC 27722-2045, USA. Settings used for the amino acid comparisons are indicated in figures 1a, 1b and 1c.

It will be understood that, for the particular polypeptides embraced herein, natural variations can exist between individual *Helicobacter felis* strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al in "The Proteins" Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting polypeptides retain their immunoreactivity. Thus, variations not essentially influencing the immunogenicity of the polypeptide compared to the wild type polypeptide as depicted in SEQ ID NO: 2 or 3 are considered to fall within the scope of the invention. Those variations in the amino acid sequence of a certain structural subunit X or Y according to the invention that still provide a polypeptide capable of inducing an immune response against infection with *H. felis* or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunogenicity".

When a polypeptide is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole polypeptide. It is also possible to use a fragment of that polypeptide that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that polypeptide, a so-called immunogenic fragment. An "immunogenic fragment" is understood to be a fragment of the full-length polypeptide of the structural subunit X or Y, that still has retained its capability to induce an immune response in the host, i.e. comprises a B- or T-cell epitope. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the polypeptide. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes. Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific polypeptide fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl.

Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzowsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).

Vaccines against e.g. *Helicobacter pylori*, which has only one urease, can be made on the basis of this urease, as was described above. In the specific case of *Helicobacter felis* however a vaccine based upon the known *Helicobacter felis* structural subunits ureA and B is not capable of providing sufficient protection against *Helicobacter felis* infection: immunity against structural subunits ureA and B allegedly does not neutralise the urease activity of the newly found heterologous structural subunits UreX and Y.

Therefore, vaccines for the protection of animals against *Helicobacter felis* infection should at least be directed against the novel urease XY.

Therefore, one form of still another embodiment of the invention relates to vaccines capable of protecting mammals such as dogs and cats against *Helicobacter felis* infection, that comprise the structural subunit X or Y, preferably X and Y, more preferably X, Y, A and B, or an immunogenic fragment of X and/or Y according to the invention together with a pharmaceutically acceptable carrier.

Still another embodiment of the present invention relates to the polypeptides according to the invention for use in a vaccine.

Still another embodiment relates to the use of the polypeptide according to the invention in the manufacturing of a vaccine for combating *Helicobacter felis* infections.

One way of making a vaccine according to the invention is by biochemical purification of the ureaseXY polypeptide or its subunits from a bacterial culture. This can e.g. be done by centrifugation of the bacteria, and the use of gel-filtration columns for separation of the urease polypeptide or its subunits from other components. Further purification may e.g. be done by selective precipitation in ammonium-sulphate, followed by centrifugation, gel electrophoresis and, if desired, separation from the urease AB subunits and dissolving the pellet in a suitable buffer. This is however a time-consuming way of making the vaccine, especially where *Helicobacter felis* is difficult to grow.

It is therefore much more convenient to use the expression products of the genes encoding the urease X and Y subunits according to the invention in vaccines. Such vaccines can easily be made by admixing ureaseXY or an UreX or UreY subunit or an immunological fragment thereof according to the invention with a pharmaceutically acceptable carrier as described below.

Furthermore vaccines can comprise live recombinant carriers as described above, capable of expressing ureaseXY, an UreX or UreY subunit or immunogenic fragments thereof according to the invention. Such vaccines, e.g. based upon a Salmonella carrier or a viral carrier infecting the gastric epithelium have the advantage over subunit vaccines that they better mimic the natural way of infection of *Helicobacter felis*.

Moreover, their self-propagation is an advantage since only low amounts of the recombinant carrier are necessary for immunisation.

Vaccines described above all contribute to active vaccination, i.e. the host's immune system is triggered by the UreX and/or Y polypeptide or immunogenic fragments thereof, to make antibodies against these polypeptides.

Alternatively, such antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the host animal. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for vaccinating immune-compromised animals. Administered antibodies against *Helicobacter* UreX or UreY can in these cases bind directly to the urease excreted by the bacteria. This has the advantage that the urease activity is directly eliminated, thus resulting in acidification of the environment and decreased or stopped *Helicobacter* growth.

Therefore, one other form of this embodiment of the invention relates to vaccines comprising antibodies against *Helicobacter felis* urease X polypeptides that have an amino acid sequence that is at least 85 % homologous to SEQ ID NO: 2 or immunogenic fragments of that polypeptide with a length of at least 40 amino acids that are capable of inducing an immune response against ureaseXY or antibodies against *Helicobacter felis* urease Y polypeptides that have an amino acid sequence that is at least 85 % homologous to SEQ ID NO: 3 or immunogenic fragments of that polypeptide with a length of at least 40 amino acids that are capable of inducing an immune response against ureaseXY.

Vaccines can also be based upon host cells as described above, that comprise ureaseXY, an UreX or UreY subunit or immunogenic fragments thereof according to the invention.

An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding polypeptides has been successful for many different polypeptides. (As reviewed in e.g. Donnelly et al., *The Immunologist* 2: 20-26 (1993)).

This way of vaccination is very attractive for the vaccination of both cats and dogs against *Helicobacter felis* infection.

Therefore, still other forms of this embodiment of the invention relate to vaccines comprising nucleic acid sequences encoding a polypeptide according to the invention or immunogenic fragments thereof according to the invention, and to vaccines comprising DNA fragments that comprise such nucleic acid sequences.

Still other forms of this embodiment relate to vaccines comprising recombinant DNA molecules according to the invention.

DNA vaccines can easily be administered through intradermal application e.g. using a needle-less injector. This way of administration delivers the DNA directly into the cells of the animal to be vaccinated. Amount of DNA in the microgram range between 1 and 100 µg provide very good results.

In a further embodiment, the vaccine according to the present invention also comprises antigens from other dog or cat pathogenic organisms and viruses, or genetic information encoding such antigens. Such organisms and viruses are e.g. Feline Infectious Peritonitis virus, Feline Immune deficiency virus, Canine and Feline Parvovirus,

Distemper virus, Adenovirus, Calicivirus, *Bordetella bronchiseptica*, *Borrelia burgdorferi*, *Leptospira interrogans*, *Chlamydia* and *Bartonella henseli*.

Also, the present invention relates to polypeptides according to the invention for use in the manufacturing of a vaccine for combating *Helicobacter felis* infections.

All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

Vaccines according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants are Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyl dipeptides, Quil A^(R), mineral oil e.g. Bayol^(R) or Markol^(R), vegetable oil, and Carbopol^(R) (a homopolymer), or Diluvac^(R) Forte. The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle compounds are e.g. aluminium hydroxide, -phosphate or -oxide, silica, Kaolin, and Bentonite.

A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)

In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology 59: 509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

In addition, the vaccine may be suspended in a physiologically acceptable diluent. It goes without saying, that other ways of adjuvating, adding vehicle compounds or diluents, emulsifying or stabilising a polypeptide are also embodied in the present invention.

Vaccines according to the invention that comprise the UreX or UreY subunit polypeptide can very suitably be administered in amounts ranging between 1 and 100 micrograms, although smaller doses can in principle be used. A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.

Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply themselves during the infection. Therefore, very suitable amounts would range between 10^3 and 10^9 CFU/PFU for respectively bacteria and viruses.

Many ways of administration can be applied. Intranasal application is a frequently used way of administering a vaccine. Oral application is also an attractive way of administration, because the infection is often located in the upper digestive tract. A preferred way of oral administration is the packaging of the vaccine in capsules, known and frequently used in the art, that only disintegrate in the highly acidic environment of

the stomach. Also, the vaccine could be mixed with compounds known in the art for temporarily enhancing the pH of the stomach.

Systemic application is also suitable, e.g. by intramuscular application of the vaccine. If this route is followed, standard procedures known in the art for systemic application are well-suited.

Another embodiment of the invention relates to diagnostic tests for the detection of *H. felis* infection. It is known that several *Helicobacter* species such as *H. bizzozeronii*, *H. felis* and *H. salomonis* are capable of infecting both cats and dogs. Of these three, *H. felis* is the species suspected to cause most of the pathology, although it is often outnumbered by *H. bizzozeronii* and *H. salomonis*. Thus, a quick and correct diagnosis of disease, in both cats and dogs, caused by *Helicobacter felis* is important. It has however been very difficult to discriminate between these three species due to the fact that they are so very closely related.

Therefore it is another objective of this invention to provide such diagnostic tools suitable for discriminating *H. felis* from other *Helicobacter* species.

On the basis of the novel urease polypeptides and the genes encoding the urease polypeptides, at least three different diagnostic tests, specifically suitable for the discrimination of *H. felis* from other members of the *Helicobacter* family were developed:

- 1) a diagnostic test based upon the presence or absence of DNA encoding the specific UreX and UreY structural subunits
- 2) a diagnostic test based upon the detection of antibodies against the specific UreX and UreY structural subunits
- 3) a diagnostic test based upon the detection of antigenic material of the specific UreX and UreY structural subunits

A diagnostic test according to 1) is e.g. based upon the reaction of bacterial DNA isolated from the animal to be tested, with specific probes or PCR-primers based upon the sequence of ureX or Y genes. If *H. felis* DNA is present in the animal, this will e.g. specifically bind to ureX or Y specific PCR-primers and will subsequently become amplified in PCR-reaction. The PCR-reaction product can then easily be detected in DNA gel electrophoresis.

The DNA can most easily be isolated from the micro-organisms present in swabs of the upper digestive tract or in the saliva of the animal to be tested. Specific primers can easily be selected from the many regions of the ureX and ureY coding sequences and the non-coding intergenic sequence that differ in sequence from the comparable regions in the ureAB coding sequences. One of the many algorithms suitable for the determination of the level of nucleic acid homology and for comparison of nucleotide sequences in general is known as "Clustal W". It has been described by Thompson et al., in Nucleic Acid Research 22: 4673-4680 (1994). The program can be found at several sites on Internet. An more recent alternative for this program is e.g. Align Plus for Windows, available from Scientific and Educational Software, P.O.Box 72045 Durham, NC 27722-2045, USA.

As follows from figure 1, a large number of possible PCR-primers can be found that are specific for ureX or ureY. An extremely specific pair of PCR-probes is e.g. formed by the 5'-located sequence CATGCACTTTTGGAAAAAGA (SEQ ID NO: 16) and the 3'-located sequence TATGGTGGTCTTCTCT (SEQ ID NO: 17). Of course many other sequences that are specific for ureX or Y or the intergenic region are suitable. Standard PCR-textbooks give methods for determining the suitability of the probes for selective PCR-reactions with ureX or ureY. PCR-techniques are extensively described in

(Dieffenbach & Dreksler; PCR primers, a laboratory manual. ISBN 0-87969-447-5 (1995)).

Another DNA-based test is based upon growth of bacterial material obtained from the swab, followed by classical DNA purification followed by classical hybridisation with radioactively or colour-labelled ureXY-specific DNA-fragments. Given the very low homology between the ureXY-coding regions and the ureAB coding regions of both *H. felis* and other *Helicobacter* species, hybridisation unambiguously indicates the presence or absence of *H. felis*. Both PCR-reactions and hybridisation reactions are well-known in the art and are i.a. described in Maniatis/Sambrook (Sambrook, J. *et al.* Molecular cloning: a laboratory manual. ISBN 0-87969-309-6).

Selective detection with PCR-primers or with classical hybridisation with ureXY-specific DNA-fragments can be done with fragments that preferably are short, but for practical reasons preferably consist of a stretch of at least 10 contiguous nucleotides of SEQ ID NO: 1. It is clear that for hybridisation experiments a probe needs to be selected that has a higher homology to SEQ ID NO: 1, than to sequences encoding the *Helicobacter* ureA or ureB subunit. Such a probe can very easily be selected with the help of the Align Plus for Windows program or the Clustal W program as discussed above. In a comparative hybridisation experiment the DNA to be diagnosed can be tested next to e.g. *H. pylori* DNA. The probe according to the invention, having a higher homology to SEQ ID NO: 1 than to a gene encoding ureAB, would bind better to *H. felis* DNA (if present in the sample) than to DNA of other *Helicobacter* species thus specifically revealing the presence of *H. felis* DNA in the sample to be tested. The sequences SEQ ID NO: 16 or 17 mentioned above are merely examples of probes very suitable for labelling and subsequent use in the *H. felis*-specific hybridisation assays as described.

Thus, one embodiment of the invention relates to a diagnostic test for the detection of DNA encoding the specific *Helicobacter* UreX and UreY subunit polypeptides. Such a test comprises a nucleic acid sequence according to the invention or a fragment thereof that is specific for the DNA encoding UreX and UreY or the intergenic region between UreX and UreY. A fragment that is specific for that DNA is a fragment that binds better to the DNA encoding UreX and UreY or the intergenic region between UreX and UreY than to the DNA encoding UreA and UreB or the intergenic region between UreA and UreB.

Methods for the detection of *Helicobacter felis* DNA comprise hybridisation of the DNA to be tested with UreX or Y DNA, or PCR-reaction of the DNA to be tested with UreX or Y DNA specific probes.

A diagnostic test according to 2) for the detection of *Helicobacter felis* antibodies in sera can be e.g. a simple sandwich-ELISA-test in which purified UreX or UreY subunit polypeptides or antigenic fragments thereof according to the invention are coated to the wall of the wells of an ELISA-plate. A method for the detection of such antibodies is e.g. incubation of purified UreX or Y polypeptide with serum from mammals to be tested, followed by e.g. incubation with a labelled antibody against the relevant mammalian antibody. A colour reaction can then reveal the presence or absence of antibodies against *Helicobacter felis* urease XY. Depending on the labelled antibodies used, the selectivity of this system can be improved by pre-incubation of the serum to be tested with urease AB followed by spinning down the precipitate, in order to avoid non-XY-specific reactions.

If antigenic fragments of the UreX or UreY structural subunits according to the invention are used for coating, this pre-incubation step can be skipped.

Another example of a diagnostic test system is e.g. the incubation of a Western blot comprising UreX or UreY polypeptide or an antigenic fragment thereof according to the invention, with serum of mammals to be tested, followed by analysis of the blot. The purified UreX and UreY structural subunits or antigenic fragments thereof according to the invention, suitable for the coating of ELISA plates or for Western blotting can easily be obtained by expression of the ureX and ureY gene as was described by Ferrero for ureA and B (Ferrero et al., *Molec. Microbiol.* 9, 323-333 (1993)).

Also, the invention relates to methods for the detection in serum of antibodies against *Helicobacter felis* antibodies in which the method comprises the incubation of serum with UreX or UreY polypeptide or an antigenic fragment thereof according to the invention.

A diagnostic test according to 3) based upon the detection of antigenic material of the specific UreX and UreY structural subunits of *Helicobacter felis* antigens and therefore suitable for the detection of *Helicobacter felis* infection can e.g. also be a standard ELISA test. In one example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the specific UreX and UreY structural subunits of *Helicobacter felis*. The antigenic material to be tested can if necessary be pre-incubated with antibodies against UreA and B. This will leave the UreX and Y specific epitopes uncovered and therefore the pre-incubated *Helicobacter* species will bind to the ELISA plate only if it comprises UreX or Y, i.e. if it specifically is *Helicobacter felis*. The use of monoclonal antibodies specific for UreX or Y and not reacting with UreA or B are the preferred antibodies in such tests, because they make the pre-incubation step superfluous. Such monoclonal antibodies can easily be obtained by immunising inbred mice with immunising fragments of UreX or Y according to the invention, by techniques also known in the art (See below: Kohler and Milstein).

The polypeptides or immunogenic fragments thereof according to the invention expressed as characterised above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds. *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987).

Monoclonal antibodies, reactive against the polypeptide according to the invention (or variants or fragments thereof) according to the present invention, can be prepared by immunising inbred mice by techniques also known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

Finally, the invention relates to methods for the detection of antigenic material from *Helicobacter felis* in which the method comprises the incubation of serum, tissue or body fluids with antibodies against UreX or UreY polypeptide or an antigenic fragment thereof according to the invention.

Example 1

The *ureX* and *ureY* genes of *Helicobacter felis* strain CS1: cloning and expression in *Escherichia coli*.

The *ureX* and *ureY* genes of *H. felis* strain CS1 were cloned as an operon into an *E. coli* T7 expression vector, pET3a, as follows:

For proper expression of the UreX and Y proteins in pET3a (Novagen, 601 Science Drive, Madison WI, USA) the genes were cloned as a *NdeI*-*Bam*HI DNA fragment into the *NdeI*-*Bam*HI sites of this vector. The *ureaseXY* operon contains an internal *NdeI* site that was mutated by overlap-extension PCR of 2 PCR fragments. For that purpose two PCR fragments (the 5' and the 3' products) were amplified using chromosomal DNA of *H. felis* CS1 as the template. The 5' PCR product contained the complete *ureX* gene and the first part of the *ureY* gene. The forward primer contained a *NdeI* restriction site and the start codon of *ureX* (GGAGTAACATATGAAACTCACA CCCAAAGAGC) (SEQ ID NO: 18), and the reverse primer contains a point mutation (CACACCC ACGACCATGTGAGGGCTTAC) (SEQ ID NO: 19). The second, 3' PCR product consisted of the 3' end of the *ureY* gene. This forward primer is complementary to the reverse primer of the first PCR product and also contained the same point mutation (GTAAGCC CTCACATGGTTCGTGGGTGTG) (SEQ ID NO: 20), and the reverse primer contained a *Bam*HI restriction site just downstream of the stopcodon of the *ureY* gene (CGAATT CGGATCCTAGAAGAAAGTGTAGCGCTGG) (SEQ ID NO: 21). The mutation in the complementary primers is made to delete the internal *NdeI* site in *ureY*, it replaces the CATATG (His- Met) by CACATG (His-Met).

After amplification of both PCR products, the complete operon was obtained by overlap-extension-PCR with the forward primer of the *ureX* and the reverse primer of the *ureY* using both PCR products as templates. The resulting PCR product was cloned into PCR-bluntII-TOPO (Invitrogen, P.O.Box 2312, 9704 CH Groningen, The Netherlands) and transformed into *E. coli* TOP10F' cells (Invitrogen). Positive clones were isolated and the *ureaseXY* genes were sub-cloned into pET3a with *NdeI*-*Bam*HI. The obtained plasmid was called pUreXY-1 and was transformed into the expression strain HMS174(DE3)/pLysS (Novagen).

The *ureX* and *ureY* genes of pUreXY-1 were expressed in HMS174(DE3)/pLysS as follows: an overnight culture was diluted 1/100 into TB Amp¹⁰⁰ Cam²⁵; this culture was incubated for 3 h at 37°C at 200 rpm; the culture was induced by adding 1 mM of IPTG and incubated for another 3 h at 37°C at 200 rpm. The induction was done twice, once in a small scale and once in a large scale.

The induced samples were analysed on a SDS-PAGE gel (fig. 2). As can be clearly seen from lane 9, expression of UreX and UreY, when induced provides the two structural subunits as polypeptide bands with a molecular weight of 25 kDa for the UreX subunit and 62 kDa for the UreY subunit.

SEQUENCE LISTING

<110> AKZO Nobel N.V.

<120> Helicobacter vaccine
3

<130> Degoedesequenties

<140>

<141>

<160> 21

<170> PatentIn Ver. 2.1

<210> 1

<211> 2883

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (206)..(886)

<220>

<221> CDS

<222> (897)..(2603)

<400> 1

rggragattt tccarcactt caagcacata ttgatcctgt gttgtgggtg gtaaattrcr 60

acttgtaaat rctattatta atttttaat aattacttat tatcatatat aataatatta 120

ttacttatat taaaaagta ataaaaagta acgaaattag gactataatc ccattgcott 180

taaaatttaa cacaaggagt aatag gtg aaa ctc aca ccc aaa gag caa gaa 232

Val Lys Leu Thr Pro Lys Glu Gln Glu

1

5

aag ttc ttg tta tat tat gcg ggc gaa gtg gct aga aag cgc aaa gca 280
Lys Phe Leu Leu Tyr Tyr Ala Gly Glu Val Ala Arg Lys Arg Lys Ala
10 15 20 25

gag ggc tta aag ctc aac caa ccc gaa gcc att gct tac att agt gcc 328
Glu Gly Leu Lys Leu Asn Gln Pro Glu Ala Ile Ala Tyr Ile Ser Ala
30 35 40

cat att atg gac gaa gcg cgc cgt gga aaa aaa acc gtt gcc cag ctt 376
His Ile Met Asp Glu Ala Arg Arg Gly Lys Lys Thr Val Ala Gln Leu
45 50 55

atg gaa gag tgc atg cac ttt ttg aaa aaa gat gaa gta atg ccc ggg 424
Met Glu Glu Cys Met His Phe Leu Lys Lys Asp Glu Val Met Pro Gly
60 65 70

gtg ggt aat atg gtt ccc gat cta ggt gta gaa gcc acc ttt cct gat 472
Val Gly Asn Met Val Pro Asp Leu Gly Val Glu Ala Thr Phe Pro Asp
75 80 85

ggg acg aaa ctt gta act gtg aat tgg ccc atc gaa cca gat gag cac 520
Gly Thr Lys Leu Val Thr Val Asn Trp Pro Ile Glu Pro Asp Glu His
90 95 100 105

ttc aaa gcg ggc gaa gtg aaa ttt ggt tgc gat aaa gac atc gag ctc 568
Phe Lys Ala Gly Glu Val Lys Phe Gly Cys Asp Lys Asp Ile Glu Leu
110 115 120

aat gca ggc aaa gaa gta acc gaa ctt gag gtt act aat gaa ggg cct 616
Asn Ala Gly Lys Glu Val Thr Glu Leu Glu Val Thr Asn Glu Gly Pro
125 130 135

aaa tcc ttg cat gtg ggt agc cat ttc cac ttc ttt gaa gct aac aag 664
Lys Ser Leu His Val Gly Ser His Phe His Phe Phe Glu Ala Asn Lys
140 145 150

gca cta aaa ttc gat cgt gaa aaa gcc tat ggc aaa cgc cta gat att 712

Ala	Leu	Lys	Phe	Asp	Arg	Glu	Lys	Ala	Tyr	Gly	Lys	Arg	Leu	Asp	Ile		
	155					160					165						
ccc	tct	ggc	aac	acg	cta	cgc	att	ggg	gca	gga	caa	acc	cgc	aaa	gtg	760	
Pro	Ser	Gly	Asn	Thr	Leu	Arg	Ile	Gly	Ala	Gly	Gln	Thr	Arg	Lys	Val		
170					175					180				185			
cag	ttg	att	cct	ctt	ggt	ggc	agt	aaa	aaa	gtg	att	ggc	atg	aac	ggg	808	
Gln	Leu	Ile	Pro	Leu	Gly	Gly	Ser	Lys	Lys	Val	Ile	Gly	Met	Asn	Gly		
				190					195					200			
ctt	gtg	aat	aac	atc	gcg	gat	gaa	cgc	cat	aaa	cat	aaa	gcg	ctt	gac	856	
Leu	Val	Asn	Asn	Ile	Ala	Asp	Glu	Arg	His	Lys	His	Lys	Ala	Leu	Asp		
			205					210					215				
aag	gcg	aaa	tct	cac	gga	ttt	atc	aag	taa	ggagactccc	atg	aaa	atg			905	
Lys	Ala	Lys	Ser	His	Gly	Phe	Ile	Lys				Met	Lys	Met			
	220						225						230				
aaa	aaa	caa	gaa	tat	gta	aat	acc	tac	gga	ccc	acc	aaa	ggc	gat	aaa	953	
Lys	Lys	Gln	Glu	Tyr	Val	Asn	Thr	Tyr	Gly	Pro	Thr	Lys	Gly	Asp	Lys		
			235					240					245				
gtg	cgc	tta	gga	gat	acc	gat	ctt	tgg	gca	gaa	gta	gaa	cat	gac	tat	1001	
Val	Arg	Leu	Gly	Asp	Thr	Asp	Leu	Trp	Ala	Glu	Val	Glu	His	Asp	Tyr		
			250					255					260				
acc	acc	tat	ggc	gaa	gaa	ctt	aaa	ttt	ggc	gcg	ggt	aaa	act	atc	cgt	1049	
Thr	Thr	Tyr	Gly	Glu	Glu	Leu	Lys	Phe	Gly	Ala	Gly	Lys	Thr	Ile	Arg		
		265					270					275					
gag	ggt	atg	ggt	cag	agc	aat	agc	cct	gat	gaa	aac	acc	cta	gat	tta	1097	
Glu	Gly	Met	Gly	Gln	Ser	Asn	Ser	Pro	Asp	Glu	Asn	Thr	Leu	Asp	Leu		
	280					285					290						
gtc	atc	act	aac	gcg	atg	att	atc	gac	tac	acc	ggg	att	tac	aaa	gcc	1145	
Val	Ile	Thr	Asn	Ala	Met	Ile	Ile	Asp	Tyr	Thr	Gly	Ile	Tyr	Lys	Ala		
295				300						305				310			

gac att ggg att aaa aac ggc aaa atc cat ggc att ggc aag gca gga 1193
Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly Lys Ala Gly
315 320 325

aac aag gac atg caa gat^sggc gta agc cct cat atg gtc gtg ggt gtg 1241
Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val Val Gly Val
330 335 340

ggc aca gaa gca cta gca ggg gaa ggt atg att att acc gct ggg gga 1289
Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr Ala Gly Gly
345 350 355

atc gat tca cac acc cac ttc ctt tct cca caa caa ttc cct acc gct 1337
Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe Pro Thr Ala
360 365 370

cta gcc aat ggc gtt aca acc atg ttt gga ggc ggc aca ggt cct gta 1385
Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr Gly Pro Val
375 380 385 390

gat ggc acg aat gcg act act atc act ccg ggc aaa tgg aac ttg cac 1433
Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp Asn Leu His
395 400 405

cgc atg ttg cgc gca gca gaa gag tat tct atg aat gtg ggc ttt ttg 1481
Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val Gly Phe Leu
410 415 420

ggc aaa ggc aat agc tct agc aaa aaa caa ctt gta gaa caa gta gaa 1529
Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu Gln Val Glu
425 430 435

gcg ggc gcg att ggt ttt aaa ttg cat gaa gac tgg ggc aca aca cca 1577
Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly Thr Thr Pro
440 445 450

agt gcg atc gat cac tgc ttg agc gtc gca gat gaa tac gat gtg caa 1625

Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr Asp Val Gln
 455 460 465 470

gtt tgt atc cac acc gat aca gtc aat gag gca ggt tat gta gat gac 1673
 Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr Val Asp Asp
 475 480 485

acc cta aat gca atg aac ggg cgc gcc atc cat gcc tac cac att gag 1721
 Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr His Ile Glu
 490 495 500

gga gcg ggt gga gga cac tca cct gat gtt atc acc atg gca ggc gag 1769
 Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met Ala Gly Glu
 505 510 515

ctc aat att cta ccc tcc tcc acc acc ccc act att ccc tat acc att 1817
 Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro Tyr Thr Ile
 520 525 530

aat acg gtt gca gaa cac tta gac atg ctc atg aca tgc cac cac cta 1865
 Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys His His Leu
 535 540 545 550

gac aaa cgc atc cgc gag gat tta caa ttt tct caa agc cgt atc cgc 1913
 Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser Arg Ile Arg
 555 560 565

ccc ggc tct atc gcg gct gaa gat gtg ctc cat gat atg ggt gtg atc 1961
 Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Met Gly Val Ile
 570 575 580

gcg atg aca agc tcg gat tcg caa gca atg ggg cgt gca ggc gaa gtg 2009
 Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala Gly Glu Val
 585 590 595

att cct cga act tgg cag act gcg gat aag aat aaa aaa gaa ttt ggt 2057
 Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys Glu Phe Gly
 600 605 610

aag ctt cct gaa gat ggc aaa gat aac gat aat ttc cgc att aag cgc 2105
Lys Leu Pro Glu Asp Gly Lys Asp Asn Asp Asn Phe Arg Ile Lys Arg
615 620 625 630

tac atc tcc aaa tac act² atc aac ccc gct ttg acc cac ggc gtg agc 2153
Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His Gly Val Ser
635 640 645

gag tat atc ggc tct gtg gaa gag ggc aag atc gcc gac ttg gtg gtg 2201
Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp Leu Val Val
650 655 660

tgg aat cct gcc ttt ttt ggc gta aaa ccc aaa atc gtg atc aaa ggc 2249
Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val Ile Lys Gly
665 670 675

ggg atg gtg gtc ttc tct gaa atg ggc gat tct aac gcg tct gtg ccc 2297
Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala Ser Val Pro
680 685 690

act ccc caa ccg gtt tat tac cgc gaa atg ttt ggg cat cac ggc aag 2345
Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His His Gly Lys
695 700 705 710

gcg aaa ttt gac acc agc atc act ttt gtt tcc aaa gtc gcc tat gaa 2393
Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val Ala Tyr Glu
715 720 725

aat ggc gtg aaa gaa aag ctg ggc tta gag cgc caa gtt cta ccg gtc 2441
Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Gln Val Leu Pro Val
730 735 740

aaa aac tgc cgt aac atc acc aag aaa gac ttc aag ttc aac gac aaa 2489
Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe Asn Asp Lys
745 750 755

acg gca aaa atc acc gtc gat ccg aaa acc ttc gag gtc ttt gta gat 2537

Thr Ala Lys Ile Thr Val Asp Pro Lys Thr Phe Glu Val Phe Val Asp
 760 765 770

ggc aaa ctc tgc acc tct aaa ccc acc tcg caa gtg cct cta gcc cag 2585
 Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser Gln Val Pro Leu Ala Gln
 775 780 785 790

cgc tac act ttc ttc tag gcacaatgcc ccotttgggg gcaggttatt 2633
 Arg Tyr Thr Phe Phe
 795

ttaggaatct tcatcaaacg cacctgcaat cgggtttgctg tgtgcgatcg tgctgcttta 2693

aaacaacttt tcatctttaa gcaatcgcca tttttaatta atttaattct..tataattaat..2753

attatattat gccccctcat..ttttaaagga gaattatgcg taggtotttg gtattgetat 2813

gtggggggttg tttggtgctg ggcgcaaagg gtattgaaac..ccatcgccctc aaaaaagtag 2873

aagccacagg 2883

<210> 2
 <211> 226
 <212> PRT
 <213> Helicobacter felis

<400> 2

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Gln Leu Met Glu Glu Cys Met His Phe

<212> PRT

<213> Helicobacter felis

<400> 3

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Lys

1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu

20 25 30

His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys

35 40 45

Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp Glu Asn Thr

50 55 60

Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr Thr Gly Ile

65 70 75 80

Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly

85 90 95

Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val

100 105 110

Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr

115 120 125

Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe

130 135 140

Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr

145 150 155 160

Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp

165 170 175

Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val

Glu Phe Gly Lys Leu Pro Glu Asp Gly Lys Asp Asn Asp Asn Phe Arg
 385 390 395 400

Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His
 405 410 415

Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp
 420 425 430

Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val
 435 440 445

Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala
 450 455 460

Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His
 465 470 475 480

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val
 485 490 495

Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Gln Val
 500 505 510

Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe
 515 520 525

Asn Asp Lys Thr Ala Lys Ile Thr Val Asp Pro Lys Thr Phe Glu Val
 530 535 540

Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser Gln Val Pro
 545 550 555 560

Leu Ala Gln Arg Tyr Thr Phe Phe
 565

<210> 4

<211> 2405

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (1)..(681)

<220>

<221> CDS

<222> (692)..(2398)

<400> 4

```

gtg aaa ctc aca ccc aaa gag caa gaa aag ttc ttg tta tat tat gcg      48
Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
   1             5             10             15

ggc gaa gtg gct aga aag cgc aaa gca gag ggc tta aag ctc aat caa      96
Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
           20             25             30

ccc gaa gcc att gcc tac att agt gcc cat att atg gac gag gcg cgc      144
Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
           35             40             45

cgt ggc aaa aaa acc gtt gct gaa ctt atg gaa gaa tgt atg cac ttt      192
Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
   50             55             60

ttg aaa aaa gat gag gtg atg ccc ggt gtg ggg aat atg gtc cct gat      240
Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
   65             70             75             80

ttg ggc gta gaa gcc act ttc ccc gat ggc acc aaa ctc gta acc gtg      288
Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
           85             90             95

```

aat tgg ccc att gaa cct gat gaa cac ttt aaa gcc ggt gaa gtg aaa 336
Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
100 105 110

ttt ggc tgt gat aaa gac att gag ctc aac gcg ggt aag gaa gtt acc 384
Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr
115 120 125

gag ctt gaa gtt acc aac gaa gga cct aaa tcc ttg cat gtg ggt agc 432
Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
130 135 140

cat ttc cac ttc ttt gaa acc aac aag gca ttg aaa ttc gat cgg gaa 480
His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg Glu
145 150 155 160

aaa gcc tat ggc aaa cgc cta gat att ccc tct ggc aac acg cta cgc 528
Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
165 170 175

att ggg gca gga caa acc cgt aaa gtg cag tta atc cct ctt ggc ggt 576
Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
180 185 190

agt aaa aaa gtg att ggc atg aac ggg ctt gtg aat aat att gcg gac 624
Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
195 200 205

gaa cgc cat aaa cac aaa gca cta gac aag gca aaa tct cac gga ttc 672
Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe
210 215 220

atc aag taa ggagactccc atg aaa atg aaa aaa caa gag tat gta aac 721
Ile Lys Met Lys Met Lys Lys Gln Glu Tyr Val Asn
225 230 235

acc tac gga ccc acc aca ggc gat aaa gtg cgc tta gga gat acc gat 769
Thr Tyr Gly Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp

240	245	250	
ott tgg gca gaa gta gaa cat gac tat acc act tat ggc gaa gag ctc			817
Leu Trp Ala Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu			
255	260	265	
aaa ttt ggc gcg ggt aaa act atc cgt gag ggt atg ggt cag agc aat			865
Lys Phe Gly Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser Asn			
270	275	280	285
agc cca gat gaa aac acc tta gat tta gtg atc acc aac gcg atg att			913
Ser Pro Asp Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met Ile			
290	295	300	
atc gac tac acc ggg att tat aaa gcc gac att ggt att aaa aat ggc			961
Ile Asp Tyr Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly			
305	310	315	
aaa atc cat ggt att ggc aag gcg ggg aac aaa gac atg caa gat ggc			1009
Lys Ile His Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp Gly			
320	325	330	
gta agc cct cat atg gtc gtg ggt gtg ggc aca gaa gca cta gca ggg			1057
Val Ser Pro His Met Val Val Gly Val Gly Thr Glu Ala Leu Ala Gly			
335	340	345	
gaa ggt atg att att acc gct ggg ggg atc gat tcg cac acc cac ttc			1105
Glu Gly Met Ile Ile Thr Ala Gly Gly Ile Asp Ser His Thr His Phe			
350	355	360	365
ctc tct ccc caa caa ttc cct acc gct cta gcc aat ggt gtt aca acc			1153
Leu Ser Pro Gln Gln Phe Pro Thr Ala Leu Ala Asn Gly Val Thr Thr			
370	375	380	
atg ttt gga ggt ggc aca ggt ccg gta gat ggc acg aat gcg acc acc			1201
Met Phe Gly Gly Gly Thr Gly Pro Val Asp Gly Thr Asn Ala Thr Thr			
385	390	395	

atc act ccg ggc aaa tgg aac ttg cac cgc atg ttg cgc gca gct gaa 1249
 Ile Thr Pro Gly Lys Trp Asn Leu His Arg Met Leu Arg Ala Ala Glu
 400 405 410

gag tat tct atg aat gtg ggc ttt ttg ggc aaa ggc aat agc tcc agt 1297
 Glu Tyr Ser Met Asn Val Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser
 415 420 425

aaa aaa caa ctc gta gaa caa gta gaa gcg ggc gcg att ggc ttt aaa 1345
 Lys Lys Gln Leu Val Glu Gln Val Glu Ala Gly Ala Ile Gly Phe Lys
 430 435 440 445

ttg cat gaa gac tqg ggc aca aca cca agt gcg atc gat cac tgc ttg 1393
 Leu His Glu Asp Trp Gly Thr Thr Pro Ser Ala Ile Asp His Cys Leu
 450 455 460

agc gta gca gat gaa tac gat gtg caa gtt tgt atc cac acc gat acg 1441
 Ser Val Ala Asp Glu Tyr Asp Val Gln Val Cys Ile His Thr Asp Thr
 465 470 475

gtc aat gag gca ggt tat gta gat gac acc cta aat gcg atg aac ggg 1489
 Val Asn Glu Ala Gly Tyr Val Asp Asp Thr Leu Asn Ala Met Asn Gly
 480 485 490

cgc gcc atc cat gcc tac cac att gag gga gcg ggc gga gga cac tca 1537
 Arg Ala Ile His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His Ser
 495 500 505

cct gat gtt atc acc atg gca ggc gag ctc aat att cta ccc tcc tcc 1585
 Pro Asp Val Ile Thr Met Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser
 510 515 520 525

acc acc ccc act att ccc tat acc att aat acg gtt gca gaa cac tta 1633
 Thr Thr Pro Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His Leu
 530 535 540

gac atg ctc atg acc tgc cac cac cta gac aaa cgc atc cgc gag gat 1681
 Asp Met Leu Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu Asp

545	550	555	
ctc cag ttt tcc caa agc cgt atc cgc ccc ggc tct att gcc gct gaa			1729
Leu Gln Phe Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu			
560	565	570	
gat gtg ctc cat gat att ggc gtg atc gcg atg aca agc tcg gat tcg			1777
Asp Val Leu His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp Ser			
575	580	585	
caa gca atg ggg cgc got ggg gaa gtg att cct aga act tgg caa act			1825
Gln Ala Met Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln Thr			
590	595	600	605
gca gac aag aat aaa aaa gaa ttt ggt aag ctt cct gaa gat ggt gca			1873
Ala Asp Lys Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala			
610	615	620	
gat aat gac aac ttc cgc atc aaa cgc tat atc tcc aaa tac acc att			1921
Asp Asn Asp Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile			
625	630	635	
aat ccc gct ttg acc cat ggc gtg agc gag tat atc ggc tct gtg gaa			1969
Asn Pro Ala Leu Thr His Gly Val Ser Glu Tyr Ile Gly Ser Val Glu			
640	645	650	
gag ggc aag atc gcc gac ttg gtg gtg tgg aat cct gct ttc ttt ggt			2017
Glu Gly Lys Ile Ala Asp Leu Val Val Trp Asn Pro Ala Phe Phe Gly			
655	660	665	
gta aaa ccc aaa atc gtg atc aaa ggc ggt atg gtg gtg ttc tct gaa			2065
Val Lys Pro Lys Ile Val Ile Lys Gly Gly Met Val Val Phe Ser Glu			
670	675	680	685
atg ggc gat tct aac gcg tct gtg ccc aca cct cag ccg gtt tat tac			2113
Met Gly Asp Ser Asn Ala Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr			
690	695	700	

cgc gaa atg ttt ggg cat cac ggc aag gcg aaa ttt gac acc agc atc 2161
 Arg Glu Met Phe Gly His His Gly Lys Ala Lys Phe Asp Thr Ser Ile
 705 710 715

act ttt gtt tcc aaa gtc gcc tat gaa aat ggc gtg aaa gaa aaa cta 2209
 Thr Phe Val Ser Lys Val Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu
 720 725 730

ggc tta gag cgc aag gtg cta ccc gtg aaa aac tgc cgc aac atc act 2257
 Gly Leu Glu Arg Lys Val Leu Pro Val Lys Asn Cys Arg Asn Ile Thr
 735 740 745

aag aaa gac ttc aaa ttc aac aac aag acg gcg cat atc act gtc gat 2305
 Lys Lys Asp Phe Lys Phe Asn Asn Lys Thr Ala His Ile Thr Val Asp
 750 755 760 765

cct aaa acc ttc gag gtc ttt gta gat ggc aaa ctc tgc acc tct aaa 2353
 Pro Lys Thr Phe Glu Val Phe Val Asp Gly Lys Leu Cys Thr Ser Lys
 770 775 780

ccc gcc tct gaa gtg cct cta gcc caa cgc tac act ttc ttc tag 2398
 Pro Ala Ser Glu Val Pro Leu Ala Gln Arg Tyr Thr Phe Phe
 785 790 795

gcacaat 2405

<210> 5
 <211> 226
 <212> PRT
 <213> Helicobacter felis

<400> 5
 Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15
 Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

225

<210> 6

<211> 568

<212> PRT

<213> Helicobacter felis

<400> 6

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Thr
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu
 20 25 30

His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys
 35 40 45

Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp Glu Asn Thr
 50 55 60

Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr Thr Gly Ile
 65 70 75 80

Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly
 85 90 95

Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val
 100 105 110

Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr
 115 120 125

Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe
 130 135 140

Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr
 145 150 155 160

Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp
 165 170 175

Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val
 180 185 190

Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu
 195 200 205

Gln Val Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly
 210 215 220

Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr
 225 230 235 240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met
 275 280 285

Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro
 290 295 300

Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys
 305 310 315 320

His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser
 325 330 335

Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile
 340 345 350

Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala

355	360	365
Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys		
370	375	380
Glu Phe Gly Lys Leu Pro ² Glu Asp Gly Ala Asp Asn Asp Asn Phe Arg		
385	390	395
Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His		
405	410	415
Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp		
420	425	430
Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val		
435	440	445
Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala		
450	455	460
Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His		
465	470	475
His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val		
485	490	495
Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Lys Val		
500	505	510
Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe		
515	520	525
Asn Asn Lys Thr Ala His Ile Thr Val Asp Pro Lys Thr Phe Glu Val		
530	535	540
Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Ala Ser Glu Val Pro		
545	550	555
		560

Leu Ala Gln Arg Tyr Thr Phe Phe
565

<210> 7

<211> 2183

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (3)..(683)

<220>

<221> CDS

<222> (694)..(2181)

<400> 7

tc gtg aaa ctc aca ccc aaa gag caa gaa aag ttc ttg tta tat tat 47
Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr
1 5 10 15

gcg ggc gaa gtg gct aga aag cgc aaa gca gag ggc tta aag ctc aat 95
Ala Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn
20 25 30

caa ccc gaa gcc att gcc tac att agt gcc cat att atg gac gag gcg 143
Gln Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala
35 40 45

cgc cgt ggc aaa aaa acc gtt gct gaa ctt atg gaa gaa tgt atg cac 191
Arg Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His
50 55 60

ttt ttg aaa aaa gat gag gtg atg ccc ggt gtg ggg aat atg gtc cct 239
Phe Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro
65 70 75

gat ttg ggc gta gaa gcc act ttc ccc gat ggc acc aaa ctc gta acc 287
Asp Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr
80 85 90 95

gtg aat tgg ccc att gaa cct gat gaa cac ttt aaa gcc ggt gaa gtg 335
Val Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val
100 105 110

aaa ttt ggc tgt gat aaa gac att gag ctc aac gtg ggt aag gaa gtt 383
Lys Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Val Gly Lys Glu Val
115 120 125

acc gag ctt gaa gtt acc aac gaa gga cct aaa tcc ttg cat gtg ggt 431
Thr Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly
130 135 140

agc cat ttc cac ttc ttt gaa acc aac aag gca ttg aaa ttc gat cgg 479
Ser His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg
145 150 155

gaa aaa gcc tat ggc aaa cgc cta gat att ccc tct ggc aac acg cta 527
Glu Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu
160 165 170 175

cgc att ggg gca gga caa acc cgt aaa gtg cag tta atc cct ctt ggc 575
Arg Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly
180 185 190

ggt agt aaa aaa gtg att ggc atg aac ggg ctt gtg aat aat att gcg 623
Gly Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala
195 200 205

gac gaa cgc cat aaa cac aaa gca cta gac aag gca aaa tct cac gga 671
Asp Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly
210 215 220

ttc atc aag taa ggagactccc atg aaa atg aaa aaa caa gag tat gta 720

Phe Ile Lys	Met Lys Met Lys Lys Gln Glu Tyr Val	
225	230	235
aac acc tac gga ccc acc aca ggc gat aaa gtg cgc tta gga gat acc		768
Asn Thr Tyr Gly Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr		
240	245	250
gat ctt tgg gca gaa gta gaa cat gac tat acc act tat ggc gaa gag		816
Asp Leu Trp Ala Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu		
255	260	265
ctc aaa ttt ggc gcg ggt aaa act atc cgt gag ggt atg ggt cag agc		864
Leu Lys Phe Gly Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser		
270	275	280
aat agc cca gat gaa aac acc tta gat tta gtg atc acc aac gcg atg		912
Asn Ser Pro Asp Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met		
285	290	295
att atc gac tac acc ggg att tat aaa gcc gac att ggt att aaa aat		960
Ile Ile Asp Tyr Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn		
305	310	315
ggc aaa atc cat ggt att ggc aag gcg ggg aac aaa gac atg caa gat		1008
Gly Lys Ile His Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp		
320	325	330
ggc gta agc cct cat atg gtc gtg ggt gtg ggc aca gaa gca cta gca		1056
Gly Val Ser Pro His Met Val Val Gly Val Gly Thr Glu Ala Leu Ala		
335	340	345
ggg gaa ggt atg att att acc gct ggg ggg atc gat tcg cac acc cac		1104
Gly Glu Gly Met Ile Ile Thr Ala Gly Gly Ile Asp Ser His Thr His		
350	355	360
ttc ctc tct ccc caa caa ttc cct acc gct cta gcc aat ggt gtt aca		1152
Phe Leu Ser Pro Gln Gln Phe Pro Thr Ala Leu Ala Asn Gly Val Thr		
365	370	375
		380

acc atg ttt gga ggt ggc aca ggt ccg gta gat ggc acg aat gcg acc 1200
 Thr Met Phe Gly Gly Gly Thr Gly Pro Val Asp Gly Thr Asn Ala Thr
 385 390 395

acc atc act ccg ggc aaa tgg aac ttg cac cgc atg ttg cgc gca gct 1248
 Thr Ile Thr Pro Gly Lys Trp Asn Leu His Arg Met Leu Arg Ala Ala
 400 405 410

gaa gag tat tct atg aat gta ggc ttt ttg ggc aaa ggc aat agt tct 1296
 Glu Glu Tyr Ser Met Asn Val Gly Phe Leu Gly Lys Gly Asn Ser Ser
 415 420 425

agc aaa aaa caa ctt gta gaa caa gta gaa gcg ggc gcg att ggc ttt 1344
 Ser Lys Lys Gln Leu Val Glu Gln Val Glu Ala Gly Ala Ile Gly Phe
 430 435 440

aaa ttg cat gaa gac tgg ggc aca aca cca agt gcg atc gat cac tgc 1392
 Lys Leu His Glu Asp Trp Gly Thr Thr Pro Ser Ala Ile Asp His Cys
 445 450 455 460

ttg agc gtg gca gat gaa tac gat gtg caa gtt tgt atc cac acc gat 1440
 Leu Ser Val Ala Asp Glu Tyr Asp Val Gln Val Cys Ile His Thr Asp
 465 470 475

acg gtc aat gag gca ggt tat gtg gat gac acc cta aat gca atg aac 1488
 Thr Val Asn Glu Ala Gly Tyr Val Asp Asp Thr Leu Asn Ala Met Asn
 480 485 490

ggg cgc gcc atc cat gcc tac cac att gag gga gcg ggc gga gga cac 1536
 Gly Arg Ala Ile His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His
 495 500 505

tca cct gat gtt atc acc atg gca ggc gag ctc aat att cta ccc tcc 1584
 Ser Pro Asp Val Ile Thr Met Ala Gly Glu Leu Asn Ile Leu Pro Ser
 510 515 520

tcc acc acc ccc act att ccc tat acc att aat acg gtt gca gaa cac 1632

gaa atg ggc gat tct aac gcg tcc gtg ccc acg cct cag ccg gtt tat 2112
 Glu Met Gly Asp Ser Asn Ala Ser Val Pro Thr Pro Gln Pro Val Tyr
 685 690 695 700

tac cgc gaa atg ttt ggg cac cac ggc aag gcg aaa ttt gac acc agc 2160
 Tyr Arg Glu Met Phe Gly His His Gly Lys Ala Lys Phe Asp Thr Ser
 705 710 715

atc act ttt cgt gtc tca agc gg 2183
 Ile Thr Phe Arg Val Ser Ser
 720

<210> 8

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 8

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Val Gly Lys Glu Val Thr
 115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

His Phe His Phe Phe Glu Thr Asn Lys Ala Leu Lys Phe Asp Arg Glu
 145 150 155 160

Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
 165 170 175

Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
 180 185 190

Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe
 210 215 220

Ile Lys
 225

<210> 9

<211> 496

<212> PRT

<213> Helicobacter felis

<400> 9

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Thr
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu

Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr
 225 230 235 240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met
 275 280 285

Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro
 290 295 300

Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys
 305 310 315 320

His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser
 325 330 335

Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile
 340 345 350

Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala
 355 360 365

Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys
 370 375 380

Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala Asp Asn Asp Asn Phe Arg
 385 390 395 400

Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His
 405 410 415

Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp
 420 425 430

Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val
 435 440 445

Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala
 450 455 460

Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His
 465 470 475 480

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Arg Val Ser Ser
 485 490 495

<210> 10

<211> 2407

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (2)..(682)

<220>

<221> CDS

<222> (693)..(2399)

<400> 10

c gtg aaa ctc aca ccc aaa gag caa gaa aag ttc ttg tta tat tat gcg 49
 Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

ggc gaa gtg gct aga aag cgc aaa gcg gag ggc tta aag ctc aac caa 97
 Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

ccc gaa gcc att gcc tac att agt gcc cat att atg gac gag gcg cgc 145

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

cgt ggc aaa aag acc gtt gcg gaa ctt atg gaa gag tgt atg cac ttt 193
 Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

ttg aaa aaa gac gag gtg atg ccc ggt gtg ggg aat atg gtc cct gat 241
 Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

tta ggc gtg gaa gct act ttt ccc gat ggc acc aaa ctc gta acc gtg 289
 Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

aat tgg ccc atc gaa ccc gat gaa cac ttc aaa gcg ggc gaa gtc aaa 337
 Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

ttt ggc tgt gat aaa gac att gaa ctc aac gca ggt aag gaa gtt acc 385
 Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr
 115 120 125

gaa cta gaa gtt acc aac gaa gga cct aaa tcc ttg cat gtg ggt agc 433
 Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

cat ttc cac ttc ttt gaa gcc aac aag gca ttg aaa ttc gat cgg gaa 481
 His Phe His Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu
 145 150 155 160

aaa gcc tat ggc aaa cgc cta gat att ccc tct ggc aac acg cta cgc 529
 Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
 165 170 175

att ggg gca gga caa acc cgt aaa gtg cag tta atc cct ctt ggc ggc 577
 Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
 180 185 190

agt aaa aaa gtg att ggc atg aac ggg ctt gtg aat aat att gca gat 625
 Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

gaa cgc cat aaa cac aaa ggc tta gaa aaa gca aaa tct cac gga ttt 673
 Glu Arg His Lys His Lys Ala Leu Glu Lys Ala Lys Ser His Gly Phe
 210 215 220

atc aaa taa ggagactccc atg aaa atg aaa aaa caa gag tat gta aat 722
 Ile Lys Met Lys Met Lys Lys Gln Glu Tyr Val Asn
 225 230 235

acc tac gga cct acc aca ggc gac aaa gtg cgc tta gga gat acc gat 770
 Thr Tyr Gly Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp
 240 245 250

ctt tgg gca gaa gta gaa cat gac tat acc act tat ggc gaa gag ctc 818
 Leu Trp Ala Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu
 255 260 265

aaa ttt ggc gcg ggt aaa act atc cgt gag ggc atg ggt cag agc aat 866
 Lys Phe Gly Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser Asn
 270 275 280 285

agt cca gat gaa aac acc cta gat tta gtc atc acc aac gcg atg att 914
 Ser Pro Asp Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met Ile
 290 295 300

att gac tac acc ggg att tac aaa gcc gac att ggc att aaa aat ggc 962
 Ile Asp Tyr Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly
 305 310 315

aaa atc cat ggc att ggc aag gca gga aac aag gac atg caa gat ggc 1010
 Lys Ile His Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp Gly
 320 325 330

gta agc cct cat atg gtc gtg ggt gtg ggc aca gaa gca tta gca ggg 1058

Val	Ser	Pro	His	Met	Val	Val	Gly	Val	Gly	Thr	Glu	Ala	Leu	Ala	Gly		
	335						340				345						
gaa	ggt	atg	att	att	acc	gct	ggg	ggg	atc	gat	tca	cac	acc	cac	ttc		1106
Glu	Gly	Met	Ile	Ile	Thr	Ala	Gly	Gly	Ile	Asp	Ser	His	Thr	His	Phe		
350					355				360						365		
ctc	tct	cca	caa	caa	ttc	cct	acc	gct	cta	gcc	aat	ggc	ggt	aca	acc		1154
Leu	Ser	Pro	Gln	Gln	Phe	Pro	Thr	Ala	Leu	Ala	Asn	Gly	Val	Thr	Thr		
			370						375						380		
atg	ttt	ggc	ggt	ggc	aca	ggt	ccg	gta	gat	ggc	acg	aat	gcg	act	acc		1202
Met	Phe	Gly	Gly	Gly	Thr	Gly	Pro	Val	Asp	Gly	Thr	Asn	Ala	Thr	Thr		
		385						390					395				
atc	act	ccg	ggc	aaa	tgg	aac	ttg	cac	cgc	atg	ttg	cgc	gca	gct	gaa		1250
Ile	Thr	Pro	Gly	Lys	Trp	Asn	Leu	His	Arg	Met	Leu	Arg	Ala	Ala	Glu		
		400					405						410				
gag	tat	tct	atg	aat	gtg	ggc	ttt	ttg	ggc	aaa	ggc	aat	agc	tcc	agt		1298
Glu	Tyr	Ser	Met	Asn	Val	Gly	Phe	Leu	Gly	Lys	Gly	Asn	Ser	Ser	Ser		
	415					420						425					
aaa	aaa	caa	ctt	gta	gaa	caa	ata	gaa	gcg	ggc	gcg	atc	ggc	ttt	aaa		1346
Lys	Lys	Gln	Leu	Val	Glu	Gln	Ile	Glu	Ala	Gly	Ala	Ile	Gly	Phe	Lys		
430					435					440					445		
ttg	cat	gaa	gac	tgg	ggc	aca	act	cca	agt	gca	atc	gat	cac	tgc	ttg		1394
Leu	His	Glu	Asp	Trp	Gly	Thr	Thr	Pro	Ser	Ala	Ile	Asp	His	Cys	Leu		
			450						455						460		
agc	gta	gca	gat	gaa	tac	gat	gtg	caa	gtt	tgt	atc	cac	acc	gat	acg		1442
Ser	Val	Ala	Asp	Glu	Tyr	Asp	Val	Gln	Val	Cys	Ile	His	Thr	Asp	Thr		
			465					470						475			
gtc	aat	gag	gca	ggt	tat	gta	gat	gac	acc	ctg	aat	gcg	atg	aac	ggg		1490
Val	Asn	Glu	Ala	Gly	Tyr	Val	Asp	Asp	Thr	Leu	Asn	Ala	Met	Asn	Gly		
		480						485						490			

cgc gcc atc cat gcc tac cac att gag gga gcg ggc gga gga cac tca 1538
 Arg Ala Ile His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His Ser
 495 500 505

cct gat gtt atc acc atg³gca ggc gag ctc aat att cta ccc tcc tcc 1586
 Pro Asp Val Ile Thr Met Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser
 510 515 520 525

aca acc ccc act atc ccc tat acc att aat acg gtt gca gaa cac tta 1634
 Thr Thr Pro Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His Leu
 530 535 540

gac atg ctc atg acc tgc cac cac cta gat aaa cgc atc cgc gag gat 1682
 Asp Met Leu Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu Asp
 545 550 555

tta caa ttt tcc caa agc cgt atc cgc ccc ggc tct atc gcc gct gaa 1730
 Leu Gln Phe Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu
 560 565 570

gat gtg ctc cat gat att ggc gtg atc gcg atg aca agc tcg gat tcg 1778
 Asp Val Leu His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp Ser
 575 580 585

caa gca atg ggg cgc gct ggc gaa gtg att cct cga act tgg cag act 1826
 Gln Ala Met Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln Thr
 590 595 600 605

gcg gat aag aat aaa aaa gaa ttt ggt aag ott cct gaa gat agt gca 1874
 Ala Asp Lys Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Ser Ala
 610 615 620

gat aac gac aac ttc cgt atc aaa cgc tac atc tcc aaa tac act att 1922
 Asp Asn Asp Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile
 625 630 635

aac ccc gct cta acc cat ggg gta agc gag tat atc gcc tct gtg gaa 1970

gcncaatg

2407

<210> 11

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 11

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala

1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln

20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg

35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe

50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp

65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val

85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys

100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr

115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser

130 135 140

His Phe His Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu

Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His Gly Ile Gly
 85 90 95

Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro His Met Val
 100 105 110

Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met Ile Ile Thr
 115 120 125

Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro Gln Gln Phe
 130 135 140

Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly Gly Gly Thr
 145 150 155 160

Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Lys Trp
 165 170 175

Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Val
 180 185 190

Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln Leu Val Glu
 195 200 205

Gln Ile Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu Asp Trp Gly
 210 215 220

Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala Asp Glu Tyr
 225 230 235 240

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met

275		280		285
Ala Gly Glu Leu Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro				
290		295		300
Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys				
305		310		315
				320
His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser				
		325		330
				335
Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile				
		340		345
				350
Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala				
		355		360
				365
Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys				
		370		375
				380
Glu Phe Gly Lys Leu Pro Glu Asp Ser Ala Asp Asn Asp Asn Phe Arg				
385		390		395
				400
Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His				
		405		410
				415
Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp				
		420		425
				430
Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val				
		435		440
				445
Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala				
450		455		460
Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His				
465		470		475
				480

(129)

特開2002-355054

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val
485 490 495

Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Lys Val
500 505 510

Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe
515 520 525

Asn Asn Lys Thr Ala His Ile Thr Val Asp Pro Lys Thr Phe Glu Val
530 535 540

Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Ala Ser Glu Val Pro
545 550 555 560

Leu Ala Gln Arg Tyr Thr Phe Phe
565

<210> 13

<211> 2452

<212> DNA

<213> Helicobacter felis

<220>

<221> CDS

<222> (48)..(728)

<220>

<221> CDS

<222> (739)..(2445)

<400> 13

aggactataa.tcccattgcc tttaaaattt aacacaagga gtaatag gtg aaa ctc 56
Val Lys Leu

aca ccc aaa gag caa gaa aag ttc ttg tta tat tat gcg ggc gaa gtg 104
 Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala Gly Glu Val
 5 10 15

gct aga aag cgc aaa gca gag ggc tta aag ctc aac caa ccc gaa gcc 152
 Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln Pro Glu Ala
 20 25 30 35

att gcc tac att agt gcc cat att atg gac gag gcg cgt cgt ggc aaa 200
 Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg Arg Gly Lys
 40 45 50

aaa acc gtt gcg gaa ctt atg gaa gag tgt atg cac ttt ttg aaa aaa 248
 Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe Leu Lys Lys
 55 60 65

gac gag gtg atg ccc ggg gtg ggg aat atg gtc cct gat ttg ggc gtg 296
 Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp Leu Gly Val
 70 75 80

gaa gcc act ttc ccc gat ggc acc aaa ctc gta act gtg aat tgg ccc 344
 Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val Asn Trp Pro
 85 90 95

atc gaa cct gat gaa cac ttt aag gcg ggt gaa gtg aaa ttt ggc tgt 392
 Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys Phe Gly Cys
 100 105 110 115

gat aaa gac att gaa ctc aac gca ggt aag gaa gtt acc gaa cta gaa 440
 Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr Glu Leu Glu
 120 125 130

gtt act aac gaa gga cct aaa tcc ttg cat gtg ggt agc cat ttc cac 488
 Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser His Phe His
 135 140 145

ttc ttt gaa gcc aac aaa gca ttg aaa ttc gat cgg gaa aaa gcc tat 536
 Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu Lys Ala Tyr

150	155	160	
ggc aaa cgc cta gat att ccc tct ggc aac aca cta cgc att ggg gca			584
Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg Ile Gly Ala			
165	170	175	
gga caa acc cgt aaa gtg cag tta atc cct ctt ggc ggt agt aaa aaa			632
Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly Ser Lys Lys			
180	185	190	195
gtg att ggc atg aac ggg ctt gtg aat aat att gcg gac gaa cgc cat			680
Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp Glu Arg His			
200	205	210	
aaa cac aaa gcg cta gac aaa gca aaa tct cac gga ttt atc aag taa			728
Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe Ile Lys			
215	220	225	
ggagactccc atg aaa atg aaa aaa caa gag tat gta aat acc tac gga			777
Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly			
230	235	240	
ccc acc aca ggc gat aaa gtg cgc tta gga gat acc gat ctt tgg gca			825
Pro Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala			
245	250	255	
gaa gta gaa cat gac tat acc acc tat ggc gaa gaa ctc aaa ttc ggt			873
Glu Val Glu His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly			
260	265	270	
gca ggt aaa act atc cgt gag ggt atg ggt cag agc aat agc cca gat			921
Ala Gly Lys Thr Ile Arg Glu Gly Met Gly Gln Ser Asn Ser Pro Asp			
275	280	285	
gaa aac acc tta gat tta gtg atc acc aac gcg atg att att gac tac			969
Glu Asn Thr Leu Asp Leu Val Ile Thr Asn Ala Met Ile Ile Asp Tyr			
290	295	300	

acc ggg att tac aaa gcc gac att ggc att aaa aat ggc aaa atc cat 1017
 Thr Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asn Gly Lys Ile His
 305 310 315 320

ggc att ggc aag gca gga aac aag gac atg caa gat ggc gta agc cct 1065
 Gly Ile Gly Lys Ala Gly Asn Lys Asp Met Gln Asp Gly Val Ser Pro
 325 330 335

cat atg gtc gtg ggt gtg ggc aca gaa gca cta gca ggg gaa ggt atg 1113
 His Met Val Val Gly Val Gly Thr Glu Ala Leu Ala Gly Glu Gly Met
 340 345 350

att att acc gct ggg ggg atc gat tca cac acc cac ttc ctc tct cca 1161
 Ile Ile Thr Ala Gly Gly Ile Asp Ser His Thr His Phe Leu Ser Pro
 355 360 365

caa caa ttc cct acc gct cta gcc aat ggc gtt aca aca atg ttt ggc 1209
 Gln Gln Phe Pro Thr Ala Leu Ala Asn Gly Val Thr Thr Met Phe Gly
 370 375 380

ggt ggc aca ggc ccc gta gat ggc acg aat gcg act acc atc act ccg 1257
 Gly Gly Thr Gly Pro Val Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro
 385 390 395 400

ggc aaa tgg aac ttg cac cgc atg ttg cgc gca gca gaa gag tat tct 1305
 Gly Lys Trp Asn Leu His Arg Met Leu Arg Ala Ala Glu Glu Tyr Ser
 405 410 415

atg aat gtg ggc ttt ttg ggc aaa ggc aat agc tct agt aaa aaa caa 1353
 Met Asn Val Gly Phe Leu Gly Lys Gly Asn Ser Ser Ser Lys Lys Gln
 420 425 430

ctt gta gaa caa gta gaa gcg ggc gcg att ggt ttt aaa ttg cat gaa 1401
 Leu Val Glu Gln Val Glu Ala Gly Ala Ile Gly Phe Lys Leu His Glu
 435 440 445

gac tgg ggc aca act cca agt gcg atc gat cac tgc ttg agc gta gca 1449
 Asp Trp Gly Thr Thr Pro Ser Ala Ile Asp His Cys Leu Ser Val Ala

450	455	460	
gat gaa tac gat gtg caa gtt tgt ata cac acc gat acg gtc aat gag			1497
Asp Glu Tyr Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu			
465	470	475	480
gca ggt tat gta gat gac acc cta aat gca atg aac ggg cgc gcc atc			1545
Ala Gly Tyr Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile			
	485	490	495
cat gcc tac cac att gag gga gcg ggt gga gga cac tca cct gat gtt			1593
His Ala Tyr His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val			
	500	505	510
atc acc atg gca ggc gaa gtg aat att cta ccc tcc tcc aca acc cct			1641
Ile Thr Met Ala Gly Glu Val Asn Ile Leu Pro Ser Ser Thr Thr Pro			
	515	520	525
act atc ccc tat acc att aat acg gtt gca gaa cac tta gac atg ctt			1689
Thr Ile Pro Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu			
	530	535	540
atg acc tgc cac cac cta gat aaa cgc atc cgc gag gat ctc caa ttt			1737
Met Thr Cys His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe			
545	550	555	560
tct caa agc cgt atc cgc ccc ggc tct atc gcc gct gaa gat gtg ctc			1785
Ser Gln Ser Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu			
	565	570	575
cat gat atc ggt gtg atc gcg atg aca agt tcc gat tcg caa gca atg			1833
His Asp Ile Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met			
	580	585	590
ggg cgc gct ggg gaa gtg att cct aga act tgg caa act gca gac aag			1881
Gly Arg Ala Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys			
	595	600	605

aat aaa aaa gaa ttt ggt aag ctt cct gaa gat ggt gca gat aat gac 1929
Asn Lys Lys Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala Asp Asn Asp
610 615 620

aac ttc cgc atc aaa cgc tat atc tcc aaa tac acc att aat ccc gct 1977
Asn Phe Arg Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala
625 630 635 640

ttg acc cat ggc gtg agc gag tat atc ggc tcl gtg gaa gag ggc aag 2025
Leu Thr His Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys
645 650 655

atc gcc gac ttg gtg gtg tgg aat cct gcc ttt ttt ggc gta aaa ccc 2073
Ile Ala Asp Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro
660 665 670

aaa atc gtg atc aaa ggc ggt atg gtg gtg ttc tct gaa atg ggc gat 2121
Lys Ile Val Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp
675 680 685

tct aat gcg tct gtg ccc act cct cag ccg gtt tat tac cgc gaa atg 2169
Ser Asn Ala Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met
690 695 700

ttt ggg cat cac ggc aag gcg aaa ttt gac acc agc atc act ttt gtt 2217
Phe Gly His His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val
705 710 715 720

tcc aaa gtc gcc tat gaa aat ggt gtg aaa gaa aaa cta ggt tta gag 2265
Ser Lys Val Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu
725 730 735

cgc aag gtg etc ccc gtg aaa aac tgc cgt aac atc acc aag aag gac 2313
Arg Lys Val Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp
740 745 750

ttc aag ttc aac gac aaa act gca aaa atc acc gtc gat ccg aaa acc 2361
Phe Lys Phe Asn Asp Lys Thr Ala Lys Ile Thr Val Asp Pro Lys Thr

755

760

765

ttc gag gtc ttt gta gat ggc aaa ctc tgc acc tct aaa ccc acc tct 2409
 Phe Glu Val Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser
 770 775 780

gaa gtg cct cta gcc caa cgc tac act ttc ttc tag gcataat 2452
 Glu Val Pro Leu Ala Gln Arg Tyr Thr Phe Phe
 785 790 795

<210> 14

<211> 226

<212> PRT

<213> Helicobacter felis

<400> 14

Val Lys Leu Thr Pro Lys Glu Gln Glu Lys Phe Leu Leu Tyr Tyr Ala
 1 5 10 15

Gly Glu Val Ala Arg Lys Arg Lys Ala Glu Gly Leu Lys Leu Asn Gln
 20 25 30

Pro Glu Ala Ile Ala Tyr Ile Ser Ala His Ile Met Asp Glu Ala Arg
 35 40 45

Arg Gly Lys Lys Thr Val Ala Glu Leu Met Glu Glu Cys Met His Phe
 50 55 60

Leu Lys Lys Asp Glu Val Met Pro Gly Val Gly Asn Met Val Pro Asp
 65 70 75 80

Leu Gly Val Glu Ala Thr Phe Pro Asp Gly Thr Lys Leu Val Thr Val
 85 90 95

Asn Trp Pro Ile Glu Pro Asp Glu His Phe Lys Ala Gly Glu Val Lys
 100 105 110

Phe Gly Cys Asp Lys Asp Ile Glu Leu Asn Ala Gly Lys Glu Val Thr
 115 120 125

Glu Leu Glu Val Thr Asn Glu Gly Pro Lys Ser Leu His Val Gly Ser
 130 135 140

His Phe His Phe Phe Glu Ala Asn Lys Ala Leu Lys Phe Asp Arg Glu
 145 150 155 160

Lys Ala Tyr Gly Lys Arg Leu Asp Ile Pro Ser Gly Asn Thr Leu Arg
 165 170 175

Ile Gly Ala Gly Gln Thr Arg Lys Val Gln Leu Ile Pro Leu Gly Gly
 180 185 190

Ser Lys Lys Val Ile Gly Met Asn Gly Leu Val Asn Asn Ile Ala Asp
 195 200 205

Glu Arg His Lys His Lys Ala Leu Asp Lys Ala Lys Ser His Gly Phe
 210 215 220

Ile Lys
 225

<210> 15

<211> 568

<212> PRT

<213> Helicobacter felis

<400> 15

Met Lys Met Lys Lys Gln Glu Tyr Val Asn Thr Tyr Gly Pro Thr Thr
 1 5 10 15

Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Trp Ala Glu Val Glu
 20 25 30

His Asp Tyr Thr Thr Tyr Gly Glu Glu Leu Lys Phe Gly Ala Gly Lys

Asp Val Gln Val Cys Ile His Thr Asp Thr Val Asn Glu Ala Gly Tyr
 245 250 255

Val Asp Asp Thr Leu Asn Ala Met Asn Gly Arg Ala Ile His Ala Tyr
 260 265 270

His Ile Glu Gly Ala Gly Gly Gly His Ser Pro Asp Val Ile Thr Met
 275 280 285

Ala Gly Glu Val Asn Ile Leu Pro Ser Ser Thr Thr Pro Thr Ile Pro
 290 295 300

Tyr Thr Ile Asn Thr Val Ala Glu His Leu Asp Met Leu Met Thr Cys
 305 310 315 320

His His Leu Asp Lys Arg Ile Arg Glu Asp Leu Gln Phe Ser Gln Ser
 325 330 335

Arg Ile Arg Pro Gly Ser Ile Ala Ala Glu Asp Val Leu His Asp Ile
 340 345 350

Gly Val Ile Ala Met Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Ala
 355 360 365

Gly Glu Val Ile Pro Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys
 370 375 380

Glu Phe Gly Lys Leu Pro Glu Asp Gly Ala Asp Asn Asp Asn Phe Arg
 385 390 395 400

Ile Lys Arg Tyr Ile Ser Lys Tyr Thr Ile Asn Pro Ala Leu Thr His
 405 410 415

Gly Val Ser Glu Tyr Ile Gly Ser Val Glu Glu Gly Lys Ile Ala Asp
 420 425 430

Leu Val Val Trp Asn Pro Ala Phe Phe Gly Val Lys Pro Lys Ile Val
 435 440 445

Ile Lys Gly Gly Met Val Val Phe Ser Glu Met Gly Asp Ser Asn Ala
 450 455 460

Ser Val Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Gly His
 465 470 475 480

His Gly Lys Ala Lys Phe Asp Thr Ser Ile Thr Phe Val Ser Lys Val
 485 490 495

Ala Tyr Glu Asn Gly Val Lys Glu Lys Leu Gly Leu Glu Arg Lys Val
 500 505 510

Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Phe Lys Phe
 515 520 525

Asn Asp Lys Thr Ala Lys Ile Thr Val Asp Pro Lys Thr Phe Glu Val
 530 535 540

Phe Val Asp Gly Lys Leu Cys Thr Ser Lys Pro Thr Ser Glu Val Pro
 545 550 555 560

Leu Ala Gln Arg Tyr Thr Phe Phe
 565

<210> 16

<211> 21

<212> DNA

<213> Helicobacter felis.

<400> 16

catgcacttt..ttgaaaaaag a

21

<210> 17

<211> 16

<212> DNA
<213> Helicobacter felis

<400> 17
tatggtgggc ttctct 16

<210> 18
<211> 32
<212> DNA
<213> Helicobacter felis

<400> 18
ggagtaacat atgaaactca cacccaaaga gc 32

<210> 19
<211> 27
<212> DNA
<213> Helicobacter felis

<400> 19
cacacccacg accatgtgag ggcttac 27

<210> 20
<211> 27
<212> DNA
<213> Helicobacter felis

<400> 20
gtaagccctc acatggtcgt ggggtgtg 27

<210> 21
<211> 34
<212> DNA
<213> Helicobacter felis

<400> 21
cgaattcggg tcctagaaga aagtgtagcg ctgg 34

4. Brief Description of the Drawings

(1~4)

Figure 1a: Comparison of the nucleic acid sequence encoding UreX and Y, including a short non-coding region bridging the two coding sequences, from *Helicobacter felis* species CS1, Kukka, Ds4, 2301 and 390 with the nucleic acid sequence encoding UreA and B, including a short non-coding region bridging the two coding sequences, from *Helicobacter felis*, *pylori* and *heilmannii*

Figure 1b: Comparison of the amino acid sequence of UreX from *Helicobacter felis* species CS1, Kukka, Ds4, 2301 and 390 with the amino acid sequence encoding UreA from *Helicobacter felis*, *pylori* and *heilmannii*

(1~2)

Figure 1c: Comparison of the amino acid sequence of UreY from *Helicobacter felis* species CS1, Kukka, Ds4, 2301 and 390 with the amino acid sequence encoding UreB from *Helicobacter felis*, *pylori* and *heilmannii*

Figure 2: Polyacrylamide gel of the expression products UreX and UreY

- Lane 7 : Biorad broad range marker
- Lane 8 : Complete cell culture before induction (small scale culture)
- Lane 9 : Complete cell culture after induction (small scale culture)
- Lane 10 : Complete cell culture after induction (large scale culture)
- Lane 11 : Supernatant after induction (large scale culture).
- Lane 12 : Biorad pre-stained marker

Fig. 1c-1




Figure 1c (1)

```

ureYCS1      ( 480) hngkakfdtsitfsvskvayengvkeklglerqvipvknrcrnitkkdkfndktakitvdpktfevfdgkldtskptsqvpplagrytff
ureYkuka     ( 480) .....k.....e.....
ureYDS4      ( 480) .....k.....n.....h.....d.....e.....
ureY2301     ( 480) .....k.....n.....h.....d.....e.....rvss
ureY390      ( 481) .....n.....qa..ka..i..e...d..aap.....l...v..h..d..n..e..yk..k...ev...aade|s...l..nl
B Pylori     ( 481) .....y..an.....qa...dk..i..e.....mq....t..h..e..n..e..yh.....ev...ank..s...lfsi.
B heilman    ( 480) .....n.....q.....i..he...g..v.....l...v..h..e..n..e..yk..k...nev...haadxi|s...l..nl.

```

Figure 1c (2)

F i g . 2




Figure 2

1. Abstract

The present invention relates to novel *Helicobacter felis* urease subunit polypeptides and to nucleic acid sequences encoding these subunit polypeptides, to DNA fragments and recombinant DNA molecules comprising the nucleic acid sequences encoding these subunit polypeptides, to live recombinant carriers and to host cells comprising nucleic acid sequences encoding these subunit polypeptides. Also, the invention relates to the subunit polypeptides for use in vaccines and the use in the manufacturing thereof, to vaccines comprising said subunit polypeptides and to methods for the preparation of such vaccines. Furthermore, the invention relates to diagnostic methods for the detection of *Helicobacter felis* specific nucleic acid sequences, *Helicobacter felis* antigenic material and to antibodies against *Helicobacter felis*.

专利名称(译)	Helicobacter felis疫苗		
公开(公告)号	JP2002355054A	公开(公告)日	2002-12-10
申请号	JP2001214711	申请日	2001-07-16
[标]申请(专利权)人(译)	阿克佐诺贝尔公司		
申请(专利权)人(译)	阿克苏诺贝尔的基础		
[标]发明人	ヨハネスヘラルドウスクステルス ジヨバンニカツトリ		
发明人	ヨハネス・ヘラルドウス・クステルス ジヨバンニ・カツトリ		
IPC分类号	G01N33/50 A61K38/00 A61K39/00 A61K39/106 A61K39/118 A61K39/12 A61K39/175 A61K39/23 A61K39/235 A61K39/39 A61K39/395 A61P1/04 A61P31/04 C07K14/205 C12N1/15 C12N1/19 C12N1/ /21 C12N5/10 C12N9/80 C12N15/09 C12Q1/68 C12R1/01 G01N33/15 G01N33/53 G01N33/566 G01N33/569		
CPC分类号	A61K39/00 A61P1/04 A61P9/10 A61P31/04 C07K14/205 C12N9/80		
FI分类号	A61K39/106 A61K39/118 A61K39/12 A61K39/175 A61K39/23 A61K39/235 A61K39/39 A61K39/395.D A61P1/04 A61P31/04 C12N1/15 C12N1/19 C12N1/21 C12N9/80.Z C12Q1/68.A G01N33/15.Z G01N33 /50.Z G01N33/53.D G01N33/53.M G01N33/566 G01N33/569.B C12R1/01 C12N15/00.ZNA.A C12N5 /00.A A61K37/02 A61K38/00 A61K38/16 C12N15/00.A C12N15/00.AZN.A C12N5/00.101 C12N5/10		
F-TERM分类号	2G045/AA40 2G045/BA11 2G045/BB50 2G045/DA12 2G045/DA13 2G045/DA36 2G045/FB02 4B024 /AA01 4B024/AA13 4B024/BA14 4B024/BA31 4B024/CA04 4B024/DA02 4B024/DA05 4B024/DA12 4B024/EA04 4B024/FA02 4B024/GA11 4B024/HA12 4B024/HA15 4B050/CC03 4B050/DD02 4B050 /LL01 4B050/LL03 4B063/QA19 4B063/QQ44 4B063/QR08 4B063/QR42 4B063/QR56 4B063/QS25 4B063/QS34 4B063/QX02 4B065/AA01X 4B065/AA01Y 4B065/AA26X 4B065/AA57X 4B065/AA72X 4B065/AA90X 4B065/AB01 4B065/BA02 4B065/CA31 4B065/CA43 4B065/CA46 4C084/AA02 4C084 /AA07 4C084/BA19 4C084/CA04 4C084/DC50 4C084/NA14 4C084/ZA68 4C084/ZB35 4C085/AA03 4C085/AA13 4C085/AA38 4C085/BA20 4C085/BA45 4C085/BA51 4C085/BA75 4C085/BA77 4C085 /CC07 4C085/CC08 4C085/DD86 4C085/EE01 4C085/EE03 4C085/EE06		
优先权	2000202565 2000-07-17 EP		
外部链接	Espacenet		

摘要(译)

要解决的问题：提供编码源自猫Helicobacter felis的抗原多肽的多核苷酸，并提供针对幽门螺杆菌的疫苗及其感染的诊断。解决方案：一种新型的幽门螺杆菌尿素酶亚基多肽；编码这些亚基多肽的核酸序列；编码这些亚基多肽的DNA片段和重组DNA分子；重组活菌载体和宿主细胞包括编码多肽的核酸序列。本发明还涉及用于疫苗的亚基多肽，其在生产中的用途，包含亚基多肽的疫苗和制备这种疫苗的方法。

6

参照分子:H.フェリス ureX CS ¹	アミノ酸	核酸
H.フェリス ureA	50%	57%
H.ピロリ ureA	52%	60%
H.ヘイルマンニ ureA	54%	62%
H.フェリス Kukka株 ureX	100%	91%
H.フェリス Ds4株 ureX	99%	91%
H.フェリス 2301株 ureX	99%	91%
H.フェリス 390株 ureX	99%	91%